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Abstract 
Chronic myeloid leukaemia (CML) is a stem cell (SC) disorder initiated by the 
reciprocal translocation between chromosome 9 and 22, giving rise to the 
Philadelphia (Ph) chromosome and the resulting expression of the oncogenic 
fusion protein BCR-ABL. The current first line of treatment is imatinib mesylate 
(IM), a tyrosine kinase inhibitor (TKI) that competes with ATP to block ABL kinase 
activity, which in turn prevents tyrosine phosphorylation of downstream molecules 
and selectively induces apoptosis of BCR-ABL cells. However, despite excellent 
cytogenetic responses, only a minority of patients achieve complete molecular 
response (CMR). We have previously identified a population of quiescent (q) Ph+ 
SC found in chronic phase (CP) CML that are relatively insensitive to IM and other 
TKIs and which may be responsible for the molecular persistence of this disease. 
This population may be insensitive because TKIs do not reach therapeutic 
concentrations within the cell. Such resistance to classical chemotherapeutic 
drugs, the phenomenon of multidrug resistance (MDR), is mediated by ABC 
transporters. In this study we have investigated whether CML SC express the 
clinically relevant ABC transporters and determine their interaction with TKIs. In 
addition, we determined whether the inhibition of these transporters increased the 
efficacy of TKI against CML SC. 
Using CML CD34+ cells isolated from newly diagnosed patients, normal CD34+ 
cells and cell lines transduced with specific transporters as controls, the relative 
expression of drug transporters were determined in CML CD34+ cells and 
intracellular staining confirmed protein expression. The interaction of drug 
transporters with TKIs was assessed using a combination of substrate 
displacement assays and radiolabelled assays. The effect of transporter inhibitors 
  3 
with TKIs on the growth and differentiation of q34+ and more mature CD34+ cells 
from CML patients in CP were assessed with regard to cell division, apoptosis and 
BCR-ABL kinase activity. 
When compared to normal CD34+ cells, CML CD34+ cells over-expressed ABCG2 
mRNA. In contrast MDR1 expression was reduced in CML CD34+ cells and MRP1 
was detected at similar expression levels in both populations. All three drug 
transporters were expressed at the protein levels in CML CD34+ cells. It was 
determined that at therapeutic concentrations (5µM) IM and nilotinib both inhibited 
ABCG2 and MDR1 and nilotinib also inhibited MRP1. Neither drug was a substrate 
for any of the transporters. In contrast, dasatinib was shown to be a substrate for 
ABCG2 and MRP1, but had no effect on MDR1. Therefore activity and 
concentration of dasatinib but not IM or nilotinib may be altered by the activity of 
these proteins. In keeping with their inhibitory activity, neither IM nor nilotinib 
demonstrated significantly increased efficacy when combined with specific ABC 
transporter inhibitors (FTC or PSC 833). Surprisingly, although dasatinib was a 
substrate for ABCG2 and MRP1, dasatinib did not further increase apoptosis, or 
reduce the qSC population. 
Therefore, although MDR1, MRP1 and ABCG2 were found to be expressed and 
functional in CML CD34+ cells and to interact with TKI, the co-treatment of TKIs 
with drug transporter inhibitors did not further increase apoptosis, reduce BCR-
ABL kinase activity or reduce the qSC population. Therefore, modulation of 
individual transporter activity is unlikely to reverse the resistance of this population 
of cells to TKI and will not improve the clinical response to these drugs. 
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1 Introduction 
1.1 Normal haemopoietic stem cell (HSC) and haemopoiesis  
Haemopoiesis is a carefully regulated process which results in the production of 
~1011 erythrocytes, leukocytes and platelets each day. All of the formed blood cell 
lineages arise from a multi-potent HSC population, which may differentiate through 
a series of intermediate lineage, committed progenitor cells.  
The HSC is a rare cell located in the bone marrow (BM). Based on limiting dilution 
studies in non-obese diabetic-severe combined immune deficient (NOD-SCID) 
mice, it has been estimated that there are approximately 3x106 HSCs in humans 
(Wang et al. 1997). The HSC has two key identifying properties; its ability to 
differentiate into multiple cell types and to self-renew (Shizuru et al. 2005).  Self-
renewal may be symmetrical, resulting in two daughter HSCs, or asymmetrical, 
producing an identical copy of itself and a downstream progenitor. Studies carried 
out on mouse BM cells have identified three distinct HSC populations that 
constitute 0.05% of mouse BM cells; long-term HSCs (LT-HSC) which are capable 
of indefinite self-renewal, short-term HSCs (ST-HSC) which have a limited time 
span for self-renewal, and multi-potent progenitors that have little or no detectable 
self-renewal capacity (Morrison et al. 1997). These populations form a hierarchy in 
which the LT-HSC gives rise to ST-HSC, which forms the multi-potent progenitor, 
which then leads to either a lymphoid or myeloid lineage progenitor (Figure 1-1).  
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Figure 1-1 Schematic diagram of the haemopoietic cell hierarchy 
Only LT-HSC and ST-HSC have the capacity for self-renewal, which is lost 
once the cell has become a multi-potent progenitor. These give rise to the 
CLP and CMP, which undergo several proliferation and differentiation steps 
to give rise to mature, terminally differentiated progeny. [LT- long term, ST- 
short term, HSC- haemopoietic stem cell, CMP- common myeloid 
progenitor, CLP- common lymphoid progenitor] 
 
For clinical and laboratory purposes, HSCs may be isolated by 
immunophenotyping using CD34, a surface glycoprotein involved in cell adhesion, 
as the surrogate marker (Berenson et al. 1988). However, the isolated CD34+ 
population is heterogeneous and only a small minority are true HSCs with multi-
lineage potential that have indefinite self-renewal. These are characterised as 
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CD34+/lin-/38low/- (Miller et al. 1999) and are predominantly in the quiescent state 
(i.e. in G0), maintained so by their microenvironment. Another method for obtaining 
enriched HSC populations is by exploiting their ability to efflux Hoechst 33342 
(Hst). Goodell et al (Goodell et al. 1997) identified the small side population (SP) 
of cells that are Hst low which have the same immature phenotype as the HSC. In 
vitro studies of these primitive cells however, are difficult due to their rarity but also 
due to the unclear mechanism of self-renewal and differentiation which, in culture 
conditions, results in loss of stem cell phenotype with the acquisition of lineage-
specific markers (Weissman 2000).  
1.2 Cancer stem cell (CSC)  
The original hypothesis, known as the “clonal genetic model”, defined cancer as a 
proliferative disease that originated from mutated tumour cells that contributed 
equally to the tumourigenic activity. However, the identification of normal HSCs 
and an improved understanding of haemopoiesis, led to the suggestion that the 
cancer cells may be organised as a similar hierarchy, with tumours originating 
from a rare population of functionally distinct CSC. The first definitive evidence for 
the CSC hypothesis and the identification of the leukaemic stem cell (LSC) was 
reported by Bonnet and Dick (Bonnet and Dick 1997). They found that only a small 
defined subset of cells were capable of initiating acute myeloid leukaemia (AML) in 
NOD-SCID mice. These cells, termed SL-IC (SCID leukaemia-initiating cell) were 
identified as CD34+CD38-, which confirmed that primitive cells rather than 
committed progenitor cells represented the cell of origin for leukaemic 
transformation (Bonnet and Dick 1997). 
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To date, the origin of LSCs is controversial (Figure 1-2). One view is that the LSCs 
are HSCs that have become leukaemic as a result of accumulated mutations. The 
reasoning for this theory is that as HSCs already possess the machinery for self-
renewal as well as various developmental pathways, they may require fewer 
mutations to maintain the ability for self-renewal than the activation of these 
pathways in a more differentiated cell. Secondly, the nature of HSCs to persist for 
long periods of time increases the opportunity for mutations to accumulate in these 
stem cells (as shown by the atomic bomb survivors who developed cancer several 
years post exposure). Evidence for this view is supported by the cells with the 
CD34+CD38- phenotype which resembles that of the normal HSC, initiating most 
AML subtypes in NOD/SCID mice (Bonnet and Dick 1997). 
In contrast, LSCs may also be a more restricted or differentiated mature cell that 
has transformed and acquired the stem cell capability of self-renewal. Cozzio et al 
(Cozzio et al. 2003) demonstrated that retroviral transduction of the potent 
leukaemic fusion gene MLL-ENL can give rise to self-renewal properties in the 
CMP and induce AML when transplanted into irradiated mice. Similarly, 
progenitors transduced with MOZ-TIF2 resulted in leukaemia, yet in contrast 
progenitors transduced with BCR-ABL did not (Huntly et al. 2004). This suggests 
that only some leukaemia oncogenes can confer self-renewing properties to 
haemopoietic progenitors.  
Following documentation of the LSC, recent studies have now suggested that the 
CSC concept may also be relevant in solid tumours. Similar to the study by Bonnet 
and Dick (Bonnet and Dick 1997), breast cancer in NOD-SCID mice was initiated 
by the isolation of a phenotypically distinct subset of breast cancer cells (Al-Hajj et 
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al. 2003) and brain cancer stem cells were able to generate new tumours in vivo 
(Singh et al. 2004); this field is ever expanding. 
 
Figure 1-2 Origin of LSC 
The LSC may arise by transformation events occurring in the HSC which 
disrupts the normal development and gives rise to the self-renewing LSC. In 
contrast the transformation may occur in the restricted progenitors. The 
mutations in these cells must reactivate the self-renewal properties in order 
to generate the LSC. [LSC-leukaemic stem cell, HSC-haemopoietic stem 
cell] 
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1.3 Chronic myeloid leukaemia (CML) 
One disease that has been established as a CSC driven disease is CML. CML is a 
clonal myeloproliferative disorder that is initiated by the reciprocal translocation 
between the 3’ end of the C-ABL (Abelson) gene from chromosome 9 and the 3’ 
end of the BCR (Breakpoint Cluster Region) gene on chromosome 22 
(t(9;22)(q34;q11)), giving rise to the abnormally small chromosome 22 (also 
termed Philadelphia (Ph) chromosome, named so after the city in which it was 
discovered) (Rowley 1973). The molecular consequence of this translocation is the 
expression of the fusion gene BCR-ABL. Depending upon the site of the 
breakpoint in BCR, two fusion proteins can be produced, one of 185kD (p185, 
seen in B cell-acute lymphoblastic leukaemia (B-ALL) and one of 210kD (p210). 
The latter constitutively active tyrosine kinase oncoprotein is seen in >95% of 
patients with CML (Druker et al. 2001). 
CML accounts for 15-20% of all leukaemias in adults with an incidence of 
approximately 1 in 100,000. CML may be diagnosed in all age groups, although 
the median age of onset is 40-60 years, with a slight male predominance of 1.4:1 
(Faderl et al. 1999). The principal cause is unclear, although there is a clear link 
with exposure to ionising radiation, as demonstrated by the atomic bomb 
survivors. CML typically has three clinical stages, presenting in an initial chronic 
phase (CP), progressing to accelerated phase (AP) and reaching blast crisis (BC) 
in typically 3-5 years, although in some cases the CP transforms rapidly to BC. In 
over 90% of cases, CML is diagnosed in CP and is characterised by an 
abnormally high white blood cell count consisting mainly of mature and immature 
myeloid cells, increased megakaryocytes in BM and splenomegaly (Sawyers 
1999). Detection of the Ph chromosome by cytogenetic analysis of BM cells, 
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however, continues to be the basis upon which CML is diagnosed. In many clinical 
centres, the development of highly sensitive quantitative PCR to detect BCR-ABL 
transcripts has become a valuable tool for monitoring responses to therapy (Lion 
et al. 1995). As the disease progresses, additional cytogenetic abnormalities arise. 
During AP there is an increase in immature cells with additional cytogenetic 
abnormalities and BC behaves like an acute leukaemia with a very poor prognosis. 
1.3.1 Role of BCR, ABL and the fusion protein BCR-ABL 
The proteins ABL1 and BCR are ubiquitously expressed in non-malignant cells 
and have many cellular regulatory functions (Laneuville 1995). BCR can modulate 
actin polymerisation through RAC (Diekmann et al. 1991), activate NF-κB 
(Montaner et al. 1998) and may influence the RAS pathway through interaction 
with the growth factor binding protein 2 (GRB2) (Goga et al. 1995; Ma et al. 1997). 
ABL1 protein is predominately nuclear, although it may also be present in the 
cytoplasm and modulates both cell cycle regulation and response to integrin 
signalling (Van Etten 1999). ABL1 also forms complexes with GRB2 and the CT10 
regulator of kinase-like (CrkL) protein.  
The role of BCR-ABL in the pathogenesis of CML was established in 1990, when 
murine BM cells transfected with the p210 oncoprotein (p210BCR-ABL) were 
transplanted into irradiated recipients, causing them to develop a 
myeloproliferative disorder closely resembling CML (Daley et al. 1990). However, 
although necessary, BCR-ABL alone may not be sufficient to cause CML as low 
BCR-ABL transcripts have also been detected in the blood of healthy individuals, 
suggesting that other factors may contribute to the transformation of this disease 
(Biernaux et al. 1995; Bose et al. 1998). 
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A consequence of BCR-ABL however, is an increase in cell proliferation. Initially it 
was assumed this was due to the most mature proliferating cells in CP CML 
causing the expansion of Ph+ cells, known as the “discordant maturation 
hypothesis”. However, this was refuted with further studies demonstrating that the 
myeloid expansion is a result of increased numbers of primitive CML progenitor 
cells (Marley et al. 1996). Holyoake et al (Holyoake et al. 1999) have also 
demonstrated deregulated mechanisms in the quiescent population leading to an 
increase in cell cycling and contributing to increased proliferation.  
BCR-ABL is exclusively localised to the cytoplasm (in contrast to ABL which 
shuttles between the nucleus and cytoplasm), resulting in the constitutive 
phosphorylation of several substrates and activation of a range of cytoplasmic and 
nuclear transduction pathways. The substrates include adaptor molecules such as 
CrkL (Oda et al. 1994; Sattler et al. 1996) and GRB2 (Pendergast et al. 1993), 
adhesion proteins and proteins with catalytic function (such as Ras-GAP). These 
in turn activate many pathways that regulate cell proliferation and apoptosis 
(Figure 1-3).  
The anti-apoptotic phosphatidylinositol-3 kinase (PI3 kinase) pathway is activated 
when it forms a complex with BCR-ABL, Cbl and the adaptor molecules Crk and 
CrkL (Sattler and Salgia 1998). This in turn activates the downstream effector AKT 
kinase, which exerts its anti-apoptotic effects through phosphorylation of 
downstream target molecules. AKT can then phosphorylate IkB kinase, inducing 
the degradation of NF-κB inhibitor IkB. The released NF-κB then translocates to 
the nucleus allowing proliferation, inhibition of apoptosis and control of 
differentiation. In addition AKT can also phosphorylate BAD, which is a pro-
apoptotic member of the BCL-2 family that binds to BCLxL, inhibiting its function. 
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Phosphorylation of BAD by AKT releases BCLxL to bind to BAX and hence 
neutralises the pro-apoptotic effects of BAX.  
 
Figure 1-3 Schematic diagram of the main signalling pathways 
activated by BCR-ABL in CML cells 
In normal HSCs, these pathways are normally activated by cytokines, 
promoting survival, differentiation and proliferation. In the absence of 
growth factors, BCR-ABL can bypass this requirement activating these 
pathways and prolonging survival by inhibiting apoptosis. The 
phosphorylation of substrates such as CrkL activates many pathways that 
regulate cell proliferation and promote cell survival. Indeed, the constitutive 
phosphorylation of CrkL may be used as a surrogate marker of BCR-ABL 
activity in the laboratory. Phosphorylation of AKT leads to cell survival. The 
phosphorylation of IκK results in the phosphorylation and degradation of 
IκB, releasing NF-κB to translocate to the nucleus where it can exert its 
anti-apoptotic and proliferative effect. Similarly BAD is phosphoryated to 
allow BCLXL to bind to BAX, neutralising its pro-apoptotic effect. BCR-ABL 
also stabilises RAS in the active form, activating the RAF-MEK-ERK 
cascade pathway, resulting in transcriptional regulation.  
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Autophosphorylation of the BCR-ABL oncogene also leads to the constitutive 
activation of the RAS pathway via interaction with the small adapter protein GRB2 
(Ma et al. 1997). RAS are a group of guanine nucleotide proteins (G-proteins) that 
can transduce external signals to transcription factors in the nucleus. Activation of 
RAS is achieved by farnesylation of RAS in the cytoplasm. Farnesylated RAS then 
translocates to the cell membrane and interacts with regulatory proteins, 
maintaining a balance between the active and inactive form of RAS. However, the 
association of BCR-ABL with the GRB2/SOS complex (son of sevenless) retains 
RAS in the active form. This results in stimulation of the RAF-MEK-ERK effector 
pathway and subsequent transcriptional control of cell growth, proliferation and 
differentiation (Sawyers et al. 1995).  
Another mechanism that may cause deregulated turnover and anti-apoptotic 
phenotype is BCR-ABL induced growth factor independence, either through 
ligand-independent receptor activation, such as the JAK/STAT (JAK-Janus 
Kinases, STAT-Signal Transducer of Transcription) pathway or autocrine 
production of cytokines. Normally, cytokines such as interleukin-3 (IL-3) activate 
JAK, causing phosphorylation of STAT5 which then translocates to the nucleus 
and upregulates transcription genes such as BCLxL which enhance cell survival, 
proliferation and differentiation (Horita et al. 2000). In the presence of BCR-ABL, 
however, the requirement of cytokines is bypassed such that JAK is activated in 
the absence of exogenous cytokines. In some cases, the constitutive activation of 
STAT5 is not always associated with activation of JAK, but activated via the SRC 
family haemopoietic cell kinase (HcK), hence bypassing the requirement of 
cytokines for translocation and activation of transcription genes (Klejman et al. 
2002). Overall, the pathways activated by BCR-ABL lead to deregulated 
proliferation and are anti-apoptotic. 
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In addition to inducing cytokine independent activation of JAK/STAT5 mediated 
signalling mechanisms, BCR-ABL also activates the autocrine production of 
growth factors. Studies have conclusively confirmed an autocrine loop for IL-3, 
granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-
colony stimulating factor (GM-CSF), in mouse BM cells transduced with bcr-abl 
expressing retroviral vectors (Zhang and Ren 1998; Abolhoda et al. 1999) and in 
primitive human CML cells (Jiang et al. 1999), which in turn maintained cell 
survival and proliferation (Strife et al. 1988; Bedi et al. 1994; Maguer-Satta et al. 
1998; Jiang et al. 1999; Fu et al. 2000; Jiang et al. 2002). The specific activation of 
IL-3 production following BCR-ABL transduction suggested that control of IL-3 
expression was a direct consequence of BCR-ABL activation, as cells with an 
inactive BCR-ABL kinase did not express IL-3 (Anderson and Mladenovic 1996) 
and, further downstream, increased STAT5 phosphorylation was a direct function 
of IL-3 stimulation (Jiang et al. 1999).  
1.3.2 Historic treatment of CML 
Following the discovery of CML in the 19th century, initial therapeutic treatments 
included administering highly toxic arsenic or performing splenectomy, both of 
which had limited success. Subsequently, the introduction of radiotherapy 
provided a good control of symptoms but did not extend survival. However, this 
remained the standard treatment until the introduction of the oral alkylating agent 
busulphan in the 1950’s, which showed a selective action on haemopoietic tissue 
despite being toxic to germinal epithelium, and the antimetabolite hydroxyurea. 
Neither, however, prevented disease progression. 
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In the 1980’s the use of Interferon α (IFNα) was introduced for the treatment of 
CML. Although it restored normal haematological values in a lower proportion of 
patients compared to those treated with busulphan or hydroxyurea, IFNα was able 
to induce Ph+ reduction in 5-15% cases (Talpaz et al. 1986) and when combined 
with arabinoside (Ara-C), induced a complete haematological response (CHR) of 
66% and major cytogenetic response (MCR) of 41%, with a survival rate of 85.7% 
within three years (Guilhot et al. 1997).  However, this treatment was associated 
with a number of side effects ranging from nausea and diarrhoea to 
thrombocytopenia and the majority of patients had minimal residual disease 
(MRD), which ultimately led to IFNα resistance. 
In addition, allogeneic BM transplantation was introduced at the same time for 
younger patients (<50-55yrs). This procedure has a significant morbidity and 
mortality of between 20-40%, due to the associated graft-versus-host disease and 
frequent infections (Sawyers 1999). Yet post-transplant, there is up to a 70% 
leukaemia-free survival and to date this remains the only curative treatment (Clift 
and Anasetti 1997; Gratwohl et al. 1998). However, due to the nature of the 
transplant and the difficulty in obtaining HLA matched donors only a minority of 
patients are suitable for these transplants. 
1.3.3 Development of a therapeutic drug for CML 
The discovery that the abnormal tyrosine kinase activity of ABL is essential for 
BCR-ABL mediated transformation and pathogenesis of CML made this an ideal 
target for therapeutic intervention. The first demonstration that synthetic inhibitors 
could be engineered to possess selective activity came from the development of a 
series of low molecular weight compounds called tyrphostins (TYRosine 
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PHOSphorylaTion Inhibitors), the most potent of which were able to selectively 
inhibit epidermal growth factor (EGF) cell-dependent proliferation, whilst not 
affecting the EGF-independent proliferation. Further development led to the 
generation of AG 490, the first synthetic compound that could inhibit proliferation in 
vivo and in vitro. Working independently, Ciba-Geigy (now known as Novartis) 
identified the phenylamino-pyrimidine compounds as being selective inhibitors 
against the platelet derived growth factor-receptor (PDGF-R) tyrosine kinase and 
began high throughput screening. The compound CGP57148, later branded as 
STI 571 ((signal transduction inhibitor 571), imatinib mesylate (IM), Glivec®, or 
Gleevec®), emerged as a potent inhibitor of PDGF-R, ABL, ARG and C-KIT 
(Druker et al. 1996; Heinrich et al. 2000; Okuda et al. 2001) (Figure 1-4).  
 
Figure 1-4 Structure of imatinib mesylate (IM) 
 
IM exerts its effect on BCR-ABL by binding to only the highly conserved NH2-
terminal anchor region of the ATP binding pocket of the enzyme, known as the 
“activation loop”, preventing phosphorylation of substrates and inhibiting 
intracellular signals (Figure 1-5). This region controls the catalytic activity of the 
kinase by switching between the active and inactive states. Crystallographic 
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studies show that IM binds to the ATP site only when the activation loop is closed, 
thus stabilizing the inactive state (Schindler et al. 2000). 
 
Figure 1-5 Mechanism of IM 
BCR-ABL requires ATP binding for phosphorylation of substrates and 
subsequent activation of downstream pathways that promote cell survival, 
proliferation and regulation. IM can compete with ATP, binding to the 
inactive state of BCR-ABL, preventing the phosphorylation of substrates 
that would activate intracellular signals. [Subs. - substrate, p- 
phosphorylation] 
 
The efficacy of this compound was validated in myeloid cell lines, demonstrating 
inhibition of cell proliferation and tumour formation (Druker et al. 1996). Colony 
forming cell (CFC) assays of peripheral blood (PB) or BM cells from CML patients 
showed a 92-98% decrease in the number of BCR-ABL colonies formed compared 
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to no inhibition of normal colony formation at 1µM IM. At 10µM, normal BM colony 
formation was inhibited by 15-20%, with substantial loss at very high doses 
(50µM), suggesting that at this dosage there was loss of selectivity causing 
inhibition of other tyrosine kinases. Experimental data with thymidine assays that 
measure proliferation also correlated with CFC assays (Gambacorti-Passerini et 
al. 1997). Murine studies demonstrated inhibition of tumour growth in mice 
inoculated with bcr-abl, with no adverse effects in the control mice, confirming 
efficacy in vivo (Druker et al. 1996) and complete eradication of tumour was 
achieved with continuous administration of IM (le Coutre et al. 1999). 
The high selectivity of this compound at suppressing BCR-ABL cell expansion in 
CML patient samples and eradicating bcr-abl tumours in mice led to its 
introduction to clinical trials. Phase I dose escalating studies were initially carried 
out in CP CML patients who had failed IFNα. Haematological and cytogenetic 
responses were observed in 98% and 53% respectively with side effects including 
nausea, myalgia, oedema and diarrhoea (Druker 2001). Phase II studies 
continued to show efficacy and low toxicity (Atallah et al. 2002), however IM 
resistance in some patients was starting to develop (Ottmann and Hoelzer 2002). 
The success of the above phase I/II trials led to a multicentre phase III, 
randomised study (IRIS, International Randomised study of IFNα plus Ara-C 
versus STI571), comparing IM with IFNα + Ara-C in newly diagnosed CP CML 
patients. Within 18 months the superiority of IM over conventional IFNα treatment 
was evident. A MCR of 87.1% was observed in patients treated with IM, compared 
to 34.7% for those treated with IFNα + Ara-C. Furthermore, complete cytogenetic 
response (CCR) was observed in 76.2% of patients treated with IM versus 14.5% 
in those with IFNα + Ara-C. In addition, fewer patients progressed to AP or BC in 
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the IM group. The efficacy and tolerance quickly resulted in the approval of IM as 
the first line of treatment for patients with newly diagnosed CML in CP (O'Brien et 
al. 2003). 
The study has now reached its sixth year with the most recent cumulative CCR 
and MCR rates at 57% and 67% respectively, and an overall survival rate of 
patients who have received IM as initial therapy of 76%. In addition, there has 
been no increase in rates of serious adverse effects with continued use of IM, 
demonstrating that it is an effective and safe therapy for CP CML patients 
(Hochhaus et al. 2007). 
1.3.4 Molecular resistance 
However, despite the efficacy of IM, molecular resistance has been noted. This is 
generally observed in CML patients at the advanced stage of disease, although it 
has also been seen in CP patients, resulting in IM being less successful (Talpaz et 
al. 2002). Resistance can be described either as primary, defined as failure to 
achieve CHR in 3 months or CCR in 12 months, or acquired, defined as loss of 
established IM response or progression to AP or BC. 
It has been speculated that IM resistance may be either BCR-ABL independent or 
BCR-ABL dependent. Worryingly, BCR-ABL independence would suggest that the 
cells are no longer reliant upon BCR-ABL to drive proliferation, but have acquired 
other oncogenic mutations (Donato et al. 2004). This would mean that kinase 
inhibitors such as IM, that specifically target BCR-ABL, would never be able to kill 
the insensitive stem cell. There is also increasing evidence that SRC family 
kinases may reduce the BCR-ABL dependence of the leukaemic cell, as patients 
who have progressed whilst being treated with IM have an increased SRC kinase 
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activity, while the BCR-ABL transcripts and protein are reduced (Donato et al. 
2003). This has led to the development of new agents that target the SRC kinase 
and inhibit other non-ATP binding sites. 
In contrast, CSC resistance may be dependent upon BCR-ABL. Firstly, it has been 
hypothesised that Ph+ cells have various mechanisms to evade the pro-apoptotic 
effect of IM. These include the development of mutations within the IM binding 
domain (Gorre et al. 2001) with in excess of 40 mutations having been detected so 
far (Branford et al. 2002). These are found within the ATP binding site (P-loop), 
activation loop (A-loop) or the carboxy terminus. Some mutations only confer a 
moderate degree of resistance, however, the mutations that are found in the P-
loop are associated with a poorer outcome (Branford et al. 2002). This is probably 
due to the mutations altering and destabilising the conformation of the ATP-
binding site and restricting the binding of IM (Shah et al. 2002). In addition, the 
single nucleotide substitution of C to T at position 315, resulting in an isoleucine 
residue instead of a threonine remains the most clinically significant due to its 
resistance to high IM concentrations and poor prognosis in CML patients. 
Threonine is vital to IM inhibition as it forms critical hydrogen bonds and the 
replacement with isoleucine results in a steric clash, preventing IM binding (Gorre 
et al. 2001). 
1.3.5 New therapeutic developments 
In order to overcome these therapeutic shortfalls of IM in resistance, the quest for 
superior drugs has led to the assessment of many new antileukaemic agents that 
may be used alone or in combination to circumvent this (Table 1-1). These include 
selective ABL inhibitors, dual SRC/ABL kinase inhibitors and other non-ATP 
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competitive inhibitors. Two agents with promising results to date are nilotinib and 
dasatinib. 
Target Mechanism Agents 
BCR-ABL activity New TKIs - ABL kinase  
                 - ABL and SRC kinase 
Nilotinib, ON012380 
dasatinib, bosutinib 
PD166326 
 
Heat shock protein 90 inhibitors 17-AAG BCR-ABL 
stability Histone deacetylase inhibitors Trichostatin A 
 
BCR-ABL 
localisation 
Nuclear trapping Leptomycin B 
 
 
Aurora kinase inhibitors MK-0457, PHA-739358 
Farnesyl transferase inhibitors 
(FTI) 
Lonafarnib, SCH66336, 
L-744,832 
Induction of apoptosis TRAIL 
PI3-kinase inhibitors Wortmannin, LY294002 
Proteasome inhibitors Bortezomib, PS341 
Protein kinase C Bryostatin 
Alternative 
targets 
Reactive oxygen species Adaphostin 
 
Table 1-1. Summary of antileukaemic agents being evaluated in CML. 
Modified and adapted from (Heaney and Holyoake 2007) 
 
1.3.5.1 Nilotinib (AMN107, Tasigna®) 
In order to eliminate IM resistance, Novartis designed a new inhibitor based on the 
crystal structure of the IM-ABL complex. The result was nilotinib (Figure 1-6), a 
high affinity aminopyrimidine-based ATP competitive inhibitor with approximately 
20x more potency than IM in killing BCR-ABL expressing cell lines (K562). 
Nilotinib can also inhibit the activity of ARG, C-KIT, and PDGF receptor kinases. In 
addition, nilotinib has shown effectiveness against all BCR-ABL mutations except 
for T315I (Manley et al. 2002; Manley et al. 2005). The additional methyl group of 
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isoleucine restricts access to the drug and hence inhibits binding. In addition, 
nilotinib, as with IM, can only bind to the inactive conformation of BCR-ABL. 
 
Figure 1-6 Structure of nilotinib  
 
In a phase I dose-escalation study, IM-resistant CML patients treated with nilotinib 
showed haematological and cytogenetic responses of 92% and 53% respectively 
for CP and 72% and 48% respectively for AP patients, with a favourable safety 
and tolerability profile. Common side effects included myelosuppression, skin rash 
and hyperbilirubinaemia. Yet, in contrast to IM, nilotinib was not associated with 
oedema. Ongoing phase II studies in patients who have failed IM therapy also 
show favourable responses (Kantarjian et al. 2006).  
1.3.5.2 Dasatinib (BMS-354825, Sprycel®) 
In addition to the requirement for more powerful BCR-ABL inhibitors, there has 
been a need to develop agents that can bind to the BCR-ABL complex regardless 
of the conformation status, thus reducing the likelihood of resistance. In addition, 
the development of new generation inhibitors that can simultaneously bind to ABL 
and SRC family kinases has been explored, as the overexpression of SRCs may 
mediate BCR-ABL independent IM resistance and may be associated with the 
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pathogenesis of the disease. One such agent is dasatinib (Figure 1-7), developed 
by Bristol-Myers Squibb. Dasatinib is a highly potent active inhibitor of SRC and 
SRC family kinases which also has inhibition against BCR-ABL, C-KIT, PDGF and 
ephrin receptor tyrosine kinases (Lombardo et al. 2004; Nam et al. 2005; 
Schittenhelm et al. 2006).  Unlike IM and nilotinib, dasatinib can form a complex 
with ABL both in the active and inactive conformation (Lombardo et al. 2004). 
Dasatinib has a 325x greater potency than IM and, like nilotinib, can effectively 
bind to all the mutations except for T315I (O'Hare et al. 2005) (Shah et al. 2004). 
 
Figure 1-7 Structure of dasatinib 
 
A phase I dose escalation study in IM resistant CML patients showed 92.5% of CP 
patients and 70% of AP patients attained haematological response. The common 
side effects included myelosuppression, pericardial effusion and oedema. 
Completed phase II trials also show positive data with a CHR in 90%, instigating 
the accelerated licence approval for use in CML patients in the U.S. and U.K. 
(Talpaz et al. 2006; Guilhot et al. 2007).  
Jordanides Niove, 2008  Chapter 1 41 
1.3.6 Disease persistence 
However, in addition to molecular resistance and despite effective CCR in CP with 
TKIs and other new agents, the majority of patients have persistent detectable 
disease by sensitive RT-PCR assay (Hughes and Branford 2003; Muller et al. 
2003; Branford et al. 2004). Investigations have described two populations of 
primitive leukaemic cells. The first subset undergo cell cycle arrest and 
accumulate in the G0/G1 phase in the presence of anti-proliferative agents, 
including IM (Jorgensen et al. 2005b), which may be encouraged into cell cycle 
with sequential pulsed therapy. The second are a deeply quiescent Ph+ stem cell 
population identified by their in vitro progenitor activity demonstrated by an LTC-IC 
assay and their ability to engraft immunodeficient mice (Holyoake et al. 1999). 
Further studies have demonstrated that these CML LSCs are insensitive to the 
pro-apoptotic effect of IM, even at concentrations 10x higher than those 
achievable in vivo (Holyoake et al. 1999; Graham et al. 2002). Even continued IM 
therapy does not eradicate these cells (Bhatia et al. 2003). In addition, these cells 
are resistant to nilotinib (Jorgensen et al. 2007a) and, although a little more 
responsive, persist in the presence of dasatinib (Copland et al. 2006). 
Furthermore, patients relapse rapidly following discontinuation with IM, further 
confirming that these cells persist. It is likely, therefore, that it is these BCR-ABL 
positive cells within the patient that are responsible for the MRD detected in the 
majority of IM treated patients and may be the cause for relapse at a later date.  
1.3.7 Disease resistance by transport 
One explanation for the failure of the TKIs to effectively eradicate the stem cell 
population is that the drug never reaches a therapeutic intracellular concentration. 
Jordanides Niove, 2008  Chapter 1 42 
This mechanism of drug resistance, termed multidrug resistance (MDR), is a 
common phenomenon and has been attributed to the broad specificity drug efflux 
pumps of the ATP binding cassette (ABC) family. These efflux proteins limit 
tumour kill by reducing the accumulation of cytotoxic agents to below therapeutic 
thresholds, either by limiting uptake, enhancing efflux or affecting membrane lipids 
(Yanovich and Taub 1983). Furthermore, they may alter the distribution within the 
cell and thus limit the exposure of the cytotoxic agents to the target (Kitazono et al. 
1999) and may provide resistance by protecting the tumour cells from multiple 
forms of caspase-dependent apoptosis (Smyth et al. 1998).  
In some cases, resistance may also be associated with progressive BCR-ABL 
gene amplification (Gorre et al. 2001), where multiple copies of the BCR-ABL gene 
can be detected in the interphase nuclei in patients who relapse after initially 
responding to IM. Characterisation by FISH (Fluorescence In Situ Hybridization) 
shows a unique inverted duplicate Ph chromosome with interstitial amplification of 
the BCR-ABL fusion gene, again suggesting that there may be insufficient IM 
present in the leukaemic cell to inhibit the increased level of oncogenic protein. 
1.4 ABC transporters 
The membrane of a living cell is mainly composed of a lipid bilayer that prevents 
the free flow of molecules across the membrane barrier and has transporters that 
actively pump solutes. Drug transporters have been classified into two major 
families: ABC transporters and solute carrier transporters (Choudhuri and 
Klaassen 2006). 
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ABC transporters were given their name in 1992 based on the most characteristic 
feature of this superfamily, namely the ATP binding cassette (Higgins 1992). 
These plasma membrane glycoproteins are present in most cells and mediate the 
transfer of a substrate across the membrane against a concentration gradient, 
using energy derived from ATP hydrolysis. In normal physiology there is uptake of 
substrates, including nutrients and biologically active substances, while toxic 
compounds are actively effluxed from tissues, secretory organs and blood-brain 
barrier, providing an important protective function (Sarkadi et al. 2004). These 
toxic compounds, however, also include specific chemotherapeutic compounds, 
which affect therapeutic intervention by lowering the effective drug concentration 
inside the cell. 
Typically, an ABC transporter is composed of four parts; two hydrophobic 
transmembrane domains (TMD) and two ATP hydrolysing domains, bound by a 
flexible linker region (Figure 1-8). The membrane domains anchor the protein to 
the membrane and form pores that allow the substrate to cross the membrane and 
therefore determine the substrate specificity. The ATP binding domains, also 
known as nucleotide binding domains (NBDs) are located in the cytoplasm and 
provide the energy to transport the substrate across the membrane. Some 
transporters consist of only one membrane integral domain and one NBD; 
however these “half transporters” must form homodimers or heterodimers for 
active function.  
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Figure 1-8 Schematic diagram of an ABC transporter 
An ABC transporter typically consists of two hydrophilic cytosolic nucleotide 
binding domains (NBD) and two transmembrane domains (TMD), each of 
which spans the membrane six times. The binding of ATP at the NBD 
provides energy for transport of substrates across the membrane. Some 
transporters e.g. ABCG2 are half-transporters and composed of only one 
NBD and one TMD. 
 
To date there are in excess of 50 members belonging to the ABC family, 
categorised into seven subfamilies. These are characterised by a high level of 
sequence homology and extensive conservation of the ATP-binding domains 
(Higgins 1995; Gottesman and Ambudkar 2001). Of these, 15 have been shown to 
have involvement in the extrusion of chemotherapeutic compounds, of which 3 
have the greatest influence in malignant cells and account for nearly all of the 
MDR.  
1.4.1 MDR1 (Multidrug resistance 1) 
Initially discovered in 1976 (Juliano and Ling 1976) and most extensively studied, 
MDR1 (also known as p-glycoprotein or p-gp, ABCB1, gp170) was the first ABC 
transporter observed to modulate drug permeability in tumour cells. Located on 
chromosome 7 and encoded by the ABCB1 gene, MDR1 is a 170kD glycoprotein 
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consisting of two 610aa half-transporters joined by a 60aa flexible linker. This 
transporter is normally expressed in the plasma membrane of the HSC 
(Chaudhary and Roninson 1991), colon, small intestine and kidney (Tan et al. 
2000). It may also play a role in the blood-brain (Rao et al. 1999) and placental 
barriers (Smit et al. 1999) by removing toxic substances and protecting vital 
organs. The substrates of MDR1 range in size and chemical structure, yet the 
common denominator is their amphipathic nature, suggesting a mechanism in their 
drug translocation. The hydrophobic parts of the drug allow rapid insertion into the 
inner hemi-leaflet of the cell membrane, but the hydrophilic residues slow the entry 
into the inner-leaflet such that the pump is able to extrude the drug. As such, 
amphipathic anticancer agents are included in the active efflux of substrates, 
including anthracyclines, taxanes, anthracenes, epipodophyllotoxins and vinca 
alkaloids (Bates et al. 2001). 
MDR1 overexpression has been shown in numerous tumour cells, including breast 
cancer (Trock et al. 1997), ovarian cancer (van der Zee et al. 1995), head and 
neck tumours (Ng et al. 1998) and non-Hodgkins lymphoma (Yuen and Sikic 
1994). Furthermore, repeated courses of cytotoxic or radiation therapy may induce 
MDR1 overexpression, hence accounting for the increasing clinical resistance in 
these diseases (Ng et al. 1998). Indeed, the presence of MDR1 is so detrimental 
to patients that those with MDR1 positive tumours have poorer prognoses than 
those with MDR1 negative neoplasms. A meta-analysis of 31 studies of MDR in 
breast cancer observed that patients expressing MDR1 were three times more 
likely to fail chemotherapy than those that were MDR1 negative (Trock et al. 
1997).   
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Some studies have also shown that MDR1 expression is associated with AML 
(Musto et al. 1991; Zhou et al. 1992). Zhou et al studied 126 adult AML samples 
and noted a significantly higher incidence of MDR1 expression in resistant patients 
(60%) in comparison to untreated or relapsing patients (27%). Furthermore, 68% 
of patients positive for MDR1 eventually developed resistance to chemotherapy, in 
comparison to 23% who did not have MDR1 expression.   
In addition, MDR1 has been associated with AML CD34+ blasts. In elderly patients 
with AML, MDR1 was expressed in 71% of cases, 58% of which demonstrated 
functional drug efflux (Leith et al. 1997). In contrast, younger AML patients who 
achieved higher remission and longer overall survival rates only expressed MDR1 
in 35% of cases (Leith et al. 1999). This suggests that the lower frequency of 
MDR1 expression in the younger AML patients may in part explain the greater 
response to chemotherapy and in turn suggest that MDR modulators may benefit 
patients with this disease.  
However, although MDR is present in the CD34+ cell population, when the cells 
were fractionated to determine the role of MDR1 in CD34+38-, the results were 
surprising. Although MDR1 protein was preferentially expressed in the CD34+38- 
population compared to the more mature CD34+38+ BM cells at levels comparable 
to those observed in normal BM, the MDR1 transport was markedly decreased in 
the primitive cells (Raaijmakers et al. 2006). This would therefore suggest that 
MDR1 modulation would not circumvent drug extrusion and may explain the 
relatively poor results in attempting to reverse drug resistance by MDR1 
modulation in clinical trials (Lee et al. 1999; Chauncey et al. 2000; Baer et al. 
2002; Greenberg et al. 2004; van der Holt et al. 2005).  
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However, even in solid tumours such as renal cell cancer and colon cancer, MDR1 
modulation therapy does not show significant response despite relatively high 
MDR1 expression levels, suggesting that there may be other mechanisms 
contributing to drug resistance. This view, combined with studies indicating that 
some cell lines with an absent MDR efflux pump still had a resistant phenotype, 
led to the identification of the second transporter as having a potential role in 
clinical multidrug resistance. 
1.4.2 MRP1 (multidrug resistance-associated protein 1) 
MRP1 (also known as ABCC1) was identified by isolating the overexpressed gene 
in a doxorubicin resistant lung cancer cell line that did not over-express MDR1 
(Cole et al. 1992). The identified gene was located on chromosome 16 and coded 
for a 190kD glycoprotein (Krishnamachary and Center 1993; Evers et al. 1996). 
Subsequent analysis has shown that MRP1 is almost ubiquitously expressed in all 
major tissues and cell types (Burger et al. 1994), with high levels in lung, testis, 
kidney, placenta, skeletal and cardiac muscles. MRP1 is predominately located in 
the basolateral membrane of epithelial cell layers, suggesting a role as a cellular 
defence by preventing the accumulation of toxic compounds in the cells (Evers et 
al. 1996). 
MRP1 functions mainly as a transporter of amphipathic organic anions. 
Leukotriene C4 (LTC4), a potent inflammatory mediator, is the highest affinity 
substrate for MRP1 protein and mrp-/- knockout mice show a reduced response to 
an inflammatory stimulus (Wijnholds et al. 1997). Like MDR1, MRP1 also 
transports hydrophobic substrates and indeed can confer resistance to many of 
the same drugs such as vinca alkaloids, anthracyclines and epipodophyllotoxins. 
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However MRP1 cannot transport these drugs when they are unmodified, but 
requires conjugation or co-transportation of the substrate with the anionic 
tripepetide glutathione (Rappa et al. 1997a). 
As MRP1 is present in virtually all human tissues and most human tumour cell 
lines and samples, it was assumed that MRP1 contributed to drug resistance. In 
cell lines, the drugs most affected by the presence of MRP1 are etoposide, 
vincristine and anthracyclines, yet the evidence in clinical practice is unclear. 
Patients with relapsed AML have higher MRP1 expression levels compared to 
those at diagnosis (Schneider et al. 1995; Zhou et al. 1995). Furthermore, 
simultaneous expression of MRP with MDR1 in AML has shown higher 
daunorubicin and etoposide resistance (Legrand et al. 1999). However, there is no 
correlation between MRP protein expression and clinical response (Filipits et al. 
1997), suggesting that overcoming resistance may require modulation of both 
transporters, and possibly others in addition, to achieve a clinical response. 
1.4.3 ABCG2  
More recently, ABCG2 (also known as BCRP, MXR, ABCP) was identified in the 
highly doxorubicin-resistant breast cancer subline MCF7/AdrVP (Doyle et al. 
1998). ABCG2 is a half transporter and requires dimerisation for efficient 
transmembrane substrate translocation (Allikmets et al. 1998; Ross et al. 1999). It 
is located on chromosome 4 and expressed on the plasma membrane of many 
primitive cell populations, including embryonic stem cells, placenta (Allikmets et al. 
1998), breast (Doyle et al. 1998), liver, muscle (Zhou et al. 2001), gastrointestinal 
tract (Maliepaard et al. 2001) and pancreas (Lechner et al. 2002). In addition, 
there has been evidence that ABCG2 is expressed in HSC. HSCs can be 
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recognised with flow cytometry by their appearance as a SP of cells, based on 
their ability to exclude Hst. Zhou et al (Zhou et al. 2001) observed SP cells from 
mouse and rhesus monkey expressed high levels of abcg2 mRNA. Moreover, the 
most primitive mouse HSC (CD34-) highly expressed abcg2 mRNA, which 
markedly decreased with stem cell differentiation (CD34+). When abcg2 
expression was enforced in BM, the SP population expanded and caused a 
reduction in mature cells, suggesting that ABCG2 may be preventing the cellular 
accumulation of a substrate essential for stem cell differentiation. However, 
knockout mice showed normal haematological parameters with no developmental 
or observable organ defects, indicating that ABCG2 is unlikely to mediate a non-
redundant role in stem cell regulatory mechanisms (Zhou et al. 2003). In addition, 
although a significant decrease of SP cells was observed in BM compared to the 
wild type mice, competitive BM transplants resulted in no significant advantage 
and ABCG2-mediated Hst transport activity can be eliminated without any 
functional defect in steady state haemopoiesis. This suggests that either ABCG2 
functionality is not required for normal stem cell function in mice or that when 
ABCG2 is knocked out, the activity of this transporter may be substituted by other 
transporters (Zhou et al. 2002).  
The only natural substrates of ABCG2 identified so far are porphyrins and 
porphyrin-like compounds (Jonker et al. 2002). Accumulation of porphyrin is 
detrimental to cells as accumulation ultimately leads to cell damaging reactive 
oxygen species and deficient mitochondrial function (Antolin et al. 1994). In 
hypoxic conditions, the survival of progenitor cells was markedly reduced in abcg2 
null mice compared to abcg2+/+, a condition which was reversed by blocking 
heme biosynthesis (Krishnamurthy et al. 2004). Also, accumulation of dietary 
pheophorbide, a chlorophyll-breakdown product, was increased in abcg2 deficient 
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mice, causing a porphyria-like syndrome of photosensitivity (Jonker et al. 2002). 
Similarly, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine 
(PhIP) and protoporphyrin XI are natural substrates (Abbott 2003), suggesting that 
ABCG2 has a physiological role in protecting primitive cells against toxic 
substances in the hypoxic environment.   
As with the other transporters, ABCG2 overexpression has been shown to induce 
resistance to anticancer drugs, including mitoxantrone, topotecan, doxorubicin, 
campothecins, flavopiridol and daunorubicin (Doyle et al. 1998; Maliepaard et al. 
1999; Ross et al. 1999; Kawabata et al. 2001; Komatani et al. 2001; Robey et al. 
2001b). There have also been studies describing elevated levels of ABCG2 in 
malignancies, especially in AML, although the data have been conflicting. Ross et 
al (Ross et al. 2000) showed that 33% of blast cells had a 5 fold increase of 
ABCG2 mRNA by RT-PCR with Sargent et al (Sargent et al. 2001) detecting a 
similar protein expression. Furthermore, ABCG2 expression was elevated in 
patients at time of relapse, in comparison to diagnosis both in adults (van den 
Heuvel-Eibrink et al. 2002) and paediatric AML patients (Steinbach et al. 2002). 
Furthermore, high expression correlated with a poorer outcome despite some 
patients having favourable cytogenetic abnormalities. In other expression studies, 
there has been no association of ABCG2 expression with prognosis, either at 
diagnosis or at relapse (Sargent et al. 2001; van der Kolk et al. 2002; van der Pol 
et al. 2003). The discrepancy may partly be attributed to possible contamination 
from normal HSC. A recent study validated ABCG2 expression in AML and 
determined that 85% of newly diagnosed AML patients had higher level of mRNA 
expression than in BM or PB compared to normal controls, yet the level was below 
that shown to correlate with drug resistance (Abbott et al. 2002). However, flow 
cytometric analysis detected that the increased level was not due to low 
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homogenous expression in every leukaemic cell, but to high expression in a small 
subpopulation which may correlate to the presence of a LSC with a very immature 
surface immunophenotype. This suggested therefore, that although the overall 
mRNA expression level detected in the whole population was below that shown to 
correlate with drug resistance, the relatively high expression in the small 
subpopulation might be above the threshold level required for drug resistance.  
1.4.4 Drug transporters and TKIs 
The advent of IM as a targeted therapeutic drug dramatically improved the 
outcome in patients suffering from CML. Yet molecular resistance leading to 
persistence of the disease led to the role of drug transporters in mediating this 
response being the topic of an increasing amount of study (Figure 1-9). Recent 
reports have shown hOCT1 to actively mediate the transport of IM into the cells 
(Thomas et al. 2004; White et al. 2006). OCT1 (Organic Cation Transporter 1) is a 
member of the solute carrier transporters encoded by the SLC22 gene family. It is 
primarily expressed on the basolateral membrane of kidney, liver, and placenta 
and has been shown to transport cyclic weak bases and a variety of drugs. 
Thomas et al demonstrated that uptake of IM was an active process by comparing 
the concentration of radiolabelled IM at 4oC and 37oC and confirming temperature 
dependence (Thomas et al. 2004). By a process of elimination using a series of 
inhibitors, the OCT identified to be involved was hOCT1 and not hOCT2 or 
hOCT3, suggesting that differential expression of this transporter may be a critical 
determinant of intracellular IM levels. Further expression studies demonstrated 
that hOCT1 mRNA in CML patients was not significantly different to normal BM 
donors. However, patients who remained at least 65% Ph+ after 10 months IM 
treatment had significantly lower hOCT1 expression prior to IM treatment 
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compared to those who achieved a CCR within 12 months (Crossman et al. 
2005a), confirming that hOCT1 mRNA expression may predict a more favourable 
molecular response to IM. In contrast, nilotinib was not shown to be a substrate for 
this transporter, despite being structurally related to IM (White et al. 2006). 
 
Figure 1-9 Intracellular drug concentration by transporters 
In the absence of drug transporters the cellular concentration will be 
equilibrated with the external medium. Influx transporters such as hOCT1 
will actively uptake IM but not nilotinib, against a concentration gradient. 
However, if the TKIs are also substrates of efflux transporters, 
overexpression will reduce the accumulation in the cell. It is the balance of 
the influx and efflux transporters that may mediate resistance to TKI. 
 
In contrast, several reports have identified active efflux by MDR1 as a contributory 
factor to IM resistance. MDR1 was originally highlighted to interact with IM using a 
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calcein extrusion assay. Generally the uptake of calcein is slow in cells that have 
active transporters; however, agents that interact with the proteins inhibit the dye 
extrusion and accelerate the calcein accumulation. The increased uptake 
suggested an interaction with IM, although the assay could not delineate between 
an interaction as a competitive substrate or as a direct inhibitor (Hegedus et al. 
2002). Other studies demonstrated that a cell line overexpressing MDR1 was 
resistant to IM, which was reversed in the presence of MDR1 inhibitors (Mahon et 
al. 2003; Mukai et al. 2003), suggesting that IM is a substrate for this transporter. 
This was further confirmed by a high-performance liquid chromatography-based 
(HPLC) method demonstrating decreased intracellular IM levels in cell lines 
overexpressing MDR1 which was also associated with loss of IM effect on cellular 
proliferation and apoptosis (Illmer et al. 2004). Furthermore, knockdown of MDR1 
in an IM resistant cell line verified sensitivity to IM and reduced CrkL 
phosphorylation (Rumpold et al. 2005). 
However, there have also been reports refuting the role of MDR1 in IM resistance. 
Ferrao et al (Ferrao et al. 2003) demonstrated no significant growth advantage in 
the retrovirally transduced MDR1 cell line, compared to the wild type and 
concluded that MDR1 was not a substrate of IM, while overexpression of BCLXL 
conferred partial protection instead. Furthermore, Zong et al demonstrated no 
difference to IM resistance in cell lines overexpressing MDR1. The lack of effect 
was further demonstrated in mice transplanted with mdr1a/1b null BM that had 
been transduced with a bcr-abl retroviral vector. Both the wild-type and mdr1a/ab 
null mice displayed similar responses to IM, with no change in incidence of 
disease (Zong et al. 2005). Similarly MDR1 expression in BM mononuclear cells 
(MNC) from CML patients did not correlate with response to IM (Carter et al. 
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2001), suggesting that MDR1 does not confer resistance to IM alone and that 
there may be other transporters contributing to the effect.  
Recently, ABCG2 expression has been put forward as a possible mechanism for 
promoting IM resistance, but with conflicting results. In cell lines, Houghton et al 
(Houghton et al. 2004) found IM to be a potent inhibitor of ABCG2 as IM increased 
topotecan accumulation in ABCG2 overexpressing cells. They found IM was not a 
substrate as there was no difference in accumulation of radiolabelled drug in the 
presence or absence of functional ABCG2. In contrast, Burger et al (Burger et al. 
2004) found IM to be a substrate as the accumulation of radiolabelled IM was 
significantly lower in the overexpressing ABCG2 cell lines compared to the wild-
type. Both of these investigations, however, used non-haemopoietic cell lines 
engineered to over-express ABCG2, neither of which represented clinical targets 
for IM. A recent study, however, in ABCG2 knockout mice demonstrated a 2.5 fold 
greater increase in brain penetration of intravenous IM with a greater increase in 
wild-type mice with ABCG2 inhibitors, suggesting ABCG2 influences the 
bioavailability and pharmacokinetics of IM (Breedveld et al. 2005). 
The role of MRP1 with IM has not been studied extensively, although an 
interaction has been confirmed (Hegedus et al. 2002). Mukai et al (Mukai et al. 
2003) have determined that IM is not a substrate for MRP1 in the K562 cell line. 
However, Lange et al (Lange et al. 2003) demonstrated that low levels of MRP1 
are predictive of IM response in BC CML, thereby suggesting IM may be a 
substrate of MRP1.    
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1.4.5 Aims 
The role of these transporters in conferring TKI resistance is still in contention. To 
date, studies demonstrate that the three main active efflux transporters confer 
resistance to many cytotoxic agents and studies have confirmed expression in 
AML cells. However, the role of drug transporters in primary cells from CML and, 
in particular, the immature population that might be responsible for disease 
resistance and persistence has not been demonstrated. Furthermore, MDR1 and 
ABCG2 have been shown to interact with current TKIs, although it has not been 
conclusively confirmed in what capacity. Therefore, this thesis will explore the 
expression and function of the three main drug transporters associated with 
malignancy and determine their effect on the efficacy of the current therapeutic 
TKI agents for CML.  
The experiments described in this thesis aim: 
1. To determine the expression and function of ABCG2, MDR1 and MRP1 in 
CP CML CD34+ cells 
2. To determine whether IM, nilotinib or dasatinib are substrates or inhibitors 
of these drug transporters  
3. To determine whether inhibition of these drug transporters alters the 
intracellular concentration of TKIs  
4. To determine the effect of drug transporter inhibition on the response of 
CML cells to IM, nilotinib and dasatinib 
5. To determine the expression of drug transporters during TKI therapy in vitro  
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6. To identify other transporters in CP CML CD34+ cells that may have an 
effect in the resistance to TKI  
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2 Materials and Methods   
2.1 Materials 
2.1.1 Tissue culture plastics 
Plastics Supplier 
Cryotube Fisher Scientific, Loughborough, UK 
Falcon tubes (FACS) Fred Baker Scientific, Cheshire, UK 
Non-adherent tissue culture dishes 
(35mm) 
Scientific Lab supplies, Coatbridge, 
UK 
Non-adherent tissue culture flasks 
(75cm3) 
Scientific Lab supplies, Coatbridge, 
UK 
Pipette tips Greiner bio one, Gloucestershire, UK 
Plates (24-well) Greiner bio one, Gloucestershire, UK 
Plates (48-well) Greiner bio one, Gloucestershire, UK 
Plates (96-well flat bottomed) Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (25cm3) Greiner bio one, Gloucestershire, UK 
Tissue culture flasks (75cm3) Greiner bio one, Gloucestershire, UK 
Table 2-1 Table of plastics used for tissue culture and suppliers 
 
2.1.2 Tissue culture reagents 
Reagent Supplier 
β-mercaptoethanol Invitrogen, Paisley, UK 
Bovine serum albumin (BSA) Sigma-Aldrich, Dorset, UK 
Bovine serum albumin, Insulin/ 
Transferrin (BIT)  
Stem Cell Technologies, British 
Columbia, Canada 
Colcemid Invitrogen, Paisley, UK 
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Sigma-Aldrich, Dorset, UK 
DNase I (Recombinant human 
DNAse) 
Stem Cell Technologies, British 
Columbia, Canada 
Dulbecco’s phosphate buffered saline 
(w/o Ca2+ and Mg2+) (PBS) 
Invitrogen, Paisley, UK 
Ethanol 100% molecular grade Sigma-Aldrich, Dorset, UK 
Filter mats Perkin Elmer, Buckinghamshire, UK 
Foetal Calf serum (FCS) Invitrogen, Paisley, UK 
GM-CSF RD Systems Inc., California, USA 
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Human serum albumin 4.5% (HSA 
4.5%) 
Scottish National Blood Transfusion 
Service, Edinburgh, UK 
Human serum albumin 20% (HSA 
20%) 
Scottish National Blood Transfusion 
Service, Edinburgh, UK 
Iscove’s modified Dulbecco’s medium 
(IMDM) 
Sigma-Aldrich, Dorset, UK 
L-glutamine 200mM (100x) Invitrogen, Paisley, UK 
Low density lipoprotein (LDL) Sigma-Aldrich, Dorset, UK 
Magnesium Chloride (1.25M) Sigma-Aldrich, Dorset, UK 
Optiphase supermix liquid scintillation 
cocktail 
Perkin Elmer, Buckinghamshire, UK 
Penicillin (5000u)/ streptomycin 
(5mg/ml) solution 
Invitrogen, Paisley, UK 
Recombinant human erythropoietin 
(rHu-Epo) 
Pharmacy, Glasgow Royal Infirmary, 
UK 
Recombinant human Flt-3 ligand (rHu-
Flt-3L) 
Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human G-CSF (rHu-G-
CSF) 
Chugai Pharma, London, UK 
Recombinant human IL-3 (rHu-IL-3)  Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human IL-6 (rHu-IL-6) Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human SCF (rHu-SCF) Stem Cell Technologies, British 
Columbia, Canada 
Recombinant human thrombopoietin 
(rHU-Tpo) 
RD Systems Inc., California, USA 
RPMI 1640 medium (RPMI) Invitrogen, Paisley, UK 
Sodium Azide Sigma-Aldrich, Dorset, UK 
Sterile water (dH20) Baxter Healthcare, Northampton, UK 
Tri-sodium citrate Sigma-Aldrich, Dorset, UK 
Trypan Blue solution (0.4%) Sigma-Aldrich, Dorset, UK 
Wax scintillant Perkin Elmer, Buckinghamshire, UK 
Table 2-2 Table of reagents used for tissue culture and suppliers 
 
2.1.3 Flow cytometry reagents 
FACS reagents Supplier 
Annexin V antibody Becton Dickinson, Oxford, UK 
Annexin V 10x Buffer Becton Dickinson, Oxford, UK 
Anti-mouse IgG2a FITC  Becton Dickinson, Oxford, UK 
Anti-rabbit IgG FITC conjugate  Sigma-Aldrich, Dorset, UK 
Anti-rabbit IgG horseradish 
peroxidase-linked secondary antibody 
Cell signalling, New England Biolabs, 
Hitchin, UK 
Carboxy-fluorescein diacetate 
succinimidyl ester (CFSE) 
Molecular Probes, Eugene, OR 
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FACS flow solution Becton Dickinson, Oxford, UK 
FACS clean solution Becton Dickinson, Oxford, UK 
Fix and Perm® A and B Caltag Laboratories, Silverstone, UK 
Mouse anti-human BXP-21 antibody Alexis Biochemicals, Nottingham, UK  
Mouse anti-human C219 antibody Alexis Biochemicals, Nottingham, UK  
Mouse anti-human glycophorin A 
FITC 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD3 PE antibody Becton Dickinson, Oxford, UK 
Mouse anti-human-CD11b FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD13 PE antibody Becton Dickinson, Oxford, UK 
Mouse anti-human-CD14 PE antibody Becton Dickinson, Oxford, UK 
Mouse anti-human-CD19 PE antibody Becton Dickinson, Oxford, UK 
Mouse anti-human-CD34 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD34 PE antibody Becton Dickinson, Oxford, UK 
Mouse anti-human-CD45 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human-CD61 FITC 
antibody 
Becton Dickinson, Oxford, UK 
Mouse anti-human QCRL-3 antibody Alexis Biochemicals, Nottingham, UK  
Mouse IgG1a FITC Becton Dickinson, Oxford, UK 
Mouse IgG1a PE Becton Dickinson, Oxford, UK 
Propidium Iodide (PI) Sigma-Aldrich, Dorset, UK 
Rabbit anti-human p-CrkL antibody Cell signalling, New England Biolabs, 
Hitchin, UK 
Viaprobe Becton Dickinson, Oxford, UK 
Table 2-3 Table of FACS reagents used and suppliers 
 
2.1.4 Supply of TKIs 
Drugs Supplier 
Dasatinib (BMS-354825, Sprycel®) Kind gift from Dr F. Lee  
Bristol-Myers Squibb, Princeton, NJ 
14C-dasatinib  Kind gift from Dr F. Lee  
Bristol-Myers Squibb, Princeton, NJ 
Imatinib Mesylate (IM, Gleevec®, 
Glivec, STI571) 
Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
14C-IM  Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
Nilotinib (AMN107, Tasigna®) Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
14C-nilotinib   Provided by Dr E. Buchdunger 
Novartis Pharma, Basel, Switzerland 
Table 2-4 Table of drugs tested and suppliers 
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14C-dasatinib (specific activity of 31.9µCi/ml) was stored at -20oC as a stock 
solution of 20.4mM in DMSO. 14C-IM (specific activity of 84µCi/mg) was stored at 
4oC as a stock solution of 100mM in dH20. 14C-nilotinib (specific activity of 
100µCi/mg) was stored at 4oC as a stock solution of 1.34mM in PBS. Dasatinib 
(MW 489) was stored in multiple aliquots at -20oC at a stock solution of 10mg/ml in 
DMSO. IM (MW 590) was stored at 4oC at a stock solution of 100mM in dH20. 
Nilotinib (MW 529.5) was stored at -20oC as a stock solution of 10mM in DMSO.  
2.1.5 Specific substrates and inhibitors of drug transporters 
Substrate Supplier 
3H-Mitoxantrone  Moravek Biochemicals, Brae, CA, USA 
BODIPY-Prazosin   Molecular probes, Eugene, Oregon, 
USA 
Fluo-3 AM Axxora, Nottingham, U.K 
Rhodamine 123 Invitrogen, Paisley, UK 
Table 2-5 Table of substrates tested and suppliers 
 
3H-Mitoxantrone (specific activity 4Ci/mmol), the known ABCG2 substrate, was 
stored at -20oC at a stock solution of 148.17µg/ml in PBS. BODIPY-Prazosin, the 
known ABCG2 substrate, was stored at -20oC at a stock solution of 250µM in 
DMSO and used at a final concentration of 200nM. Fluo-3 AM, the known MRP1 
substrate, was stored at -20oC, diluted with DMSO and used at a final 
concentration of 5µg/ml in DMSO. Rhodamine 123, the known MDR1 substrate, 
was stored at -20oC at a stock solution of 1mg/ml in 100% ethanol and used at a 
final concentration of 0.5µg/ml.  
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Inhibitors Supplier 
Fumitremorgin C (FTC) Axxora, Nottingham, U.K 
PSC 833 Gift from Novartis 
MK571  Axxora, Nottingham, U.K 
Table 2-6 Table of inhibitors tested and suppliers 
 
FTC, the specific ABCG2 inhibitor, was stored at 4oC at a stock solution of 10mM 
in DMSO and used at a final concentration of 10µM. PSC 833, the MDR1 inhibitor, 
was stored at -20oC at a stock solution of 10mM in DMSO and used at a final 
concentration of 5µM. MK571, the specific MRP1 inhibitor, was stored at -20oC at 
a stock solution of 10mM in dH20 and used at a final concentration of 30µM in 
K562 and CML CD34+ cells and 100µM in the transduced MRP cell line (K-MRP). 
2.1.6 Cell lines  
Cells Disease Supplier 
AML3  
(OCI-AML3) 
AML Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA) 
AML3.3 
(OCI-AML3 transfected 
to over-express 
ABCG2) 
AML Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA). 
AML6.2  
(OCI-AML3 transfected 
to over-express 
ABCG2) 
 
AML Donated by Dr B. Sorrentino  
(St Jude Children’s Research 
Hospital, Memphis, USA) 
HL60 APML Donated by Dr J. Mountford  
(Royal Infirmary, Glasgow, UK) 
ATCC® no. CCL-240 
HL60-BCRP  
(HL60 transfected to 
over-express ABCG2) 
AML Donated by Dr J. Mountford  
(Royal Infirmary, Glasgow, UK) 
K562-WT (K-WT) CML BC Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer 
Research, Christie Hospital NHS 
Trust, Manchester, UK) 
ATCC® no. CCL-243 
K562-MDR-GFP (K-
MDR: K562-WT 
CML BC Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer 
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transfected to over-
express MDR1 and 
GFP) 
Research, Christie Hospital NHS 
Trust, Manchester, UK) and 
generated as described (Southgate 
et al. 2006). 
K562-MRP-GFP 
(K-MRP: K562-WT 
transfected to over-
express MRP1 and 
GFP) 
CML BC Donated by Dr L. Fairbairn  
(Paterson Institute for Cancer 
Research, Christie Hospital NHS 
Trust, Manchester, UK) and 
generated as described (Southgate 
et al. 2006). 
Table 2-7 Table of cell lines used and suppliers 
 
2.1.7 Tissue culture media 
2.1.7.1 RPMI/ 10% FCS/ 1% L-glutamine (RPMI medium) 
RPMI 1640 500ml 
FCS 50ml 
L-glutamine (200mM) 5ml 
 
2.1.7.2 Serum-free medium (SFM) 
IMDM   77.4ml       
BIT 20ml 
Penicillin (5000u)/ streptomycin 
(5mg/ml) solution  
1ml 
L-glutamine 1ml  
ß-mercapto-ethanol (200mM) 200µl (400µM) 
LDL (10mg/ml) 400µl (40µg/ml)  
Filter sterilised 
 
2.1.7.3 Serum-free medium supplemented with growth factor cocktail 
medium (5GF) 
 Volume Final concentration 
SFM 10ml  
IL-3 (50µg/ml) 4µl  20ng/ml 
IL-6 (50µg/ml) 4µl  20ng/ml 
Flt-3L (50µg/ml) 20µl  100ng/ml 
G-CSF (20µg/ml) 10µl  20ng/ml 
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SCF (50µg/ml) 20µl  100ng/ml 
 
2.1.7.4 Differentiation media 
 Volume Final concentration 
SFM 10ml  
G-CSF (20µg/ml) 2.5µl  5ng/ml 
IL-3 (50µg/ml) 0.2µl  1ng/ml 
Epo (1000U/ml) 10µl  1U/ml 
rHu-Tpo (5µg/ml) 1µl  5ng/ml 
GM-CSF (10µg/ml) 3µl 30ng/ml 
 
2.1.8 Buffers and solutions 
2.1.8.1 Annexin buffer 
Annexin 10x buffer 1ml 
IMDM 9ml 
  
2.1.8.2 Fix perm wash - PBS/ 1% BSA/ 0.1% Azide 
BSA 10g  
Sodium Azide 1g 
PBS To 1L 
 
2.1.8.3 Freezing solution- for CML samples  
HSA 4.5% 8ml 
DMSO 2ml   
 
2.1.8.4 Freezing solution- for cell lines 
FCS 8ml 
DMSO 2ml 
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2.1.8.5  Lysis buffer -PBS/ 0.2M NaOH/ 1%v/v SDS 
NaOH 8g 
SDS 10g 
PBS To 1L 
 
2.1.8.6 PBS/ 2% FCS (PBS/2%) 
PBS 98ml 
FCS 2ml 
 
2.1.8.7 PBS/ 20% FCS (PBS/20%) 
PBS 80ml 
FCS 20ml 
 
2.1.8.8  PBS buffer- PBS/ 2mM EDTA/ 0.5%v/v HSA  
EDTA 2mM  
HSA 2.5ml  
PBS To 500ml 
 
2.1.8.9 Thawing solution for cryopreserved CD34+ or unmanipulated cell 
aliquots from liquid nitrogen (DAMP)  
 Volume Final concentration 
PBS 418.75ml  
Tri-sodium citrate (0.155M) 53ml 8.2mM 
HSA 20% 25ml 1% 
DNase I (~2500U/vial (1ml) 2ml 10U/ml 
MgCl2 (400x, 1.0M) 1.25ml 2.5mM 
 
2.1.8.10 Wash buffer 
DMEM 90ml 
FCS 10ml 
Table 2-8 Composition of buffers and solutions 
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2.1.9 Primers and probes for RT-PCR 
ABCG2: 
forward (ABCG2F): 5’-TGG CTG TCA TGG CTT CAG TA-3’ 
reverse (ABCG2R): 5’- GCC ACG TGA TTC TTC CAC AA-3’ 
 probe (ABCG2P): 5’-AGC AGG GCA TCG ATC TCT CAC CCT G –3’ 
Actin:   
forward (ACTINF): 5’-CGT GAT GGT GGG CAT GGG TCA G-3’ 
reverse (ACTINR): 5’-CTT AAT GCT ACG CAC GAT TTC C-3’ 
2.2 Cell handling and selection 
2.2.1 Cell lines 
The cell lines were grown in suspension culture in RPMI media. The cells were 
maintained at 10ml in 25cm3 tissue culture flasks and passaged every two days by 
removing ¾ (7.5ml) of the volume and replacing with warm fresh media to 
maintain a density of between 1x105-1x106.  
2.2.2 Normal CD34+ cells 
For qPCR analysis, RNA (1µg aliquots) derived from normal CD34+ cells isolated 
from mobilized PB (mPB), was purchased from Cambrex Bioscience (Wokingham, 
United Kingdom) and Stem cell Technologies UK (Vancouver, Canada) and stored 
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at -80oC. In addition CD34+ cells were obtained from patients with non-stem cell 
haematological malignancies (e.g. non-Hodgkin’s lymphoma or multiple myeloma) 
and were classed as ‘non-CML’ cells and used as comparisons. These cells were 
isolated and selected as for the CML CD34+ counterparts and stored in liquid 
nitrogen. 
2.2.3 Selection of CD34+ cells from CML samples 
All samples were collected with the approval from the Local Research and Ethics 
Committee and with written informed patient consent from patients at diagnosis of 
chronic phase CML. Each sample was determined to be Ph+ by FISH and BCR-
ABL+ by PCR. Cells were collected by leukapheresis prior to any drug treatment. 
Enrichment for CD34+ cells was achieved using the sterile CliniMACS system 
(Miltenyi Biotech, Surrey, UK), which positively selects for CD34+ cells and was 
performed by the stem cell banking unit within the research group. Briefly, micro 
magnetic MACS beads coupled with anti-CD34+ monoclonal antibody (Miltenyi 
Biotec, Germany) were added to the sample, which in turn bound to the sample. 
The sample was then passed through a magnetic field where the target cells were 
retained in the column and the unlabelled cells flushed through and discarded. The 
bound cells were then eluted after removal from the magnetic field, collected and 
stored in cryotubes within the vapour phase of liquid nitrogen until required. 
2.2.4 Freezing cells 
Between 2x106-2x107 CD34+ selected cells and 5x106-1x107 cell-line cells were 
resuspended in the appropriate freezing solution and aliquoted into cryotubes. The 
cryotubes were cooled overnight in a polystyrene box at -80oC to provide a 
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controlled temperature reduction and then transferred to the vapour phase of liquid 
nitrogen for storage.  
2.2.5 Recovering frozen cells 
CML cells were removed from liquid nitrogen and immediately thawed at 37oC in a 
water bath until most of the ice crystals had melted. The cells were then recovered 
by slowly adding 10ml of thawing solution (DAMP) drop-wise over a 20 mins 
period with constant agitation to prevent clumping of the cells. The cells were spun 
at 1,000rpm for 10 mins, the supernatant was poured away and the pellet 
loosened by flicking. The pellet was then washed twice in DAMP and centrifuged, 
then resuspended in 5GF media for counting and cell viability. The CML cells were 
then plated in 35mm non-adherent tissue culture dishes at ~2x106/ml. 
Cell lines were thawed in a 37oC water bath and recovered slowly as above but in 
PBS/2%. The cells were then washed twice more with PBS/2% and resuspended 
in 10ml of RPMI media, then plated in 25cm3 tissue culture flasks. 
2.2.6 Cell counting and viability assessment 
All cell counts were performed on a Hawksley BS.748 improved Neubauer 
counting chamber (Weber Scientific International, West Sussex, UK).  The cells 
were counted using trypan blue exclusion. Trypan Blue was diluted at 1:10 with 
PBS. Ten µl of the diluted solution was then added to 10µl of the cell suspension 
(1:1 dilution). Approximately 15µl of the mixture was transferred to a 
haemocytometer. Cells that have damaged membranes are porous and absorb 
the trypan blue dye, so appear with a distinctive blue colour under the microscope 
where as the cells with an intact membrane do not absorb the dye. Hence, the 
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unstained cells were counted and the remaining stained dead cells were deemed 
non-viable. 
2.3 Flow Cytometry 
Flow Cytometry is a quantitative technique that permits the visualisation of cells by 
multiple parameters using fluorescent emissions. In comparison to 
spectrophotometry, it is capable of measuring fluorescence per cell, hence 
allowing accurate analysis of single cells. All the flow cytometric analyses were 
carried out on a Becton Dickinson FACSCalibur. 
Following antibody staining (section 2.3.1), the cells were visualised with either a 
linear or log scale, as appropriate, on a forward scatter (FSC) vs. side scatter 
(SSC) dot plot. FSC detects cell size whilst SSC determines cytoplasmic 
granularity. The resulting dot plot view allowed the live cells to be distinguished 
from the smaller debris and dead cells (Figure 2-1A). When required, the smaller 
debris and other cell populations were excluded from further analysis by drawing a 
gate around the key live population using the flow cytometry software palette. The 
cells within this graphical boundary formed the basis for all further analysis.   
The cells were then visualised either in a log scale FL1 (FITC) vs. FL2 (PE) dot 
plot or a histogram (Figure 2-1B). Isotype controls were used to determine the 
emission of non-specific binding and these cells were positioned in the first log 
decade of the parameter(s) by altering the voltage settings. Additionally, positive 
controls were required to compensate for spectral overlap between the 
fluorochromes using the compensation settings. This was achieved by subtracting 
as a percentage, the fluorescence observed in the detector that should not emit 
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fluorescence. This allocates the cells in the bottom right hand and top left hand 
corners of the FACS dot plot according to the fluorescent conjugate used (Figure 
2-1C). Once the flow cytometer was optimally compensated, the test samples 
were run and the percentages of the discrete population calculated. At least 
10,000 of viable gated cells were collected in all experiments. 
 
Figure 2-1 Analysis of a flow cytometry plot 
A. A FSC vs. SSC dot plot showing the cellular composition of BM. B. The 
gated cells stained with isotype FITC and PE shown on FL1 vs. FL2 dot 
plot. Using the voltage settings the cells were positioned in the first decade 
of the parameters. C. Uncompensated PE staining (panels 1 and 2) and 
uncompensated FITC staining (panels 3 and 4). D. Compensated PE 
staining with all the cells positioned in the top left corner, within the first 
parameter of FL1 (panel 1), compensated FITC staining with all the cells in 
the bottom right hand corner within the first parameter of FL2 (panel 2), dual 
staining of FITC and PE (panel 3) 
A. B. 
C. 
D. 
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2.3.1 Detection of surface receptors 
Prior to any experiments, all samples were confirmed as ≥97% CD34+ and 
negative for glycophorin A or lymphoid markers (Table 2-9). Briefly, the 
appropriate antibody conjugated to a fluorochrome was added to 1x105 cells at 
1:100 dilution for 20 mins at room temperature, then washed twice in PBS/2% and 
spun at 1000rpm for 10 mins, then resuspended in FACS flow solution.  
In addition live populations were gated using PI by staining at 1µg/ml for 5 mins 
prior to the washing stage of antibody staining to discriminate dead cells. Cells 
with damaged porous membranes absorb PI, which then binds to DNA by 
intercalating between the bases. Hence, unstained cells with impermeable 
membranes were viable and subsequently gated for analysis in the FL3 channel, 
which detects PI. 
Antibody Target cell(s) Dilution 
CD3 T-lymphocytes 1:100 
CD11b Monocytes, granulocytes 1:100 
CD19 B-lymphocytes 1:100 
CD13 Monocytes, granulocytes 1:100 
CD14 Monocytes 1:100 
CD34 Haemopoietic progenitor 1:100 
CD45 Leucocytes 1:100 
CD61 Megakaryocytes 1:100 
Glycophorin A Erythroid cells 1:100 
Table 2-9 Table of surface antibodies used for identification of cell 
populations 
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2.3.2 Detection of intracellular receptors 
2.3.2.1 Detection of intracellular protein 
Using the Fix & Perm® Cell Permeabilisation kit, the cells were permeabilised and 
stained according to the manufacturer’s instructions. Briefly 1x105 cells were 
resuspended in 100µl of fixing reagent (reagent A) from the fix & perm kit and 
incubated for 15 mins. The cells were then washed in 3ml of fix perm wash, 
centrifuged at 1200rpm for 3 mins, blotted, and resuspended in 100µl of 
permeabilising reagent (reagent B) from the kit, with either 1µl (1 in 100 dilution) of 
the primary monoclonal antibody to MDR1 (C219), or MRP1 (QCRL-3), or 0.875µl 
(1 in 125 dilution) of the primary monoclonal antibody to ABCG2 (BXP-21), or the 
equivalent dilution of the isotype control for 1hr. The cells were washed in fix perm 
wash and spun at 1200rpm for 3 mins twice, then resuspended in 100µl of fix perm 
wash with the secondary antibody (anti-mouse IgG2a FITC conjugate, i.e. 0.875µl 
for ABCG2 or 1µl for MDR1 or MRP1) and incubated at room temperature in the 
dark for 30 mins. The cells were again washed twice with fix perm wash and 
analysed by flow cytometry. 
2.3.2.2 CrkL phophorylation by flow cytometry 
There is no specific antibody that is able to detect the activity of BCR-ABL. 
However, it is known that one of the prominent downstream substrates 
constitutively phosphorylated by the BCR-ABL oncoprotein is the 39kD adaptor 
protein CrkL. This protein is the major tyrosyl phoshophoprotein detected in CML 
neutrophils and it has been shown that CrkL phosphorylation is inhibited in a 
concentration dependent manner when CML cells are treated with IM, correlating 
Jordanides Niove, 2008  Chapter 2 72 
with BCR-ABL phosphorylation. The specificity of CrkL phosphorylation to BCR-
ABL may therefore be used to indirectly assess the status of this oncoprotein. 
The rabbit anti-human phospho-CrkL (p-CrkL) antibody used for this assay 
detected endogenous levels of CrkL only when it was phosphorylated at tyrosine 
207, the BCR-ABL phosphorylation site. Measuring the difference in the geometric 
mean (GM) of p-CrkL peaks determined the effect of the treatments on the 
inhibition of BCR-ABL. 
Samples for analysis of p-CrkL levels were prepared by permeabilisation and 
staining using the Fix & Perm® Cell permeabilisation kit as above (section 2.3.2.1), 
but with minor modifications. Following resuspension with 100µl fixing reagent, the 
cells were resuspended in 25µl of permeabilising reagent with 2.5µl of the p-CrkL 
antibody for 1hr. The cells were washed twice and resuspended in 100µl fix perm 
wash with 2µl of the secondary anti-rabbit IgG FITC conjugate and incubated at 
room temperature in the dark for 30 mins. In addition 1x105 HL60 cells were 
treated alongside the test population and used as BCR-ABL negative controls. 
2.3.3 Assessment of apoptosis and necrosis  
For analysis of cell death, cells were incubated with 5µl annexin V-FITC and 10µl 
Viaprobe in 100µl annexin buffer for 15 mins in the dark. The cells were then 
topped with 400µl annexin buffer and read by flow cytometry within the hour to 
identify necrotic (Viaprobe detected in FL-3) and apoptotic (Annexin V detected in 
FL1) cells.  
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2.3.4 Substrate displacement assay 
The activity of drug transporters may be determined by measuring transport of 
specific fluorescent compounds against concentration gradients. Using flow 
cytometry, the GM for each resulting histogram can be used as a measure of 
fluorescence to calculate the efflux values. Cells with an inactive efflux transporter 
will retain the fluorescent compound resulting in a higher fluorescent GM 
compared to cells with an active efflux transporter. Conversely, cells with an active 
transporter will have decreased dye retention. The addition of a competing 
substrate or an inhibitor in these cells would then reduce the efflux of the known 
substrate resulting in an increase in fluorescence and hence confirming active 
efflux. Similarly, if the addition of a test compound, i.e. drug, also increased the 
fluorescence, then it can be assumed that the compound is interacting with the 
protein either as a competitive substrate or inhibitor (Figure 2-2).  
To measure the function of transporters, the assay was based on a previously 
published efflux assay (Robey et al. 2001a), but with minor modifications. 
Approximately 1x106 cells were resuspended in wash buffer ± inhibitor or ± drug 
and incubated in a water bath at 37oC for 15 mins. This provided the opportunity 
for the action of the drug and inhibitors on the transporters to take effect. The 
fluorescent compound was then added and incubated for a further 30 mins at 37oC 
for ABCG2 or 1hr for MDR1 and MRP1 (a final concentration of 200nM BODIPY-
prazosin, 0.5µg/ml Rhodamine or 5µg/ml Fluo-3 AM for ABCG2, MDR1 or MRP1 
respectively). This loading step allowed the cells to take up the fluorescent 
compound and establish uptake and efflux in the cells if present.   
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Figure 2-2 Substrate displacement assay 
Schematic diagram demonstrating the substrate displacement assay. A. 
Cells with an inactive transporter retain the fluorescent substrate (dark 
green), cells with an active transporter efflux the substrate and have low 
fluorescence (light green). The addition of a competing substrate or inhibitor 
at increasing concentrations reduces the efflux and increasingly retains the 
dye (progressively darker green). B. Replacing the known competitive 
substrate or inhibitor with the test compound (i.e. TKI) will determine no 
interaction (i.e. not an inhibitor or a competitive substrate), as shown by plot 
overlaying the active efflux transporter or an interaction with the transporter 
(i.e. an inhibitor or a competitive substrate), as shown by the increased 
fluorescence. 
 
The cells were then washed in ice-cold wash buffer to stop the loading, spun for 
10 mins at 1000rpm, resuspended in 1ml wash buffer +/- drug +/- inhibitor and 
incubated for 60 mins for ABCG2 or 90 mins for MDR1 and MRP1 at 37oC. This 
step allowed the active transporters to efflux the compound and the drug and/or 
A. 
B. 
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inhibitors to maintain their action on the transporters. The action of the 
transporters was then stopped by washing in ice-cold medium and centrifuging at 
1000rpm for 10 mins. The cells were then placed on ice in the dark and analysed 
immediately by flow cytometry. All the dyes can be detected in the FL1 channel. 
Debris was eliminated by gating around the viable cell population on FSC vs. SSC 
dot plot and at least 10,000 viable events were collected.  
2.4 Cellular techniques 
2.4.1 Tracking of CD34+ cells 
2.4.1.1 Carboxy-fluorescein diacetate succinimidyl ester (CFSE) staining 
CFSE is an intracellular fluorescein-based dye that permits the tracking of stem 
cell divisions. This is due to the intensity of the fluorescent stain within a cell 
partitioning equally between the daughter cells with each cell division, thereby 
allowing the identification of every cell division by tracking the decreasing 
brightness. Figure 2-3A shows the intensity of CFSE halving with each cell division 
and Figure 2-3B the subsequent FACS histogram identifying the ‘fingers’, which 
each represent a cell division.  
Following successful thawing and recovery of cells (section 2.2.5) and 
resuspension in PBS/2%, a stock solution of 5mM CFSE (in DMSO) was diluted at 
1 in 10 dilution with PBS/2% and added to 5ml of cells at a final concentration of 
1µM. The cells were then incubated in a water bath at 37oC for exactly 10 mins (as 
the staining is time dependent). The cells were immediately diluted with 10x 
volume of ice-cold PBS/20% in order to stop the staining reaction and the cells 
centrifuged for 10 mins at 1000rpm. The supernatant was discarded and the cells 
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washed in fresh PBS/2%, then resuspended in 5GF at a concentration of 2x106/ml 
and incubated overnight in 35mm non-adherent tissue culture dishes (at 37oC in 
5% CO2) to allow the excess dye to leach out of the cells. 
 
 
Figure 2-3 Tracking a cell with CFSE stain 
A. A schematic diagram of the brightness of the CFSE stain in a cell halving 
in the daughter cells with each division. B. A histogram of a FACS plot 
showing the classic ‘fingers’ pattern with the undivided cells showing the 
highest fluorescence and the intensity halving with each division. A single 
peak can be gated to determine the percentage of cells in the total 
population that have undergone the equivalent number of divisions. 
[U.D=undivided] 
 
2.4.1.2 Cell division tracking with CFSE 
After CFSE staining and overnight incubation, 500µl of cells at 2x105/ml were 
aliquoted into a 48-well plate (1x105 per well). The conditions included TKI alone, 
TKI +/- drug transporter inhibitors, drug transporter inhibitors alone, an untreated 
control, an unstained control (i.e. no CFSE staining) and 100ng/ml colcemid®. The 
plate was then incubated for 72hrs (at 37oC in 5% CO2).  
A. B. 
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Following 72 hrs incubation, each well was resuspended in PBS/2%, counted and 
then stained with the CD34-PE antibody and PI for analysis by flow cytometry. The 
cells treated with colcemid® were used to identify the position of the undivided 
population on the FACS plot and the untreated cells to differentiate the position of 
each division. The region gates were then positioned such that the fluorescence 
intensity was halved with each cell division. The cells unstained for CFSE were 
used to alter the voltage settings and optimally compensate for spectral overlap. 
2.4.1.3 Calculation of cell recovery 
Following 72 hrs treatment, the effect of TKIs on cell survival and proliferation was 
determined. The viable cell population was initially gated in FSC vs. SSC dot plots 
and PI staining eliminated any dead cells. By selecting the cell population (R10) 
(Figure 2-1A) that are also PI negative (R9) (Figure 2-4B) and plotting these on a 
third dot plot, the upper right quadrant (R1) represents the percentage of viable 
cells that are CD34+ (Figure 2-4C). 
A histogram plotting these viable cells (i.e. those in R1 and R9 and R10) identified 
the quiescent population and subsequent division peaks. The undivided region 
was guided by the colcemid® control and the subsequent regions spanning the 
peaks were positioned by halving the GM according to the halving of the CFSE 
fluorescence intensity. The percentage of viable cells that were undivided and 
CD34+ (R2) could then be measured. Similarly, cells that had undergone one 
division, two divisions etc could also be measured (R3, R4, R5 etc) (Figure 2-4D).  
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Figure 2-4 Gates and regions used for calculation of cell recovery 
A. A FSC vs. SSC FACS dot plot gating on the live population (R10). B. A 
FSC vs. FL3 FACS dot plot presenting only the cells in R10. The gate 
eliminated any additional apoptotic or necrotic cells that were positive for PI 
staining (R9). C. A FL1 vs. FL2 FACS dot plot presenting only the cells that 
were in R10 and R9. D. A histogram presenting only the cells that were in 
R10 and R9 and R1. The separate peaks represent cells divisions. Each 
peak may be separated by a separate region. Region 2 (R2) represents 
cells that are undivided, R3 represent cells that have undergone 1 division, 
R4 represent cells that have undergone 2 divisions etc.  
 
The percentages of cells, after 72 hrs treatment, recovered from the starting 
population in each division, were calculated as below. 
 
A. B. C. 
D. 
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The percentage of total viable CD34+ cells recovered in each division was 
calculated by dividing the absolute number of CD34+ cells in a division region by 
the total number of starting cells and then multiplying by 100. 
In addition, the above calculations were repeated for the total number of viable 
cells (i.e. CD34+ and CD34-). This was achieved by expanding the gate in Figure 
2-4C (R1) to encompass the upper right and lower right quadrant.  
 
2.4.2 Long term cell proliferation 
Following successful recovery from frozen and overnight incubation (section 2.2.5) 
500µl of 2x105/ml cells were plated in a 48 well plate and incubated +/-10µM FTC 
in 5GF media. On day 4 and day 7, the wells were split by removing half the media 
from the surface ensuring the cells in the dish that have settled on the well bed 
were not disturbed and replenished with equal amounts of fresh 5GF media +/- 
10µM FTC. The cells were counted and analysed for CD34+ expression by surface 
staining on days 4, 7 and 10. 
2.4.3 Long term cell differentiation 
Following successful recovery from frozen and overnight incubation (section 2.2.5) 
1ml of 2x105/ml cells were added to a 24 well plate and incubated +/-10µM FTC in 
5GF media for 3 days. The cells were then harvested with PBS/2% and spun for 
10 mins at 1000rpm, then resuspended in 4mls of differentiation media and the 
resuspended cells were split into 2 wells. On day 7, the wells were again split at 
1:1 by removing 1ml media from the surface ensuring the cells that have settled on 
the well bed were not disturbed and replaced with 1ml fresh differentiation media. 
Jordanides Niove, 2008  Chapter 2 80 
The cells were then analysed by flow cytometry on day 10 with antibodies against 
surface markers that would be present on differentiated cells.  
2.5 Biochemical techniques 
2.5.1 Determination of cellular drug levels. 
To directly determine the activity of TKIs with regard to drug transporters, specific 
substrates and TKIs may be labelled with radiolabelled isotypes and the cellular 
concentration measured by scintillation counting. An accumulation of radiolabelled 
drugs, in the presence of specific inhibitors, in comparison to the absence of 
inhibitors, would suggest that the drug might be a substrate of the protein. No 
difference in the presence or absence of specific inhibitors however would suggest 
that the drug is not a substrate for the transporter (Figure 2-5A). 
Similarly, adding known substrates with radiolabelled isotypes in the presence of 
TKIs would determine if these drugs are inhibitors of these drug transporters. An 
increase in the level of specific radiolabelled substrates in the presence of a TKI 
would suggest it is an inhibitor of the transporter (Figure 2-5B). 
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Figure 2-5 Radiolabelled assays to determine interaction of TKI 
A. Radiolabelled assay to determine if TKI is a substrate of an efflux 
transporter using parental (WT) and transduced (+ve cell line) cell lines. 
The cellular concentration of TKI increases relative to the increasing TKI 
concentration in the parental cell line (black). Similarly the overexpressing 
cell line with the specific inhibitor will demonstrate similar CPM (green) with 
increasing TKI concentration. A similar degree of CPM in the 
overexpressing cell line in the absence of the specific inhibitor will 
determine that the TKI is not a substrate (panel 1, dashed blue). In contrast 
a reduced accumulation of TKI in the overexpressing cell line in the 
absence of a specific inhibitor will determine that the TKI is a substrate 
(panel 2, dashed blue). B. Radiolabelled assay to determine if TKI is an 
inhibitor of an efflux transporter using parental (WT) and transduced (+ve 
cell line) cell lines. The cellular concentration of substrate increases relative 
to the increasing substrate concentration in the parental cell line (black). 
The overexpressing cell line will have a much reduced accumulation of the 
substrate (green), which will be returned to a concentration similar to the 
parental cell line in the presence of the specific inhibitor (red). A similar 
degree of CPM in the overexpressing cell line with the specific inhibitor 
when it is replaced with the TKI will determine that the TKI is an inhibitor 
(panel 1, dashed blue). In contrast no increase in accumulation in the 
overexpressing cell line in the presence of TKI will determine that the TKI is 
not an inhibitor (panel 2, dashed blue). 
A. 
B. 
WT 
+ve cell line + inhibitor 
+ve cell line + TKI 
WT 
+ve cell line 
+ve cell line + inhibitor  
+ve cell line + TKI 
WT 
+ve cell line + inhibitor 
+ve cell line + TKI 
WT 
+ve cell line 
+ve cell line + inhibitor  
+ve cell line + TKI 
Jordanides Niove, 2008  Chapter 2 82 
2.5.1.1 Standard curve of radiolabelled drug 
To determine the efficiency of the scintillation counter in detecting the isotopes, a 
standard curve measuring the counts per minute (CPM) against increasing 
concentrations of radiolabelled drug were prepared. In the scintillation vials, 500µl 
of radiolabelled drug were added in increasing concentrations with 3ml of 
scintillant fluid, mixed well, and counted on a Microbeta TriLux scintillation counter 
(Perkin Elmer, Wellesley, MA, USA). The results were plotted on Sigma plot 
software and analysed using GraphPad Prism software to provide a standard 
curve, which in turn allowed the interpolation of unknown amounts of drug in cell 
pellets.  
2.5.1.2 Radiolabelled inhibitor assay 
The cells (5x105 cell lines or 1x105 CML CD34+) were resuspended in 500µl wash 
buffer and initially incubated at 37oC for 15 mins +/- inhibitor to allow the action of 
the inhibitor to take effect. Following incubation, 500µl of 14C-IM, 14C-nilotinib or 
14C-dasatinib was added at the desired concentration +/- inhibitor and the cells 
were incubated for a further 1hr to allow loading and effluxing of drug from the 
cells. The cells were then washed three times in ice-cold PBS/2% to stop the 
activity of the protein and spun at 2000rpm for 3 mins. The pellet was then 
resuspended in 100µl dH20, vortexed briefly and 200µl lysis buffer was added and 
incubated for 1hr at 37oC to solubilise the cells and release the drug. The lysed 
cells were then placed in 4ml scintillation vials with 3ml of scintillant Beta phase 
Optimix, mixed well, and the CPM measured by the Microbeta TriLux scintillation 
counter. Each determination was carried out in triplicate within a single 
experiment. 
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2.5.1.3 Radiolabelled substrate assay 
As above, the cells (5x105 cell lines or 1x105 CML CD34+) were resuspended in 
500µl wash buffer and incubated at 37oC for 15 mins +/- inhibitor +/- drug to allow 
the action of the inhibitor and drug to take effect. Following incubation 500µl of 3H-
mitoxantrone was added at the desired concentration +/-drug +/- inhibitor. The 
cells were incubated for a further 1hr to allow loading and effluxing of the specific 
radiolabelled substrate. The cells were then washed three times in ice-cold 
PBS/2% to stop the activity of the protein and spun at 2000rpm for 3 mins. The 
pellet was then resuspended in 100µl dH20, vortexed briefly and 200µl lysis buffer 
was added and incubated for 1hr to solubilise the cells and release the substrate 
from the cells. The lysed cells were then placed in 4ml scintillation vials with 3ml of 
scintillant Beta phase Optimix and the CPM measured by the Microbeta TriLux 
scintillation counter. Each assay was carried out in triplicate. 
2.6 Molecular techniques 
2.6.1 Cell pellets for storage 
Following successful thawing or after drug treatment, cells that were required for 
subsequent RNA extraction were washed twice in PBS and spun at 8,000rpm for 2 
mins. The pellet was then briefly air-dried and snap-frozen in liquid nitrogen for 20 
secs. The resulting pellet was stored at -80oC until further use. 
2.6.2 RNA synthesis  
Total RNA was isolated from pellets using the RNeasy Mini Kit (Qiagen, Crawley, 
United Kingdom) according to the manufacturer’s instructions. The resulting RNA 
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was quantitated using a nanodrop spectrophotometer Nd-1000 (Labtech 
International, East Sussex, UK). An absorbance at 260nm quantified nucleic acid 
and the ratio of 260/280 determined purity (pure RNA ratio is 2.0).  
 
Figure 2-6 Agilent images 
An electropherogram plot of a good quality (A) or degraded (B) RNA and 
ladder (C). The same data represented as a gel image (D). Lane 1 
represents the ladder and lanes 2-6 represent samples. Samples 2 and 3 
show degradation, samples 4 and 5 show good quality RNA, sample 1 
demonstrates a little degradation. 
 
The integrity of the RNA was observed on a DNA600 LabChip kit using the 
Agilent 2100 Bioanalyser (Agilent Technologies, Wokingham, United Kingdom). 
This system allowed rapid separation of fragments according to their size by 
molecular sieving through the microchannels of the well. These fragments were 
detected by fluorescence at the detection point and the data was displayed either 
as a gel like image or an electropherogram plot (Figure 2-6) .The chip was 
prepared for sample loading by spinning a gel dye mix through a spin filter and 
A. B. 
C. D. 
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injected into the loading well of the chip. One µl of denatured sample was loaded 
(each chip can analyse 12 samples in each run) along with an upper and lower 
marker, and a ladder marker. Each run was completed in 30 mins. Two clean 
bands on the gel indicated good quality RNA.  Multiple bands indicated the RNA 
had degraded.  
2.6.3 cDNA synthesis 
RNA that was deemed of good quality was synthesised to cDNA either by the 
Superscript II reverse transcriptase kit and random hexamers (Invitrogen, Paisley, 
U.K) or by the High Capacity cDNA Archive kit (Applied Biosystems, Warrington, 
U.K) according to the manufacturer’s instructions.    
2.6.4 Conventional RT-PCR for analysis of ABCG2 expression 
Diane Gilmour, a colleague from Glasgow Royal Infirmary, Glasgow, carried out all 
the conventional PCR. 
PCR primers (Sigma-Genosys, Haverhill, United Kingdom) for the analysis of 
ABCG2 expression were as described previously (section 2.1.9). The PCR 
conditions used were the following: 94°C for 3 mins, followed by 40 cycles of 94°C 
for 45 secs, 55°C for 30 secs, 72°C for 90 secs, final extension of 72°C for 10 
mins, yielding an amplified product of 202 base pairs (bp).  
Correction for loading of RNA and PCR efficiency was achieved by β-actin, an 
endogenous control gene. The PCR reaction conditions were the following: 94°C 
for 2 mins, followed by 35 cycles of 94°C for 1 mins, 58°C for 45 sec, 72 °C for 1 
mins, final extension of 72°C for 5 mins to yield an amplified product of 500bp. 
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2.6.5 Quantitative RT-PCR for analysis of ABCG2 expression 
Diane Gilmour carried out the real-time PCR for the analysis of ABCG2 expression 
using single primers and probes. 
The mRNA levels of ABCG2 and the endogenous reference gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were measured using the ABI PRISM 
7900HT sequence detector (Applied Biosystems (ABI), Warrington, U.K). The 
ABCG2 PCR products were detected using a probe containing a FAM reporter and 
TAMRA quencher. For the GAPDH reaction VIC replaced FAM. The GAPDH 
mRNA levels were measured using the pre-developed Taqman Assay reagents for 
human GAPDH (Applied Biosystems, Warrington, U.K).  
Two µl of the first strand reaction was used as template and added to 300nM of 
forward and reverse ABCG2 primers and 200nM of probe, made to a total volume 
of 50µl with qPCR Mastermix Plus (Eurogentec, Southampton, UK). Each reaction 
was carried out in triplicate. Samples were run on the ABI PRISM 7900 with the 
following reaction conditions: 50°C for 2 mins, 95°C for 10 mins followed by 40 
cycles of 95°C for 15 sec and 60°C for 1 mins. The relative expression levels of 
ABCG2 were calculated using the validated 2-∆∆CT method to calculate the relative 
expression. 
2.6.6 Quantitative RT-PCR by Taqman Low Density Array 
technology 
The expressions of transporter genes were measured using Taqman Low Density 
Array (TLDA) cards (Applied Biosystems, Warrington, U.K) (Figure 2-7). TLDA 
Jordanides Niove, 2008  Chapter 2 87 
cards are micro fluidic cards that allow 384 reactions to run simultaneously. Each 
well contains custom-made lyophilised primers and probes and are all supplied by 
8 ports in total, with each port delivering mastermix and cDNA to 48 wells in a total 
reaction volume of 2µl. The plate may be designed to detect from a minimum of 12 
genes in quadruplicate, to 384 genes (including 3 endogenous controls) singly.  
 
Figure 2-7 TLDA card 
 
The cDNA required for the Taqman was synthesised from 100ng of RNA and 
prepared to a total volume of 50µl. This was then added in equal volume to the 
Taqman universal master mix (Applied Biosystems, Warrington, U.K) and 100µl 
pipetted into each loading port. The plate was then spun twice at 1200rpm for 
1min, sealed and placed into the ABI PRISM 7900HT real-time PCR system. 
The genes of interest for this project were chosen, ordered and preloaded from a 
database of ~47,000 optimised human, mouse and rat assays 
(http://www.appliedbiosystems.com). The customised TLDA card ordered had 24 
genes in duplicate and included all the available drug transporters, genes for stem 
cells and an array of endogenous controls. The list is in table 2-1. 
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Gene Alternative name(s) Assay ID NCBI gene ref. 
18S  18S N/A 
ABL1  Hs00245443_m1 NM_005157 
ABCB1 MDR1, P-gp Hs00184491_m1 NM_000927 
ACTB β-actin Hs99999903_m1 NM_001101 
ABCC1 ABCC, MRP1 Hs00219905_m1 NM_004996 
ABCC4 MOAT-B, MRP4 Hs00195260_m1 NM_005845 
ABCG2 ABCP, BCRP, MXR Hs00184979_m1 NM_004827 
AKT1 PKB, RAC-α Hs00178289_m1 NM_001014431 
BCR  Hs00244731_m1 NM_004327 
CASP3  Hs00234385_m1 NM_004346 
CD34  Hs00156373_m1 NM_001025109 
CD38  Hs00233552_m1 NM_001775 
GAPDH  Hs99999905_m1 NM_002046 
HIF1A HIF-1α Hs00153153_m1 NM_181054 
PROM1 CD133 Hs00195682_m1 NM_006017 
SLC22A1 OCT1 Hs00427554_m1 NM_003057 
SLC22A2 OCT2 Hs00161893_m1 X98333 
SLC22A3 OCT3 Hs00222691_m1 NM_021977 
SLC22A4 OCTN1 Hs00268200_m1 NM_003059 
SLC22A5 OCTN2 Hs00161895_m1 NM_003060 
SLC22A6 OAT1 Hs00191220_m1 NM_153276 
SLC22A7 OAT2 Hs00198527_m1 NM_153320 
SLC22A8 OAT3 Hs00188599_m1 NM_004254 
SLC22A9 OAT4 Hs00375768_m1 NM_080866 
Table 2-10 A table of genes included on the TLDA card with their 
alternative names, assay ID and NCBI gene reference 
 
2.7 Statistics 
The results are shown as the mean +/- standard error (s.e) values unless 
otherwise stated. Differences between treatments in samples were assessed 
using paired student’s t-test while differences between groups that were not linked 
were assessed using normal student’s t-test. A level of p<0.05 was deemed 
significant.
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3 Results 1- ABCG2 in CML CD34+ cells 
There is a population of persisting stem cells in CML that is likely to be responsible 
for the MRD detected in the majority of IM treated patients (Bhatia et al. 2003) and 
it has been shown that increasing the IM concentration against  CML CD34+ cells 
does not eliminate the primitive quiescent cells in vitro (Graham et al. 2002). It has 
been hypothesised that this may be due to sub optimal intracellular drug 
concentrations, because of the activity of drug resistance proteins, including ABC 
proteins (Hegedus et al. 2002). 
ABCG2 mRNA expression has been observed in normal HSCs and in particular in 
cells in the G0/G1 phase of cell cycle. As described in section 1.1, HSCs can be 
recognised using flow cytometry by their appearance as a small side population 
(SP) of cells, evident by their ability to exclude Hst. This was found to be 
attributable to ABCG2 activity (Zhou et al. 2001), thus identifying ABCG2 as an 
important molecular marker for the SP phenotype and the most primitive stem cell 
associated transporter. 
ABCG2 expression has also been shown in AML, although evidence relating to the 
level and correlation with disease relapse has been conflicting. Elevated levels of 
ABCG2 have been shown to be attributable to a small subpopulation rather than 
the homogeneous expression of the whole population, suggesting ABCG2 
expression is predominantly restricted to LSCs (Abbott et al. 2002). 
However, although ABCG2 is expressed in AML and normal HSCs, it has not been 
previously shown if ABCG2 is expressed on primitive CML CD34+ cells. To date 
there has only been an indication of an unidentified transporter other than MDR1 
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or MRP1 mediating resistance in CML MNCs (Carter et al. 2001). Hence, the 
following studies were designed to:  
1. determine the expression of ABCG2 in CML CD34+ cells 
2. confirm the function of ABCG2 in CML CD34+ cells 
3. identify whether the current TKIs are substrates or inhibitors of ABCG2 
4. ascertain the effect of ABCG2 in the treatment of CML HSCs with TKIs 
3.1 Expression of ABCG2 mRNA  
The expression of ABCG2 was first investigated in CML CD34+ cells using semi-
quantitative RT-PCR. Distinct bands in all the CML samples tested (n=8) were 
shown in Figure 3-1A panel 1, with bands of the same size as that seen in the 
positive controls AML3.3 and AML6.2 (two transduced AML cells expressing 
ABCG2 at low and high levels respectively) and placenta, a naturally high 
expressing tissue. In panel 2, the signals from CML CD34+ cells were shown to be 
stronger compared to normal mPB CD34+ cells, suggesting that CML CD34+ may 
have higher levels of ABCG2. To confirm, the experiment was replicated using 
sensitive Taqman® technology, with single probes and primers, designed 
specifically to isolate and amplify the ABCG2 gene. Human placenta was again 
used as a positive control and GAPDH as the endogenous reference gene. As 
shown in Figure 3-1B, a signal was detected at an earlier cycle in the CML 
samples in comparison to normal PB indicating a higher level of mRNA 
expression.  
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∆CT Normal ∆CT CML 
14.51 11.25 
13.47 12.94 
16.95 12.50 
16.04 13.11 
 11.22 
 14.60 
 11.71 
 
Figure 3-1 Expression of ABCG2 mRNA in CML CD34+ cells 
Expression of ABCG2 mRNA in normal and CML CD34+ cells. A. Semi- 
quantitative PCR assay of cDNA synthesised from mRNA from two 
transduced cell lines, AML3.3 and AML6.2; CD34+ cells from 4 normal 
controls and from 8 CML CD34+ cells. NTC- no template control. All 
samples were positive for β-actin control. Samples 1-4 in left panel were 
included in the set of 1-8 in right panel. B. Taqman amplification plot of 
placenta (n=2 in duplicate), CML and normal samples (n=4 in duplicate). C. 
Mean ∆CT of all CML and normal samples tested by taqman technology. All 
samples were tested in duplicate. 
 
A. 
B. 
C. 
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The advantage of the qPCR over the semi-quantitative PCR is the ability to 
relatively quantify the gene in one sample and compare it to another sample. This 
is independent of the initial amount of starting material as the amount of gene in 
the sample is quantified relative to the amount of endogenous gene present. This 
provides a relative value that may then be used to compare samples and 
accurately determine differing expression. This comparative crossing threshold 
method is achieved by subtracting the endogenous control Ct (cycle number at 
which the curve intersects the threshold) from the target gene Ct (in this case 
ABCG2) to give a ∆Ct (Figure 3-1C). To obtain a comparison between samples, 
the ∆Ct of the calibrator sample (in this case a normal mPB CD34+ sample) is 
calculated and then subtracted from the ∆Ct value of the target sample (CML 
CD34+) to give ∆∆Ct. The resulting number is then used as the power figure in the 
equation 2- ∆∆Ct to give expression levels of normalised ABCG2 in CML CD34+ in 
comparison to the normal samples (Figure 3-2). 
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∆Ct =  Ct [gene] - Ct [endogenous control] 
 
 ∆∆CT= ∆Ct [target sample] - ∆Ct [calibrator sample] 
 
2-∆∆Ct = Expression level of target sample in relation to calibrator 
sample 
RQ-(-2.7) =  6.5 fold greater in target (CML) compared to calibrator (normal) 
 
Figure 3-2 A representative example of the calculation for relative 
quantification 
 
Using the equation above, data from 7 CML and 4 normal samples resulted in 
mean ∆Ct values of 15.2±0.8 and 12.5±0.5 respectively (p<0.01) and a ∆∆Ct of 
2.76. Using the equation 2-∆∆Ct this assay determined that CML CD34+ cells 
expressed 6.8 fold more ABCG2 than their normal counterparts (Figure 3-3). 
Jordanides Niove, 2008  Chapter 3 94 
 
Figure 3-3 Expression of ABCG2 mRNA expression in CML CD34+ cells 
relative to normal CD34+ cells 
Relative quantification (2-∆∆CT) of ABCG2 expression in CML CD34+ cells 
(dark grey fill; n=8 in dupicate) compared to normal CD34+ cells (black fill; 
n=4 in duplicate). 
 
3.2 Expression of ABCG2 protein 
CML samples were also tested for protein expression using the specific antibody 
BXP-21. This antibody has been generated against an N-terminal intracellular 
epitope (Maliepaard et al. 2001) and hence requires permeabilisation of the cell 
membrane in order to access the epitope. The BXP-21 antibody was initially 
optimised by comparing the staining in the HL60 cell line transduced with ABCG2 
(HL60-BCRP), a cell line in which approximately 60% of the cells express ABCG2, 
against a wild type control (HL60-WT) that does not express ABCG2. Serial 
dilutions of the antibody established that a 1:125 dilution of the antibody followed 
by the same dilution of the secondary antibody produced the most distinct peaks 
(Figure 3-4). 
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Figure 3-4 Optimisation and validation of the ABCG2 antibody  BXP-21 
Increasing dilutions of the ABCG2 antibody BXP-21 in HL60 cell line 
transduced to over-express ABCG2 in 60% of the cells (HL60-BCRP). 
Panel 1 represents cells stained with the FITC isotype. Panels 2-6 illustrate 
increasing dilutions of the BXP-21 antibody and resulting percentages. A 
dilution of 1:125 produced the optimal segregation in the two populations. 
 
Following optimisation, the assay was carried out in parental AML3 (ABCG2-ve) 
(Figure 3-5A) and transduced AML6.2 (ABCG2+ve) (Figure 3-5B) cells. A 
significant increase in fluorescence was shown in the transduced cells (AML6.2- 
isotype geometric mean (GM)=4.3 vs. AML6.2-BXP21 GM=12.7) demonstrating 
protein expression.  
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Figure 3-5 Expression of ABCG2 protein in cell lines and CML CD34+ 
cells 
A representative example of ABCG2 protein expression in AML3 (A), 
AML6.2 (B) and CML CD34+ cells (C) with the isotype (black fill) and the 
ABCG2 test antibody BXP21 (white fill). n=4 for cell lines, n=7 for CML 
CD34+ cells. Each sample was run in duplicate and all replicates were 
consistent. 
 
The protein expression of ABCG2 was then measured in 7 CML samples (Figure 
3-5C). The staining was positive in all the samples and staining resulted in 
significantly higher mean fluorescence than the isotype control counterpart 
(isotype GM=3.8±0.2, BXP 21 GM=7.8±0.8, p<0.002). Furthermore, in 5 of the 7 
samples >25% of the cells (range 25.3-79.0%) were positive for ABCG2 staining 
A. 
B. 
C. 
AML3 
AML6.2 
CML 
CD34+ 
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indicating that the increase in fluorescence and subsequent higher GM was not 
due to a small subpopulation of cells but to an expression of the ABCG2 protein by 
more than a quarter of the cells. 
3.3 Function of ABCG2 protein  
It has been previously described that in some cases the level of ABCG2 mRNA 
and/or protein expression may not always correlate with function (Suvannasankha 
et al. 2004). Hence the CML CD34+ cells were tested in a substrate displacement 
assay to confirm that the ABCG2 protein was also functional by tracking a 
fluorescent ABCG2 substrate in the presence or absence of a known inhibitor.  
BODIPY-Prazosin is a fluorescent conjugate of the specific ABCG2 substrate, 
Prazosin (Robey et al. 2001a) that can be detected by flow cytometry and FTC is a 
specific chemosensitising agent isolated from Aspergillus fumigatus (J. Antibiotics 
49:527 (1996), that is a specific inhibitor of ABCG2. The combination of specific 
substrate and inhibitor was used to demonstrate inhibition of functional efflux. This 
assay was first optimised and validated in cell lines before being conducted in 
primary CML samples. 
The substrate displacement assay was optimised in the parental and transduced 
cell lines. It was initially established that an incubation period of 15 mins with FTC 
prior to the addition of BODIPY-Prazosin was required, to allow effective protein 
inhibition. To determine the optimal concentration of BODIPY-Prazosin, serial 
dilutions were then added in the transduced AML6.2 cell line. A concentration of 
200nM BODIPY-Prazosin resulted in maximal efflux, which in turn was maximally 
inhibited by 10µM FTC to a similar degree to that of AML3 (Figure 3-6). The 
significant increase in fluorescence confirmed that ABCG2 was functional in these 
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cell lines and that this assay could be used to examine the function of ABCG2 in 
CML CD34+ cells. 
 
Figure 3-6 Function of ABCG2 protein in cell lines and CD34+ cells  
ABCG2 function by efflux of a known substrate in a cell line model (A), CML 
CD34+ cell (B) and non-CML CD34+ cells (C). A. Unstained cells (black fill), 
AML6.2 and BODIPY/Prazosin (light grey fill), AML3 and BODIPY/Prazosin 
(dark grey fill) and AML6.2 and BODIPY/Prazosin with 10µM FTC (black 
line). B. and C. Unstained cells (black fill), with BODIPY/Prazosin (light grey 
fill), with BODIPY/Prazosin and 10µM FTC (dark grey fill).  
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Six CML patients were tested for function of ABCG2 (Figure 3-6B demonstrates a 
representative example). In order to reduce inter-experimental variation, cells with 
10µM FTC were considered to be maximally loaded with BODIPY-Prazosin and 
classed as the control condition. The mean data from the 6 CML samples 
indicated a significant efflux from the cells in the absence of FTC (54.4±19.3% 
retention in comparison to the control, p=0.04), indicating functional ABCG2 
protein. In contrast, no difference in fluorescence was detected in the non-CML 
samples (n=3), demonstrating no functional ABCG2 in these cells (Figure 3-6C). 
3.4 Interaction of IM with ABCG2 protein 
The substrate displacement assay was repeated as above but this time the 
inhibitor FTC was replaced by the TKI IM. This drug was added at increasing 
concentrations in the parental and transduced cell lines AML3 and AML6.2 to test 
its effect on the ABCG2 protein. The addition of IM resulted in a dose dependent 
decrease in efflux of BODIPY-Prazosin. Furthermore, at >0.5µM IM, a similar 
decrease in reduction was seen to that with 10µM FTC, suggesting that ABCG2 
mediated efflux was inhibited by IM at a clinically achievable dose (Figure 3-7A). 
The substrate displacement assay was then repeated in CML CD34+ cells. The 
efflux of BODIPY-Prazosin in CD34+ cells was inhibited by the addition of 
therapeutic IM concentrations (Figure 3-7C) with 5µM IM resulting in retention 
values of 223.5±66.4%, p=0.03, in comparison to the CD34+ cells with the 
substrate alone (54.4±19.3%, Figure 3-7D). Although appearing to result in more 
retention, the effect observed with IM was statistically similar to that shown with 
FTC and no significant additive effect resulted from the combination of both drugs. 
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In contrast, the addition of IM to non-CML CD34+ cells showed no significant 
retention (Figure 3-7B). 
 
Figure 3-7 Efflux inhibition of an ABCG2 substrate by IM 
Interaction of IM with the protein ABCG2 in cell line AML 6.2 (A), non-CML 
cell (B) and CML cells (C). Unstained cells (black fill), with BODIPY-
Prazosin (light grey fill), with BODIPY-Prazosin and 10µM FTC (dark grey 
fill), with BODIPY-Prazosin and 0.1µM (green line), 0.5µM (pink line) or 
5µM IM (black line), AML6.2 and 10µM FTC (blue line) D. Percentage of 
efflux by ABCG2. Cells with BODIPY-Prazosin and 10µM FTC (dark grey-
fill) were considered to have maximal retention, BODIPY-Prazosin alone 
(light grey-fill) and BODIPY-Prazosin with 5µM IM (white fill); n=6 in 
duplicate, ns=not significant. 
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Non-CML 
CD34+ 
 
CML 
CD34+ 
CML 
CD34+ 
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The interaction of IM with ABCG2 in CML cells suggested that IM may be either 
acting as an inhibitor by blocking the transporter and hence retaining the substrate 
within the cell or, alternatively, behaving as a competitive substrate and being 
preferentially effluxed out of the cell by ABCG2.  
3.5 Assessment of IM as a substrate of ABCG2  
The substrate displacement assay above demonstrated an interaction of IM with 
ABCG2, however, it cannot delineate between reduction of efflux by inhibitory 
activity or as a competitive substrate. Other groups have also investigated the 
effect of IM, but with conflicting results. Houghton et al (Houghton et al. 2004) 
have shown IM to be a potent inhibitor, but not a substrate of ABCG2, where as 
Burger et al (Burger et al. 2004) have observed IM to be a substrate for this 
transporter. The investigations however, were performed in cell lines engineered 
to over-express ABCG2 that were Ph- and therefore not responsive to IM.  
In order to determine the mechanism of IM binding to ABCG2, the cellular 
concentration of radiolabelled IM was determined in AML3 (ABCG2-ve) and 
AML6.2 (ABCG2+ve). A reduction of IM accumulation in the cell line with 
functional ABCG2 protein would suggest that IM is a substrate, while no difference 
would determine that IM is not a substrate. There was no significant reduction of 
14C-IM in AML6.2 in comparison to AML3 indicating that the presence of ABCG2 in 
the transduced cell line did not reduce the drug concentration and suggests that 
IM was not a substrate of ABCG2. The IM in the cell was not altered even with the 
addition of the specific ABCG2 inhibitor FTC; further confirming that IM was not 
effluxed by ABCG2 (Figure 3-8A). 
Jordanides Niove, 2008  Chapter 3 102 
[IM] uM
0 2 4 6 8 10 12
CP
M
0
10000
20000
30000
40000
50000
60000
AML3 
AML3 + FTC 
AML6.2 
AML6.2 + FTC 
[IM] uM
0 2 4 6 8 10 12
CP
M
0
5000
10000
15000
20000
25000
30000
CML
CML + FTC
 
Figure 3-8 Radiolabelled IM in cell lines and CML CD34+ cells 
Cellular concentration of 14C-IM in cell lines (A) and CML CD34+ (B) cells in 
the presence and absence of FTC. A. ABCG2-ve cell line AML3 (red lines, 
circles) and ABCG2+ve cell line AML6.2 (blue lines, triangles) in the 
presence (black symbols) or absence (white symbols) of FTC. B. CML 
CD34+ cells in the presence (black symbols) and absence (white symbols) 
of FTC. All data are mean of duplicate analyses of n=3. 
 
A. 
B. 
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The protocol was then repeated in 3 CML CD34+ cells with 5µM 14C-IM and again 
demonstrated that ABCG2 inhibition by 10µM FTC had no effect on the cellular 
concentration of IM in these cells (Figure 3-8B), confirming that IM was not a 
substrate of ABCG2. 
3.6 Assessment of IM as an inhibitor of ABCG2  
In order to establish whether ABCG2 was an inhibitor of ABCG2, a radiolabelled 
assay was designed using a specific ABCG2 substrate. Radiolabelled 3H-
mitoxantrone was added to the two cell lines AML3 (ABCG2-ve) and AML6.2 
(ABCG2+ve) and the level of 3H-mitoxantrone was assessed in the presence and 
absence of the specific ABCG2 inhibitor, FTC. In AML3 cells, 3H-mitoxantrone 
accumulated in the cell in a dose dependent manner and as expected the cellular 
concentration was significantly reduced in the ABCG2+ve cell line (AML3 vs. 
AML6.2 p<0.001 at 50ng/ml and 100ng/ml). As expected, the addition of 10µM 
FTC, in the ABCG2+ve cell line, restored the concentration of the radiolabelled 
substrate within the cell to that of the ABCG2-ve cells (AML3 vs. AML6.2 + FTC 
p=n/s, AML6.2 vs. AML6.2 + FTC p<0.001 at 50ng/ml and 100ng/ml). When the 
assay was repeated with 5µM IM instead of the specific inhibitor FTC there was a 
similar degree of ABCG2 inhibition, with a similar accumulation of 3H-mitoxantrone 
(AML3 vs. AML6.2 + IM p=n/s, AML6.2 vs. AML6.2 + IM p<0.01 at 50ng/ml, 
p<0.001 at 100ng/ml) (Figure 3-9A) suggesting that IM was an inhibitor of ABCG2.  
Assessment of CML CD34+ cells in this protocol produced a similar pattern. The 
addition of 10µM FTC significantly increased the concentration of mitoxantrone at 
100ng/ml (CML vs. CML + FTC p=0.003). Replacing the inhibitor with 5µM IM 
demonstrated similar retention of the mitoxantrone (CML vs. CML + IM p=0.004 at 
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50ng/ml, p=0.01 at 100ng/ml). This increased accumulation of mitoxantrone by the 
addition of IM confirmed that IM was an inhibitor of ABCG2 (Figure 3-9B). 
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Figure 3-9 Radiolabelled mitoxantrone in cell lines and CML CD34+ 
cells 
Cellular concentration of 3H-mitoxantrone in cell lines (A) and CD34+ (B) 
cells in the presence and absence of FTC or IM. A. ABCG2-ve cell line 
AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) in 
the presence of 10µM FTC (red lines), 5µM IM (blue lines) or alone (black 
lines). B. CML CD34+ cells with mitoxantrone alone (black line), + 10µM 
FTC (red line), + 5µM IM (blue line). All data are mean of duplicate 
analyses of n>3. *=p<0.05 
A. 
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3.7 Cellular concentration of IM 
By plotting increasing concentrations of radiolabelled IM in scintillant against their 
corresponding CPM, a standard curve can be generated. The curve can then be 
extrapolated to predict the cellular IM concentration by generating the equation: 
 ng= -44.21+0.01629*CPM (as calculated by graphpad prism software) 
In CML CD34+ cells, 11899 counts were observed in 5x105 cells with 5µM 14C-IM. 
This equated to a cellular concentration of IM equivalent to 150ng per 5x105 cells 
and represented an uptake of 5.1% of the available 14C-IM in the incubation 
medium.   
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Figure 3-10 Standard curve of radiolabelled IM 
Increasing concentrations of 14C-IM in scintillant plotted against counts per 
minute (CPM)  
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3.8 Assessment of nilotinib interaction with ABCG2  
In addition to the conflicting data in the literature regarding the interaction of IM 
with ABCG2, there had been no studies to date determining the interaction of the 
new generation drugs nilotinib or dasatinib with ABCG2. Therefore, the assay 
using radiolabelled drug was repeated with 14C-nilotinib. As with 14C-IM, no 
significant difference in the cellular level was demonstrated between the two cell 
lines, AML3 and AML6.2. Furthermore, the addition of the specific inhibitor FTC 
did not alter the cellular concentration (Figure 3-11A). This showed that the 
presence of ABCG2 protein did not reduce the drug concentration, suggesting that 
nilotinib was not a substrate of ABCG2.  
Replacing the cell lines with primary CML cells replicated the cell line results with 
no difference in cellular nilotinib concentration, confirming that, like IM, nilotinib 
was not a substrate of ABCG2 (Figure 3-11B).  
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Figure 3-11 Radiolabelled nilotinib in cell lines and CML CD34+ cells 
Cellular concentration of 14C-nilotinib in cell lines (A) and CML CD34+ (B) 
cells in the presence and absence of FTC. A.  ABCG2-ve cell line AML3 
(red lines, circles) and ABCG2+ve cell line AML6.2 (blue lines, triangles) in 
the presence (black symbols) and absence (white symbols) of FTC. B. CML 
CD34+ cells in the presence (black symbols) and absence (white symbols) 
of FTC. All data are mean of duplicate analyses of n=3. 
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To test whether nilotinib is an inhibitor of ABCG2 the assay with 3H-mitoxantrone 
was performed. As previously demonstrated, the cellular concentration in the 
ABCG2+ve cell line was significantly reduced (AML3 vs. AML6.2 p<0.05 at 
50ng/ml and 100ng/ml). Furthermore, the addition of 10µM FTC not only restored 
the cellular accumulation but also significantly increased the retention of 
mitoxantrone in relation to the ABCG2-ve cell line (AML6.2 vs. AML6.2 + FTC 
p<0.001 at 50ng/ml and 100ng/ml), although this was not significantly different to 
AML3 (AML3 vs. AML6.2 + FTC p=ns). Replacing FTC with 5µM nilotinib also 
resulted in a significant mitoxantrone accumulation (AML6.2 vs. AML6.2 + nilotinib 
p<0.05 at 50ng/ml, p<0.001 at 100ng/ml) suggesting that nilotinib was acting as an 
inhibitor (Figure 3-12A). 
Replacing the cell lines with primary CML cells replicated the pattern generated by 
the cell lines with significant accumulation by the addition of nilotinib compared to 
CML alone (p=0.04 at 100ng/ml). This confirmed, that, like IM, nilotinib was not a 
substrate of, but an inhibitor for ABCG2 (Figure 3-12B). 
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Figure 3-12 Radiolabelled mitoxantrone in cell lines and CML CD34+ 
cells 
Cellular concentration of 3H-mitoxantrone in cell lines (A) and CD34+ (B) 
cells in the presence and absence of FTC or nilotinib. A.  ABCG2-ve cell 
line AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) 
in the presence of 10µM FTC (red lines), 5µM nilotinib (blue lines) or alone 
(black lines). B. CML CD34+ cells with mitoxantrone alone (black line), + 
10µM FTC (red line), + 5µM nilotinib (blue line). All data are mean of 
duplicate analyses of n=3. *=p<0.05 
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3.9 Cellular concentration of nilotinib 
Increasing concentrations of radiolabelled nilotinib were plotted against their 
corresponding CPM, to generate a standard curve. The curve was then 
extrapolated to predict the cellular nilotinib by the equation: 
 ng= 15.56+0.005711*CPM (as calculated by graphpad prism software) 
In CML CD34+ cells, 5629 counts were observed in 5x105 cells with 5µM 14C-
nilotinib, equating to a cellular concentration of 48ng per 5x105 cells, representing 
an uptake of 1.8% of the available 14C-nilotinib in the incubation medium.   
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Figure 3-13 Standard curve of radiolabelled nilotinib 
Increasing concentrations of 14C-nilotinib in scintillant alone plotted against 
counts per minute (CPM) 
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3.10 Assessment of dasatinib interaction with ABCG2 
The assay using radiolabelled drug was repeated with 14C-dasatinib. However, 
unlike nilotinib and IM, when the ABCG2+ve cell line was incubated with 14C-
dasatinib, the level accumulated in the cells was significantly lower (p<0.001 at 
150nM, 300nM and 600nM) in comparison to the ABCG2-ve cell line. Furthermore, 
the addition of 10µM FTC to the ABCG2+ve cell line restored the level of 
radiolabelled drug in the cell to a similar level to the ABCG2-ve cell line (AML6.2 
vs. AML6.2+ FTC p<0.001 at 150nM, 300nM and 600nM, AML6.2 + FTC vs. AML3 
p=ns) (Figure 3-14). This suggested that dasatinib was effluxed from the cell via 
ABCG2, suggesting that it was a substrate, and the blocking of this transporter by 
the specific inhibitor restored the cellular drug level to that of the cell line with no 
ABCG2 (AML3-ve). 
The experiment was also attempted in CML CD34+. However, the specific activity 
of the radiolabelled drug was too low to produce statistically significant CPM 
values in this assay. In addition, combination of the small number of cells available 
at each concentration for this assay (only 1x105 per data point for CD34+ CML 
cells in comparison to 5x105 per vial for cell lines) and the low concentration of 
drug required (nM for dasatinib in comparison to µM for IM and nilotinib) meant 
that the CPM accrued were not enough to distinguish from the background level 
and determine efflux activity.  
The above assay in cell lines suggested that dasatinib was a substrate of ABCG2. 
However, to confirm this speculation the assay was repeated with 3H-mitoxantrone 
in the presence and absence of 150nM dasatinib to determine whether it is an 
inhibitor.  
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Figure 3-14 Radiolabelled dasatinib in cell lines 
Cellular concentration of 14C-dasatinib in cell lines in the presence and 
absence of FTC. ABCG2-ve cell line AML3 (red lines, circles) and 
ABCG2+ve cell line AML6.2 (blue lines, triangles) in the presence (black 
symbols) and absence (white symbols) of FTC. All data are mean of 
duplicate analyses of n=3. *p<0.05  
 
As expected, the concentration of 3H-mitoxantrone was significantly reduced in the 
ABCG2+ve cells and only restored to the level similar to ABCG2-ve cells when the 
transporter was inhibited by the addition of 10µM FTC. Replacing the specific 
inhibitor with 150nM dasatinib did not however, have the same effect and indeed 
3H-mitoxantrone in the ABCG2+ve cell line remained significantly reduced and at a 
similar level to the cell line alone (Figure 3-15). This was significantly different to 
the addition of 5µM nilotinib or 5µM IM and suggested that dasatinib does not act 
as an inhibitor of ABCG2.  
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Figure 3-15 Radiolabelled Mitoxantrone in cell lines and CML CD34+ 
cells 
Cellular concentration of 3H-mitoxantrone in cell lines (A) and CD34+ (B) 
cells in the presence and absence of FTC or dasatinib. A.  ABCG2-ve cell 
line AML3 (black symbols) and ABCG2+ve cell line AML6.2 (white symbols) 
in the presence of 10µM FTC (red line), 150nM dasatinib (blue line) or 
alone (black line). B. CML CD34+ cells with mitoxantrone alone (black line), 
+ 10µMFTC (red line), + 150nM dasatinib (blue line). All data are mean of 
duplicate analyses of n=3, ns=not significant 
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When the experiment was repeated in 3 CML CD34+ cells, there was again no 
significant accumulation of 3H-mitoxantrone in the presence of dasatinib, 
confirming that in CML CD34+ cells, dasatinib was not an inhibitor at therapeutic 
concentrations. 
3.11 Effect of ABCG2 inhibition on CML CD34+ cells 
following 72hrs culture 
To ascertain the effect of the aberrant ABCG2 expression in CML, CD34+ cells 
were cultured with TKIs, in the presence and absence of the specific inhibitor FTC, 
to determine if the inhibition of the transporter further enhanced the overall kill with 
dasatinib specifically (apparent substrate for ABCG2), but also with IM and 
nilotinib (not expected if both drugs act as pure inhibitors of ABCG2).  
Consistent with previous reports (Graham et al. 2002; Jorgensen et al. 2005a), 
treatment of CD34+ cells with 5µM IM for 72hrs resulted in a reduction in the total 
number of cells in comparison to the 5GF alone (14.0±3.7 x105 in 5GF alone, 
4.7±1.3 x105 with IM, p=0.04) (Figure 3-16A). Blocking the ABCG2 transporter by 
the addition of 10µM FTC had no effect on the total number of viable cells 
compared to the 5GF alone (13.6±3.3 x105 with FTC, p=ns), indicating that FTC 
alone was not toxic to the cells. This was of importance to confirm since any 
additional differences in the presence of IM would be due to a synergistic or 
additive effect rather than a toxic effect.  
When the cells were cultured in the combination of IM and FTC, an enhanced 
reduction was observed in the total number of cells in comparison to the 5GF 
alone. However, this did not reach statistical significance when compared to IM 
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alone (3.9±1.1 x105 with IM + FTC, p=ns) (Figure 3-16A). This suggested that the 
inhibition of ABCG2 in the absence of IM did not have an effect on CML cells and 
did not significantly enhance the reduction of total cells in combination with IM.   
Similarly, treatment of CD34+ cells with nilotinib for 72hrs resulted in a reduction of 
total number of cells (16.4±2.8x105 in 5GF alone, 5.6±0.7x105 with nilotinib, 
p=0.03). The combination of nilotinib and FTC demonstrated no further reduction 
in the total number of cells in comparison to the nilotinib alone (6±0.6x105 with 
nilotinib and FTC, p=ns), suggesting that, as expected, the co-treatment of IM or 
nilotinib with the ABCG2 inhibitor did not significantly enhance the reduction of 
total cells (Figure 3-16B). 
The treatment of CD34+ cells with dasatinib for 72hrs resulted in a reduction of 
total number of cells (16.4±2.8x105 in 5GF alone, 7.3±1.6x105 with dasatinib, 
p=0.006). Unexpectedly, the combination of dasatinib with FTC did not significantly 
reduce the number of total cells in comparison to dasatinib alone (5.2±0.9x105 with 
dasatinib and FTC, p=ns), indicating that blocking the transporter with FTC does 
not significantly enhance the reduction of total cells by dasatinib, despite this TKI 
being a substrate for this transporter (Figure 3-16C). 
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Figure 3-16 Inhibition of ABCG2 in total viable cells 
Total number of cells remaining following 3 days in culture in the presence 
of FTC and IM n=6 (A), nilotinib n=4 (B), or dasatinib n=4 (C); CD34+ cells 
treated with 5GF alone (ND-black fill), +10µM FTC (dark grey fill), +TKI 
(light grey fill) or combination of 10µM FTC and TKI (white fill). CD34+ cells 
were seeded at 1x105 cells at d0 (dotted line) All data are mean of duplicate 
analysis, *=p<0.05, ns=not significant.  
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3.12 Assessment of q34+ cells following 72hrs culture 
Following 72hrs of culture, the population of cells remaining quiescent was 
assessed for enhanced reduction in the presence of FTC and in combination with 
TKIs. These experiments were performed using CFSE to track cell division, with 
the quiescent population identified on a FACS plot by their maximal bright 
fluorescence that was comparable to the cells treated with colcemid (see section 
2.4.1). The recovered q34+ cells were then calculated as a percentage of the 
starting cell number. The different conditions were plotted relative to the no drug 
control to identify the effect of treatment on the quiescent population. 
There was no significant reduction in the presence of FTC alone (Figure 3-17). 
Similarly the addition of IM, nilotinib or dasatinib did not significantly reduce the 
q34+ population, but accumulated the cells arrested in the G0/G1 phase, although 
this was not significant. These findings correlate with published reports that have 
also reported accumulation of q34+ in the presence of TKIs (Graham et al. 2002; 
Copland et al. 2006; Jorgensen et al. 2007b). The combination of the ABCG2 
inhibitor with any of the TKIs also showed no significant reductions. These results 
therefore suggest that blocking the ABCG2 protein did not enhance the ability of 
the TKIs to target the most primitive quiescent CML stem cells. 
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Figure 3-17 Inhibition of ABCG2 on quiescent CD34+ CML cells 
Percentage of q34+ following 72hrs of culture as a percentage of input cells 
with IM; n=6 (A), nilotinib; n=4 (B) or dasatinib, n=4 (C). No drug control 
(ND, black fill), + FTC (dark grey fill), + TKI alone (light grey fill), + TKI + 
FTC (white bar). All data are mean of duplicate analysis, ns=not significant.  
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3.13 Assessment of CrkL phosphorylation 
To further define the effects of ABCG2 inhibition on the efficiency of TKI to inhibit 
BCR-ABL activity, the phosphorylation of the downstream BCR-ABL substrate 
CrkL was examined at 16 and 72hrs. As previously reported (Hamilton et al. 
2006), at 16hrs, the addition of the TKIs significantly reduced the percentage of p-
CrkL compared to the untreated control (IM- 52.5±11.3%, nilotinib- 46±5.2%, 
dasatinib- 45.4±5.5%, untreated control 100%, p<0.05, Figure 3-18A). At 72hrs 
(Figure 3-18B), the p-CrkL remained significantly reduced with nilotinib 
(62.2±12.2%, p=0.03) and dasatinib (65.1±9.2%, p=0.01), but was not inhibited 
with IM at this time point. These data confirm that these TKIs inhibit the activity of 
BCR-ABL. This was in contrast to FTC, which, as expected, did not significantly 
reduce p-CrkL at either 16hrs (87.8±6.4%, p=ns) or 72hrs (98.3±13.4%, p=ns), 
demonstrating that FTC alone does not inhibit BCR-ABL activity. 
When co-treating CML CD34+ cells with TKIs in combination with FTC, there was 
no further reduction in p-CrkL compared to TKIs alone, at 16hrs (IM 52.5±11.3%, 
vs. IM+ FTC 66±22.7%, nilotinib 46±5.2% vs. nilotinib + FTC 67±23.4%, dasatinib 
45.4±5.5% vs. dasatinib + FTC 48.8±4.7%, p=ns for all combinations) or at 72 hrs 
(p=ns for all combinations), confirming that blocking ABCG2 does not enhance the 
potency of the TKIs (Figure 3-18). 
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Figure 3-18 BCR-ABL inhibition as a measure of percentage p-CrkL in 
CML CD34+ cells 
Percentage of GM p-CrkL remaining relative to no drug control (ND) and in 
the presence (grey fill) or absence (black fill) of FTC at 16hrs (A) or 72hrs 
(B) n=5 for IM, n=6 for nilotinib and dasatinib, *p<0.05 
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3.14 Assessment of apoptosis 
In order to determine the effect of blocking ABCG2 transporter by FTC, CML 
CD34+ cells were stained with annexin and viaprobe to determine early and late 
apoptosis respectively. A significant increase in apoptosis was observed in the 
presence of nilotinib compared to the untreated control (37.7±3% vs. 19.0±4.6%, 
p=0.01). In contrast, the treatment with FTC alone did not significantly increase 
apoptosis (23.3±4.4%), demonstrating that FTC was not toxic to the cells. 
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Figure 3-19 Apoptosis in the presence and absence of FTC 
Percentage of cells undergoing apoptosis following treatment with TKIs in 
the presence (dark grey fill) or absence (black fill) of FTC; *p<0.05; n=3, 
ND-no drug, F-FTC. 
 
The co-treatment of TKIs with FTC did not result in any further increase in 
apoptosis demonstrating that inhibition of ABCG2 does not further enhance the 
apoptotic effect of TKIs. 
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3.15 Effect of ABCG2 inhibition on CD34+ CML cells 
A closer inspection as to the effect of FTC on the cells following a 72hr culture 
period revealed differences in the phenotype of the cells. Whilst FTC alone did not 
reduce the absolute number of cells compared to the 5GF control, nor alter the 
number of qCD34+ cells, treatment resulted in a significant decrease in the 
proportion of CD34+ cells remaining compared to 5GF alone (4.45±0.8x105 in 5GF 
alone, 2.5±0.5 x105 with FTC, p=0.01) and this reduction was of a similar degree 
to that seen with IM alone (1.7±0.3 x105 with IM, FTC vs. IM, p=ns, Figure 3-20).  
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Figure 3-20 Inhibition of ABCG2 in viable CD34+ cells 
Total number of viable CD34+ cells remaining following 72hrs in culture in 
5GF alone (black fill), + 10µM FTC (dark grey fill), + 5µM IM (light grey fill) 
or 5µM IM + 10µM FTC (white fill). CD34+ cells were seeded at 1x105 cells 
at d0 (dotted line) n=6 in duplicate; *=p<0.05; ns=not significant, [ND-no 
drug] 
 
The combination of IM and FTC further reduced the CD34+ cells compared to 
treatment with either IM or FTC alone (1.2±0.3 x105, p=0.04 either drug alone). 
Furthermore, the combination was the only treatment under which the CD34+ cells 
did not significantly increase from the initial cells seeded at d0 of 1x105. Therefore, 
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combining the inhibition of ABCG2 with IM treatment may enhance the ability of IM 
to reduce the CML CD34+ cells. 
3.16 Effect of ABCG2 inhibition on proliferation and 
differentiation of CD34+ cells 
The reduction of CD34+ cells by inhibition of ABCG2 suggested that functional 
ABCG2 might have an effect on survival or differentiation. To validate this, a 
number of experiments were carried out to identify how FTC may target the CD34+ 
cells. CML CD34+ cells (n=4) were cultured in a combination of growth factors 
designed to support differentiation rather than proliferation over a long time period 
and assayed for a range of surface markers to determine if ABCG2 inhibition led to 
altered differentiation. The presence of FTC did not alter the total cell number after 
10 days (Figure 3-21).  
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Figure 3-21 Effect of ABCG2 inhibition on long-term proliferation 
Total cell counts following long-term culture in differentiation media in the 
presence (white symbols) or absence (black symbols) of FTC; n=4 in 
duplicate. 
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Furthermore, there was no significant difference by paired t-test analysis in a 
range of surface markers that are characteristic of differentiating cells in the 
presence or absence of FTC (Figure 3-22), suggesting that the reduction of CD34+ 
cells by the inhibition of ABCG2 was not due to alteration of the number of 
maturing cells in the CML cultures. 
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Figure 3-22 Effect of ABCG2 inhibition on the maturation of CML cells  
The percentage of cells expressing mature surface markers following 
culture in differentiation media including G-CSF, GM-CSF, rHu-Epo, rHu-
Tpo, low IL-3 for 7 days, in the presence (grey fill) or absence (black fill) of 
10µM FTC; n=4 in duplicate.  
 
3.17 Effect of ABCG2 inhibition on CD34+ cells by 
apoptosis 
In section 2-14 (see Figure 3-19), the apoptotic effect of FTC was observed at 
72hrs with no significant difference compared to 5GF alone. The experiment was 
repeated but with additional time points to determine whether apoptosis occurred 
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at an earlier stage compared to the control arm, which may explain the difference 
in CD34+ count.    
CD34+ CML cells (n=3) were cultured in control 5GF media ± FTC and assayed 
with annexin V and viaprobe and analysed periodically. Analysis revealed there 
was no significant difference between the 5GF alone and cells treated with the 
inhibitor FTC throughout the 72hr period (Figure 3-23), suggesting that early 
induction of apoptosis did not account for the reduction of CD34+ cells. 
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Figure 3-23 Assessment of early apoptosis by ABCG2 inhibition 
The percentage of cells undergoing apoptosis in the presence (grey) or 
absence (black) of FTC. All data are mean of n=3 in duplicate. 
 
Jordanides Niove, 2008  Chapter 3 126 
3.18 Effect of ABCG2 inhibition on proliferating CD34+ 
cells 
The effect of FTC in CD34+ cells was examined further in the 72hr cultures using 
the stain CFSE. This allows the cells to be tracked at each division as the CFSE 
intensity within a cell is halved during each division, hence identifying the 
proliferating and non-proliferating cells.  
For this analysis the cells were grouped into 2 categories, ‘non-proliferating’ and 
‘proliferating’. The non-proliferating category included the cells that had not divided 
at all (CFSEmax) and those that had undergone one cycle of replication. The 
rationale for adding the cells that had completed one cycle of replication was 
based on the view that when the drug was added and experiment initiated, the 
cells may all be in different stages of cycle. Some cells may therefore complete the 
division despite the addition of the drug at this stage. Hence, the first opportunity 
for a dividing cell to “see” the drug and arrest would be after division 1. 
As demonstrated in Figure 3-24A, there was no effect of FTC on the total cells 
remaining after culture in either the proliferating or the non-proliferating 
compartment. The data was then reanalysed to include only the cells that had 
CD34+ expression and plotted at each division. The percentage of non-
proliferating CD34+ cells (the undivided cells and those that had undergone 1 
division) were not significantly different in the presence of FTC compared to 5GF 
alone (Figure 3-24B), which matched the cell data shown in Figure 3-24A. 
However, the expansion of CD34+ cells within the proliferating set of cells was 
significantly reduced in the presence of FTC in comparison to growth factor alone 
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(5GF alone vs. FTC, p=0.03), suggesting a reduction in the expression of CD34 by 
cells that are proliferating.  
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Figure 3-24 Effect of ABCG2 inhibition on cell division in CML cells 
following 72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
The number of total cells (A) or CD34+ cells (B) that remain undivided 
(U.D), have divided once (Div 1), twice (Div 2) etc. were calculated using 
the % of cells detected in each division, the cell number and % CD34+ cells 
within each division (see calculation in 2.4.1.3). Cells treated with 5GF 
alone (black fill) compared with cells treated with 10µM FTC alone (grey fill). 
The divisions are grouped as ‘non-proliferating’ (CFSE max and 1 division) 
and ‘proliferating’ (2 or more divisions). All data are mean of duplicate 
analyses of n=4 samples; * p<0.05, ns=not significant. 
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3.19 Summary 
These experiments demonstrate that ABCG2 was not only present in CML CD34+ 
cells, but also that ABCG2 expression was 6.8 fold higher in the leukaemic cells in 
comparison to normal HSCs. In addition, the protein was expressed showing that 
mRNA was translated. Furthermore, the ABCG2 protein was functional in CML 
CD34+ cells as evidenced by the retention of the fluorescent substrate in the 
presence of FTC.  
Replacing FTC with increasing concentrations of IM also reduced the efflux of the 
substrate, with a similar reduction to FTC observed at 5µM IM, indicating an 
interaction with ABCG2. Further analysis with radiolabelled IM and mitoxantrone 
demonstrated that IM was an inhibitor and not a substrate of ABCG2, suggesting 
that the intracellular concentration will not be affected by the aberrant expression 
of ABCG2. The experiments were repeated for the new generation drugs nilotinib 
and dasatinib. Similarly to IM, nilotinib was also shown to be an inhibitor and not a 
substrate of ABCG2. Interestingly, the accumulation of nilotinib in the CML CD34+ 
cells were lower than that observed with IM and this may be explained by the lack 
of OCT1 effect for uptake of nilotinib. Hence in a short tem assay, IM will 
accumulate to higher levels than nilotinib.  
In contrast, inhibiting ABCG2 with FTC increased the intracellular concentration of 
dasatinib. Furthermore, efflux of radiolabelled mitoxantrone was not affected in the 
presence of dasatinib, confirming that dasatinib is a substrate and not an inhibitor 
of ABCG2. These data suggested that inhibition of the ABCG2 transporter may 
increase the intracellular concentration of dasatinib and might enhance the effect 
of dasatinib in reducing the total cells. 
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Following 72hrs culture of CML CD34+ with TKIs and FTC, there was no further 
reduction of total cells in comparison to TKIs alone. This was supported by 
analysis of CrkL phosphorylation, which showed no significant difference in the 
presence or absence of FTC, either at 16 or 72hrs, indicating no additional BCR-
ABL inhibition. Apoptosis analysis confirmed no difference when inhibiting the 
ABCG2 transporter. These results were expected for both IM and nilotinib as they 
were demonstrated to interact as inhibitors of ABCG2. The inhibition by FTC 
therefore, would not increase the cellular concentration and hence not further 
enhance the effect of IM and nilotinib on the leukaemic cells. However, dasatinib 
was observed to be a substrate for ABCG2. Hence it could be postulated that the 
inhibition of ABCG2 by FTC would increase the accumulation of dasatinib within 
the CML CD34+ cells (as occurred in the cell line), predicting an enhanced 
dasatinib effect. Unexpectedly, no difference was observed suggesting two 
possible scenarios. It may be that the drug has reached its maximal effect, such 
that increasing the intracellular concentration will not further inhibit BCR-ABL or 
enhance cell kill. Alternatively, it may also suggest that the maximal intracellular 
concentration required for full inhibition is prevented by active efflux of dasatinib by 
other transporters that are functional on CML CD34+ cells. 
In conclusion, these data suggest that although ABCG2 is over-expressed and 
functional in CML CD34+ cells, inhibition of this protein does not reduce the total 
number of cells with any of the tested TKIs, does not increase apoptosis and does 
further inhibit BCR-ABL, inferring that the aberrant ABCG2 expression does not 
mediate resistance in CML CD34+ cells. 
In addition, although ABCG2 did not mediate CML stem cell resistance to TKIs, 
inhibition by FTC apparently reduced the number of CD34+ cells remaining 
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following 72hrs of culture. Further analysis showed this reduction was not due to 
increased differentiation or apoptosis or reduced proliferation overall, but due to a 
reduction in proliferating cells that expressed the CD34+ phenotype. This suggests 
that inhibition of ABCG2 may have a role in the behaviour of CML CD34+ cells by 
down-regulating the expression of CD34+.  
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4 Results 2- MDR1 in CML CD34+ cells 
The data described in chapter 3 demonstrated that although ABCG2 is over-
expressed and functional in CML CD34+ cells, inhibition of this transporter does 
not reduce the total number of cells in combination with any of the three TKIs 
tested, or increase apoptosis or further inhibit BCR-ABL activity, demonstrating 
that the aberrant ABCG2 expression does not mediate resistance in CML CD34+ 
cells. However, it is well known that ABC transporters are promiscuous and share 
many substrates. Furthermore, recent literature has demonstrated MDR1 to be of 
importance with elevated expression in many tumours and active extrusion of 
chemotherapeutic agents (van der Zee et al. 1995; Trock et al. 1997).  
Several reports have identified active efflux of IM by MDR1 as a contributory factor 
to multidrug resistance. Increased resistance, combined with reduced IM 
accumulation in cell lines (Mahon et al. 2000) and CML cells overexpressing 
MDR1 (Thomas et al. 2004) suggests that IM is a substrate for this transporter. In 
contrast, other studies report no increased sensitivity to IM in mice transplanted 
with mdr1 null BM retrovirally transduced with bcr-abl (Zong et al. 2005).  
At the beginning of the project, only MNC from CML patients had been tested for 
MDR1 expression and no correlation between MDR1 expression and response 
was observed with therapeutic doses of IM (Carter et al. 2001). However CML is a 
stem cell disease, hence to determine the role of MDR1, it was necessary to 
analyse the CD34+ population. The following studies were designed to examine 
the expression of MDR1 in CML HSCs and to identify any interaction of the current 
TKIs with MDR1.  
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4.1 Expression of MDR1 mRNA  
In order to optimise experiments that would determine expression, function and 
the role of MDR1 in the presence of TKIs in CML CD34+, a valid cell line model 
was required. The K562 WT cell line was chosen as a model for transduction as it 
has no MDR1 expression. This cell line, generated and donated by Dr L.Fairbairn, 
was transduced to express the MDR1 gene, producing the K-MDR cell line 
(MDR1+ve).  
The expression of MDR1 in cell lines and CML CD34+ cells was investigated using 
real time qPCR. The Taqman Low Density Array (TLDA) cards consisted of a 
range of targets including the 3 clinically relevant efflux transporters (ABCG2, 
MDR1, MRP1), the clinically relevant influx transporter (SLC22a1/OCT1), an 
additional 8 OCT transporters (SLC22a2-9), and a range of endogenous controls 
(18S, GAPDH, β-actin). The two cell lines K-WT and K-MDR were analysed on the 
TLDA card. As seen in Figure 4-1A, K-WT had no expression of MDR1, whilst the 
K-562 cell line transduced with MDR1 (K-MDR) had a Ct value of 19.9±0.98, 
confirming effective transduction. 
The expression of MDR1 was also investigated in CML CD34+ and normal 
counterparts. Figure 4-1B shows the CML samples consistently expressed MDR1 
mRNA, although the signal was detected at a later cycle than normal samples 
indicating a lower level of mRNA expression. Using GAPDH as the endogenous 
control, 7 CML CD34+ and 11 normal CD34+ samples gave ∆Ct values of 
8.33±0.47 and 5.44±0.24 respectively (p=0.0003) and a ∆∆Ct of 2.89. Using the 
equation 2-∆∆CT to determine relative quantification, this assay determined that 
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CML CD34+ cells expressed 7.41 fold less MDR1 than their normal counterparts 
(Figure 4-1C). 
 
Figure 4-1 Expression of MDR1 mRNA in cell lines and CML CD34+ 
cells  
Expression of MDR1 mRNA. A. Taqman amplification plot of the cell line K-
WT and the transduced cell line K-MDR. B. Taqman amplification plot of 
CML and normal CD34+ cells (n=2 in duplicate). C. Relative quantification 
(2-∆∆CT) of MDR1 expression in CML CD34+ cells (dark grey fill; n=11 in 
duplicate) compared to normal CD34+ cells (black fill; n=7 in duplicate). 
B. 
A. 
C. 
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4.2 Expression of MDR1 protein 
The MDR1 protein was detected using the specific antibody C219. This antibody 
recognises an internal, highly conserved amino acid sequence found on MDR1 
and MDR3 isoforms (Georges et al. 1990). Serial dilutions of the antibody in the 
two cell lines established that a 100x dilution of the antibody followed by the same 
dilution of the secondary antibody produced the most distinct peaks. The assay 
demonstrated protein expression in the transduced cells (K-MDR isotype GM=3.27 
vs. K-MDR-C219 GM=4.89). 
 
Figure 4-2 Expression of MDR1 protein in cell lines and CML CD34+ 
cells 
A representative example of MDR1 protein expression in K-WT (A), K-MDR 
(B) and CML CD34+ cells (C) with the isotype (black fill) and the MDR1 test 
antibody C219 (white fill); n=3 in duplicate, all replicates were consistent. 
A. 
B. 
C. 
K-WT 
K-MDR 
CML 
CD34+ 
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The protein expression was then measured in 3 CML samples. However, the 
staining was undetectable in all 3 samples with no difference to controls (isotype 
GM, 2.96±0.7, C219 GM 2.98±0.4, p=ns). 
4.3 Function of MDR1 protein 
The protein assay suggested that CML CD34+ cells had no detectable MDR1 
protein. However, the apparent absence of expression may be attributable to the 
sensitivity of the assay. Intracellular staining is often less sensitive than assays 
such as Western blotting for protein detection, hence the level in CML CD34+ cells 
may be below the threshold of detection. Indeed, even though the transduced cell 
line K-MDR had high mRNA expression, there was only a small increase in the 
GM in the transduced cell line, suggesting that the assay may be less sensitive. 
For complete analysis of MDR1 in CML, the CD34+ samples were tested for MDR1 
function, which by association will also confirm protein expression.  
The substrate displacement assay was carried out with the fluorescent substrate 
rhodamine 123 and the specific inhibitor PSC 833, a cyclosporin A analog. Initially, 
the assay was validated in the parental and transduced cell lines. In the K-WT cell 
line the addition of rhodamine 123 resulted in maximal retention, which was not 
further increased in the presence of PSC 833 (Figure 4-3A).  
The cell line K-MDR was then tested (Figure 4-3B). The background fluorescence 
observed in the K-MDR cell line isotype control (black fill) was due to the green 
fluorescent protein (GFP) present in the vector, which had been added to confirm 
effective transduction. Two peaks were identified in the isotype control, a large 
peak on the right and a smaller peak within the first decade. The smaller peak 
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accounting for ~20% of the population represent the cells that were not effectively 
transduced with MDR1, as they do not possess the background GFP.   
It was established that the cell line K-MDR effluxed 50ng/ml of rhodamine 123 
resulting in two distinct peaks. The larger peak with the lower fluorescence (left 
peak of light grey fill) represented the cells expressing MDR1. The smaller peak 
with the higher fluorescence, accounting for ~20% of the population, represented 
the cells that do not express MDR1, and were assumed to be the same small 
population as those demonstrated in the isotype control. The efflux of rhodamine 
123 in MDR1 expressing cells was maximally inhibited by 5µM PSC 833, 
confirming that MDR1 was functional in the cell line K-MDR.  
This assay was then repeated in 3 CML patients (Figure 4-3C). As with the 
analysis of ABCG2, cells with the transporter inhibitor 5µM PSC 833 were 
considered to be maximally loaded with rhodamine 123 and classed as the control 
condition. The mean data from 3 CML samples indicated some efflux from the 
cells in the absence of PSC 833, suggesting a low level of functional MDR1 
protein, although the difference observed was not significantly different (Figure 
4-3D). 
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Figure 4-3 Function of MDR1 protein in cell lines and CD34+ cells  
MDR1 function by efflux of a known substrate in K-WT (A), K-MDR (B) and 
CML CD34+ cells (C). Unstained cells (black fill), cells with rhodamine 123 
(light grey fill), cells with rhodamine 123 and 5µM PSC 833 (dark grey fill). 
D. Percentage of efflux by MDR1 in CML CD34+ cells. Rhodamine 123 and 
5µM PSC 833 (dark grey-fill) was considered to have maximal retention, 
rhodamine 123 alone (light grey-fill). R-rhodamine, P-PSC 833, ns=not 
significant.  
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4.4 Interaction of IM with MDR1 by a substrate 
displacement assay 
The substrate displacement assay was repeated by replacing the specific inhibitor 
with IM. This drug was added at increasing concentrations in the two cell lines to 
test its effect on the MDR1 transporter. The addition of IM resulted in a small dose 
dependent decrease in efflux of rhodamine 123 in K-MDR (Figure 4-4A). This 
interaction suggested that IM was acting as a possible weak inhibitor or 
competitive substrate for this transporter.  
 
 
Figure 4-4 Efflux inhibition of a MDR1 substrate by IM  
Interaction of IM with the protein MDR1. A- Cell line K-MDR with rhodamine 
123 (blue fill), with rhodamine and 0.5µM (green line), 1µM (pink line), 
2.5µM (light blue line) or 5µM IM (dark blue line); n=3 in duplicate. B- CML 
CD34+ cells with rhodamine 123 (light grey fill), with rhodamine and 5µM 
PSC 833 (dark grey fill), with rhodamine and 5µM IM (black line); n=3 in 
duplicate. 
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However, when this assay was repeated in CML samples, only 1 of 3 tested 
demonstrated an increase in fluorescence in the presence of IM, suggesting that 
IM was a very weak inhibitor/substrate that did not significantly affect the 
transporter (Figure 4-4B).    
4.5 Assessment of IM as a substrate of MDR1  
The substrate displacement assay above demonstrated some reduction of efflux 
by IM with MDR1 in cell lines and a small reduction in 1 of 3 CML samples. The 
reduction of efflux in the cell lines may be by inhibitory activity or as a competitive 
substrate. In order to test whether IM is a substrate for MDR1, increasing 
concentrations of radiolabelled IM were used to track the cellular retention in K-WT 
(MDR1-ve) and K-MDR (MDR1+ve). There was no significant accumulation of 14C-
IM in K-WT in comparison to K-MDR, indicating that the presence of MDR1 did not 
reduce the drug concentration within the cell and that IM was not a substrate of 
MDR1. Furthermore, 14C-IM did not accumulate in K-MDR cells in the presence of 
the known inhibitor PSC 833, further confirming that IM was not effluxed by MDR1 
(Figure 4-5A). 
The experiment was also repeated in 3 CML samples. Similarly, there was no 
significant increase in IM accumulation in the presence of PSC 833. These results 
suggest, either that IM was not a substrate for this transporter or that the MDR1 
was insufficiently expressed in these cells for the effect to be apparent (Figure 
4-5B).  
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Figure 4-5 Radiolabelled IM in cell lines and CML CD34+ cells 
Cellular concentration of 14C-IM in cell lines (A) and CML CD34+ (B) cells in 
the presence and absence of PSC 833. A. K-WT (MDR1-ve) (red lines, 
circles) and K-MDR (MDR1+ve) cell line (blue lines, triangles) in the 
presence (black symbols) and absence (white symbols) of PSC 833. B. 
CML CD34+ cells in the presence (black symbols) and absence (white 
symbols) of PSC 833. All data are mean of duplicate analyses of n=3. 
A. 
B. 
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4.6 Interaction of nilotinib with MDR1 by a substrate 
displacement assay 
The substrate displacement assay with rhodamine 123 was repeated, this time 
with nilotinib as a potential inhibitor. This drug was again added at increasing 
concentrations in the two cell lines to test its effect on the MDR1 protein. As with 
IM, the addition of nilotinib resulted in a dose dependent decrease in efflux of 
rhodamine 123. However, the decrease in efflux was to a higher degree with 
nilotinib, with 5µM resulting in a reduction of efflux similar to that seen with 5µM 
PSC 833, suggesting that MDR1 mediated efflux was inhibited by nilotinib at a 
clinically achievable dose (Figure 4-6A). This interaction suggested that nilotinib 
was acting as an inhibitor or as a strong competitive substrate for this transporter.  
The assay was repeated using CML CD34+ cells (Figure 4-6B). The low level of 
rhodamine 123 efflux was inhibited by therapeutic nilotinib concentrations, with 
5µM nilotinib resulting in retention values of 70.6±9.8%, in comparison to the 
CD34+ cells with the substrate alone (56.2±11.5%), however this did not reach 
statistical significance (Figure 4-6C). This may be due to the low protein 
expression observed in CML CD34+ cells, resulting in insufficient efflux to 
reproducibly see the inhibition.  
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Figure 4-6 Efflux inhibition of a MDR1 substrate by nilotinib  
Interaction of nilotinib with the protein MDR1. A. Cell line K-MDR with 
rhodamine 123 (blue fill), with rhodamine and 0.5µM (green line), 1µM (pink 
line), 2.5µM (light blue line) or 5µM nilotinib (dark blue line); n=3. B. CML 
CD34+ cells with rhodamine 123 (light grey fill), with rhodamine and 5µM 
PSC 833 (dark grey fill), with rhodamine and 5µM nilotinib (black line); n=3. 
C. Percentage of efflux by rhodamine 123. Rhodamine 123 and 5µM PSC 
833 (dark grey-fill) was considered to have maximal retention, rhodamine 
123 alone (light grey-fill) and rhodamine 123 with 5µM nilotinib (white fill); 
n=3 in duplicate. R-rhodamine, P-PSC 833, ns=not significant.  
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4.7 Assessment of nilotinib as a substrate of MDR1  
The substrate displacement assay above again cannot delineate between 
reduction of efflux by inhibitory activity or competitive substrate. In order to 
establish the interaction of nilotinib with MDR1, increasing concentrations of 
radiolabelled nilotinib were used to track the cellular concentration in K-WT 
(MDR1-ve) and K-MDR (MDR1+ve).  There was no significant accumulation of 
14C-IM in K-WT in comparison to K-MDR, indicating that the presence of MDR1 did 
not reduce the drug concentration within the cell and hence suggesting that 14C- 
nilotinib was not a substrate of MDR1. Similarly, the addition of PSC 833 did not 
alter the cellular accumulation; further confirming that nilotinib was not effluxed by 
MDR1 (Figure 4-7A).  
The intracellular accumulation was also observed in 3 CML CD34+ samples 
(Figure 4-7B). There was no significant accumulation of 14C-nilotinib in the 
presence of the inhibitor PSC 833. The results of this experiment combined with 
the substrate displacement assay suggested that nilotinib was a potent inhibitor, 
and not a substrate of, MDR1. 
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Figure 4-7 Assessment of radiolabelled nilotinib accumulation in the 
presence of MDR1 protein 
Cellular concentration of 14C-nilotinib in cell lines (A) and CML CD34+ (B) 
cells in the presence and absence of PSC 833. A. K-WT (MDR1-ve) (red 
lines, circles) and K-MDR (MDR1+ve) cell lines (blue lines, triangles) in the 
presence (black symbols) and absence (white symbols) of PSC 833. B. 
CML CD34+ cells in the presence (black symbols) and absence (white 
symbols) of PSC 833. All data are mean of duplicate analyses of n=3. 
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4.8 Interaction of dasatinib with K-MDR 
Finally, the substrate displacement assay was repeated in the presence of 
dasatinib. As before, this drug was added at increasing concentrations in the two 
cell lines to test its effect on the MDR1 protein. The addition of dasatinib however, 
resulted in no significant difference between the two cell lines, even at therapeutic 
concentrations, suggesting that dasatinib is not an inhibitor for this transporter 
(Figure 4-8A). 
Similarly, no significant difference was observed in 3 CML CD34+ samples, 
confirming that dasatinib was not an inhibitor of MDR1 in primary cells (Figure 
4-8B). 
 
Figure 4-8 Efflux inhibition of a MDR1 substrate by dasatinib 
Interaction of dasatinib with the protein MDR1. A. Cell line K-MDR with 
rhodamine 123 (blue fill), with rhodamine and 50nM (green line) and 150nM 
(pink line) dasatinib; n=3. B. CML CD34+ cells with rhodamine 123 (light 
grey fill), with rhodamine and 5µM PSC 833 (dark grey fill), with rhodamine 
and 150nM dasatiniib (black line no fill); n=3.  
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4.9 Assessment of dasatinib as a substrate of MDR1  
The substrate displacement assay above demonstrated no interaction of dasatinib 
with MDR1, demonstrating that dasatinib is not an inhibitor. However, to 
conclusively determine whether dasatinib was a substrate, increasing 
concentrations of radiolabelled dasatinib were added to measure the cellular 
retention in K-WT (MDR1-ve) and K-MDR (MDR1+ve), in the presence and 
absence of PSC 833. Although not significant, there was less accumulation of 14C-
dasatinib in the K-MDR transduced cell line compared to the wild type (Figure 4-9). 
However, the concentration of 14C-dasatinib was not restored by the addition of the 
specific MDR1 inhibitor, nor was the accumulation significantly increased. This 
suggested therefore that dasatinib was not a substrate of MDR1.  
However, the significant difference in the two cell lines suggested that there might 
be another transporter that is capable of effluxing this TKI from these cells. Indeed, 
the results from chapter 3 have confirmed that dasatinib was a substrate for 
ABCG2 and hence the reduced accumulation in K-MDR might be due to the action 
of this transporter. Furthermore, expression analysis of these cell lines (detailed in 
chapter 5) demonstrated that although only transfected with MDR1, K-MDR cells 
had significantly elevated levels of ABCG2 (16.4 fold) compared to K-WT. Hence, 
it can be postulated that ABCG2 attributed to the difference in the dasatinib 
accumulation in the two cell lines.    
As previously, this assay could not be performed using CML samples due to the 
low specific activity of dasatinib and the low cell numbers available for each assay 
(as detailed in 3.10). 
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Figure 4-9 Radiolabelled dasatinib in cell lines  
Cellular concentration of 14C-dasatinib in cell lines cells in the presence and 
absence of PSC 833. K-WT (MDR1-ve) (red lines, circles) and K-MDR 
(MDR1+ve) cell line (blue lines, triangles) in the presence (black symbols) 
and absence (white symbols) of PSC 833, n=3 in duplicate  
 
4.10 Effect of MDR1 inhibition on CML CD34+ cells 
following 72hrs culture 
The previous experiments determined that IM was a weak and nilotinib a strong 
inhibitor of the MDR1 transporter, while dasatinib was neither a substrate nor an 
inhibitor for this protein. As with the ABCG2 transporter, the three TKIs were 
tested in combination with the inhibitor PSC 833 to determine and confirm any 
effect of transporter inhibition on CML CD34+ cells in culture. 
As shown in chapter 3, treatment of CD34+ cells with 5µM IM, 5µM nilotinib, or 
150nM dasatinib for 72hrs resulted in a reduction in the total number of cells in 
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comparison to the 5GF alone (p<0.05) 
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Figure 4-10). Blocking the MDR1 transporter by the addition of 5µM PSC 833 also 
resulted in a reduction in the total number of cells in comparison to 5GF alone 
(17.7±2.19x105 in 5GF alone, 8±1.2x105 with PSC 833, p=0.002), indicating that 
PSC 833 alone had an effect on the cells. 
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Figure 4-10 Inhibition of MDR1 in total viable cells 
Total number of cells following 3 days in culture, in the presence of TKIs 
alone (dark-grey fill) or combined with PSC 833 (light grey fill). In addition, 
total number of cells in 5GF alone (black fill), or PSC 833 alone (white fill) 
are plotted. CD34+ cells were seeded at 1x105 cells at d0 (dotted line); n=4 
for IM, n=6 for nilotinib, n=7 for dasatinib. All data are mean of duplicate 
analysis, *=p<0.05, ns=not significant, [ND-no drug] 
 
The combination of nilotinib or dasatinib and PSC 833 further reduced the total 
number of cells in comparison to the drug alone (6.17±0.9x105 with nilotinib, 
3.37±1.3x105 with nilotinib and PSC 833, p=0.01, 8±1.3x105 with dasatinib, 
2.77±0.5x105 with dasatinib and PSC 833, p=0.001). Although these data would 
appear to imply that there is an additive effect with the combination, the reduction 
of cells in the presence of PSC 833 alone suggests that it this may not be due to 
an increase in TKI effect, but based upon a separate PSC 833 action that is 
unconnected to the action of TKI. 
* 
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4.11 Assessment of q34+ cells following 72hrs culture  
Following 72hrs culture, the population of cells remaining quiescent was assessed 
for further reduction in the presence of PSC 833 ± TKI. There was no significant 
reduction in the presence of PSC 833 alone. Similarly the combination with TKIs 
also did not further reduce the q34+ population (IM 11.7±8.3 vs. IM + PSC 3.6±0.9, 
nilotinib 8±4.4 vs. nilotinib + PSC 6.5±2, dasatinib 5.2±1.7 vs. dasatinib + PSC 
5.1±1.5, p=ns for all combinations). These results therefore demonstrated that 
blocking the MDR1 transporter did not enhance the reduction of q34 cells in the 
presence of TKIs. 
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Figure 4-11 Inhibition of MDR1 on quiescent CD34+ CML cells 
Percentage of q34 following 72hrs of culture as a percentage of input in the 
presence of TKIs or 5GF alone (black bars) or combined with PSC 833 
(grey bars), n=4 for IM, n=6 for nilotinib, n=7 for dasatinib, [ND-no drug] 
 
ND             IM             Nil             Das 
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4.12 Effect of PSC 833 on cell division in CML cells 
following 72hrs culture 
To dissect the effect of PSC 833 alone on cells following 72hrs culture, the stain 
CFSE was used to track cell division. The data was then analysed either as the 
whole population (top right and bottom right quadrant as detailed in section 
2.4.1.3, Figure 4-12B) or as the population that are still CD34+ (Figure 4-12C).  
As demonstrated in Figure 4-12B, although there was no significant difference 
between the non-proliferating and proliferating populations, there was a trend 
towards a higher number of cells in the early divisions compared to the later 
divisions, just reaching statistical significance at division 4 (p=0.05). This would 
suggest that PSC 833 was acting as an anti-proliferative agent, and hence 
accounting for the significant reduction in total cells (Figure 4-12A).  
Additionally, the total number of CD34+ cells at each division was also analysed 
(Figure 4-12C). There was no significant difference at any division, nor when 
comparing the non-proliferating with the proliferating population. However, there 
again was a trend towards higher number of cells in the early divisions compared 
to the later divisions, supporting the observation of PSC 833 acts as an anti-
proliferative agent.  
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Figure 4-12 Effect of PSC 833 on cell division in CML cells following 
72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
A. A representative FACS histogram plot demonstrating the anti-
proliferative effect of PSC 833 (black line) compared to untreated control 
(grey fill). B and C. The percentage of total cells and CD34+ cells in each 
division following 72hrs culture respectively. The cell numbers are 
expressed as a percentage of the starting cell number. Cells treated with 
5GF alone (black fill) compared with cells treated with 5µM PSC 833 alone 
(grey fill). The divisions are grouped as ‘non-proliferating’ (CFSE max and 1 
division) and ‘proliferating’ (2 or more divisions). All data are mean of 
duplicate analyses of n=4 samples, * p=0.05, ns=not significant. U.D- 
undivided, Div 1- division 1, etc. 
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4.13 Assessment of CrkL phosphorylation 
To define the effects of MDR1 inhibition in the presence of TKIs, the downstream 
substrate CrkL was examined at 16 and 72hrs for BCR-ABL activity. As 
demonstrated in the previous chapters, the addition of the TKIs significantly 
reduced p-CrkL at 16 hrs (p<0.05), with significant reduction retained with nilotinib 
and dasatinib at 72hrs (p<0.05). The treatment with PSC 833 alone also 
demonstrated significant CrkL phosphorylation compared to the untreated control 
at 16hrs (PSC 833- 50.6±6.4% vs. ND- 100%; p=0.01), which was restored to 
control levels at 72hrs.  
However, the co-treatment of PSC 833 with either TKI did not further reduce p-
CrkL at 16rs or 72hrs (p=ns for all combinations), suggesting that blocking MDR1 
does not further enhance the potency of the TKIs.  It can therefore be suggested 
that the inhibition of MDR1 does not further increase the ability of TKIs to reduce 
p-CrkL and does not increase their potency. 
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Figure 4-13 BCR-ABL inhibition as a measure of percentage p-CrkL in 
CML CD34+ cells 
Percentage of GM p-CrkL remaining relative to no drug control (ND) in the 
presence (grey fill) or absence (black fill) of PSC 833 at 16hrs (A) or 72hrs 
(B) n=5, *=p<0.05. 
 
*
B. 
A. 
Jordanides Niove, 2008  Chapter 4 155 
4.14 Assessment of apoptosis  
In order to determine the effect of blocking the MDR1 transporter by PSC 833, 
CML CD34+ cells were stained with annexin and viaprobe to determine early and 
late apoptosis. As shown in chapter 3, apoptosis was increased in the presence of 
nilotinib (p=0.01). However, this was not enhanced when co-treated with PSC 833 
(TKI vs. TKI + PSC 833, n/s for all combinations), suggesting that inhibition of 
MDR1 does not further induce the apoptotic effect of the TKIs. 
In addition, increased apoptosis was also observed in the presence of PSC 833 
alone compared to growth factor alone (ND-18.95±4.6% vs. PSC 833 30.37±5.1%, 
p=0.03). These data suggest that MDR1 inhibition does not further enhance the 
apoptotic effect of the TKIs, but that PSC 833 alone increased apoptosis in a 
manner unrelated to TKIs.  
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Figure 4-14 Apoptosis in the presence and absence of PSC 833 
Percentage of apoptosis in the presence (dark grey) or absence (black) of 
PSC 833; * p<0.05; n=3, ND-no drug, P-PSC 833 
*
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4.15 Summary 
The previous experiments demonstrated that although MDR1 was expressed in 
CML CD34+ cells, it was significantly lower (7.41 fold) than the expression in 
normal counterparts. Although there was some protein function, it was weak, and 
the protein was immeasurable by intracellular staining. Intracellular staining as an 
assay has reduced sensitivity compared to other protein detection assays such as 
Western blotting and the low expression might have been due to the level being 
below the threshold range of the assay. Confirmation of protein expression might 
have been demonstrated with the more sensitive Western blot assay. However, 
the substrate displacement assay was able to confirm both protein expression and 
protein function at low levels, demonstrating that this assay was more sensitive.  
Replacing the specific MDR1 inhibitor with TKIs demonstrated interactions with 
this transporter. The effect was more obvious in the cell line model as high MDR1 
expression allowed the interaction with increasing concentrations to be easily 
assessed. Increasing concentrations of IM in the MDR1 overexpressing cell line 
demonstrated a small reduction of efflux, suggesting that it might be acting either 
as a substrate or weak inhibitor. However, the effect was only seen in 1 of the 3 
CML patient samples tested, suggesting that the level of MDR1 present in CML 
CD34+ was either insufficient to see any effect of IM or that the IM interaction was 
so weak that it did not affect efflux via MDR1. In contrast, nilotinib showed a 
stronger interaction with MDR1 in the MDR1 cell line model. At therapeutic 
concentrations (>1µM), nilotinib increased rhodamine 123 retention to a similar 
degree as PSC 833 in cell lines. However, as above, the degree of efflux seen in 
the CML samples was small and was not significantly altered by nilotinib.  
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Although the MDR1 protein was minimal in CML CD34+ cells, the significant 
increase in fluorescence in cell lines demonstrated that these TKIs have an 
interaction with MDR1. Assays with radiolabelled IM and nilotinib in cell lines 
demonstrated no significant difference in the presence of the inhibitor PSC 833, 
suggesting that IM and nilotinib were not substrates of this transporter. Therefore 
the interaction observed in the substrate displacement assay suggested that these 
drugs were inhibitors of MDR1. Repeating the assay in CML CD34+ cells further 
confirmed that IM or nilotinib were not substrates for this transporter. 
In contrast, the addition of dasatinib did not increase rhodamine 123 fluorescence 
in the cell lines or CML, even at the maximal therapeutic concentration, suggesting 
that dasatinib was not an inhibitor for this transporter. Further assessment with 
radiolabelled dasatinib also demonstrated no reduction in retention in the MDR1 
positive cells, demonstrating that dasatinib was not a substrate for this transporter 
either. Interestingly, the intracellular concentration of dasatinib in the transduced 
cell line was lower than the wild-type, suggesting that there might be increased 
expression of another transporter in this cell line. Drug transporters are 
promiscuous in that they actively efflux many shared compounds and are often co-
expressed and co-regulated. Further analysis of the expression of the wild type (K-
WT) and the transduced cell line (K-MDR) (and detailed in chapter 6) showed 
elevated expression of ABCG2 in K-MDR. The data presented in chapter 3 
demonstrated that dasatinib was a substrate for ABCG2, hence the reduced 
cellular concentration in the transduced cell line might be attributable to the 
increased endogenous expression of ABCG2. However, the cell line model in this 
assay was only used to test the difference in cellular concentration of dasatinib in 
the presence or absence of PSC 833. As there was no difference in retention 
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when MDR1 was blocked in the two cell lines, then it was conclusively determined 
that dasatinib was not a substrate for MDR1. 
As with ABCG2, for completion, the effect of blocking this transporter in the 
presence of TKIs was tested. The treatment with PSC 833 significantly reduced 
the total number of cells remaining after culture. However, this was not selective 
for the CD34+ population nor targeted the quiescent population. Instead PSC 833 
alone reduced the number of cells remaining both by exerting an anti-proliferative 
effect and by inducing apoptosis, as demonstrated by the trend of increased 
number of cells at the earlier divisions both in the total and CD34+ population. The 
co-treatment with TKI and PSC 833 did result in significantly lower total cell 
numbers compared to TKIs alone, however this can be attributed to the additional 
anti-proliferative and apoptotic effects seen with PSC 833 alone. Furthermore, 
there was no further reduction in p-CrkL and more importantly, there was no 
reduction in the q34+ population.   
Interestingly, there was a significant reduction in p-CrkL with PSC 833 alone at 
16hrs compared to the untreated control. This reduction by PSC 833 might either 
be a consequence of the increased concentration of an endogenous substrate 
caused by blocking MDR1, or the direct inhibition of p-CrkL by PSC 833. The 
underlying mechanism for this surprising result though, has not been resolved. 
Furthermore, there was no further increase in apoptosis with the combination of 
PSC 833 and TKIs compared to TKIs alone, although PSC 833 alone significantly 
increased both apoptosis. Therefore, it can be concluded that the additive 
reduction of cell number and reduced p-CrkL was not due to potentiation of TKI 
activity or concentration. 
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5 Results 3- MRP1 in CML CD34+ cells 
The previous two chapters have concentrated on the clinically relevant ABC 
transporters ABCG2 and MDR1. For completion, the third transporter implicated in 
MDR in other forms of leukaemia was also studied. There have been fewer reports 
describing the role of MRP1 in mediating drug resistance, however it has been 
demonstrated that it can transport many of the same chemotherapeutic agents as 
MDR1 (Rappa et al. 1997b). MRP1 is also expressed in virtually all human tissues 
and most tumour cell lines, suggesting that MRP1 may contribute to drug 
resistance (Burger et al. 1994). Indeed, AML cells from patients who have 
relapsed compared to those with responsive disease have higher expression 
levels of MRP1 (Zhou et al. 1995) and increased resistance to chemotherapeutic 
agents correlates with simultaneous MDR1 and MRP1 expression (Legrand et al. 
1999). 
The analyses of ABCG2 and MDR1 have shown different interaction profiles for 
the current TKIs. Dasatinib is a substrate for ABCG2, but does not interact with 
MDR1. In contrast, IM and nilotinib are both inhibitors for ABCG2 and MDR1. The 
following experiments were therefore designed to identify any interaction of the 
current TKIs in relation to MRP1 and to examine the expression and function of 
MRP1 in CML CD34+ cells. 
5.1 Expression of MRP1 mRNA  
As for the other transporters, the expression of MRP1 was investigated in CML 
CD34+ cells and compared to normal counterparts using real time PCR. As shown 
in Figure 5-1, CML samples expressed MRP1 mRNA at similar amplitude in 
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comparison to normal PB CD34+ cells. Using GAPDH as the endogenous control, 
11 CML CD34+ and 7 normal CD34+ samples gave ∆Ct values of 4.8±0.4 and 
4.7±0.4 respectively and a ∆∆Ct of 0.11. Using the equation 2-∆∆CT this assay 
determined that CML CD34+ cells expressed equal amounts of MRP1 to normal 
PB CD34+ cells (1.08 fold) (Figure 5-1C). 
 
Figure 5-1 Expression of MRP1 mRNA in cell lines and CML CD34+ cells  
Expression of MRP1 mRNA. A. Taqman amplification plot of the cell line K-
WT and the transduced cell line K-MRP. B. Taqman amplification plot of CML 
and normal CD34+ samples. C. Relative quantification (2-∆∆CT) of MRP1 
expression in CML CD34+ cells (dark grey fill; n=11) compared to normal 
CD34+ cells (black fill; n=7). 
A. 
C. 
B. 
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In order to optimise experiments that would determine expression, function and 
the interaction of MRP1 with TKIs in CML CD34+, a valid cell line model that 
expressed MRP1 was required. The K562 WT cell line, generated and donated by 
Dr L.Fairbairn, was transduced to express the MRP1 gene, producing the K-MRP 
cell line. These two cell lines were then analysed on the TLDA card. However, as 
seen in Figure 5-1A, there was endogenous expression of MRP1 in the wild-type 
control cell line, with a similar expression to the expression level in CML samples 
(K-WT ∆Ct 4.7±0.2 n=3; CML ∆Ct 4.8±0.4 n=11), although this expression was 
greatly increased in the transduced K-MRP cell line (K-MRP ∆Ct -0.03, n=2).  
5.2 Expression of MRP1 protein 
The MRP1 protein was detected using the specific antibody QCRL3. This antibody 
detects an intracellular epitope of the 190kD transmembrane phosphoglycoprotein 
and does not cross react with human MDR1 (Hipfner et al. 1994). As for the 
antibody staining for MDR1, serial dilutions of the antibody established that a 100x 
dilution of the antibody, followed by the same dilution of the secondary antibody, 
produced the most distinct peaks. Following optimisation, the assay was carried 
out in parental K-WT (MRP1+ve, Figure 5-2A) and transduced K-MRP cells 
(MRP1++ve, Figure 5-2B). K-WT cells demonstrated an increase in fluorescence 
compared to the isotype (K-WT isotype GM=3.2±0.3 vs. test GM=5.3±0.6, p=0.01), 
while the transduced cells demonstrated an even higher increase in fluorescence 
(K-MRP isotype GM=3.7±0.6 vs. K-MRP1 GM=12.1±1.1 p=0.02), demonstrating 
protein expression in both cells lines.  
The antibody staining for MRP1 was repeated in 3 CML samples (Figure 5-2C). 
The assay demonstrated positive staining in all the samples, resulting in 
Jordanides Niove, 2008   Chapter 5 162 
significantly higher mean fluorescence than the isotype control (isotype GM, 
3.0±0.7, QCRL3 GM 5.0±1.0, p=0.02).  
 
Figure 5-2 Expression of MRP1 protein in cell lines and CML CD34+ 
cells 
A representative example of MRP1 protein expression in K-WT (A), K-MRP 
(B) and CML CD34+ cells (C) with the isotype (black fill) and the MRP1 test 
antibody QCRL3 (white fill); n=3 in duplicate, all replicates were consistent.  
 
Comparing the change in GM (∆GM) in the K-WT cell line to the ∆GM in the CML 
sample demonstrated that the two samples had similar protein levels (K-WT 
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∆GM=2.1, CML ∆GM=2). This correlated with similar mRNA expression levels 
demonstrated by the TLDA card in section 5.2. 
5.3 Function of MRP1 protein 
To confirm the function of MRP in the transduced cell line, the substrate 
displacement assay was repeated with the fluorescent MRP1 substrate Fluo-3 AM, 
in a similar manner to the use of BODIPY-Prazosin for the function of ABCG2 and 
rhodamine 123 for the function of MDR1. The specific inhibitor of MRP1 used for 
these experiments was the competitive antagonist of the leukotriene D4 (LTD4) 
receptor, MK571 (Gekeler et al. 1995).  
Using the K-WT cell line, it was established that the cell line actively effluxed Fluo-
3 AM, and that this efflux was inhibited by the addition of 30µM MK571 (Figure 
5-3A). The use of K-MRP cells in this assay was complicated by the presence of 
GFP as a marker, as both GFP and fluo-3 AM are detected in the FL1 channel 
(Figure 5-3C). The presence of GFP meant that when fluo-3 AM was added to the 
K-MRP cells, no further increase in fluorescence was observed. This may be 
either because there was maximal efflux or the fluorescence emitted by GFP was 
so bright it masked the signal.  
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Figure 5-3 Function of MRP1 protein in cell lines and CD34+ cells 
MRP1 function by efflux of a known substrate in K-WT (A and B), K-MDR 
(C and D) and CML CD34+ cells (E). Unstained cells (black fill), cells with 
fluo-3 AM (light grey fill), cells with fluo-3 AM and 30µM MK571 (dark grey 
fill), cells with fluo-3 AM and 100µM MK571 (black line). F. Percentage of 
efflux by MRP1 in CML CD34+ cells. Fluo-3 AM and 30µM MK571 (dark 
grey fill), was considered to have maximal retention, fluo-3 AM alone (light 
grey-fill) *=p<0.001. F-Fluo3-AM 
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To test this, the function of MRP1 in the transduced cell line was measured in the 
presence of fluo-3 AM and the inhibitor. At 30µM MK571, a small inhibition in efflux 
was observed, however, increasing the concentration of the inhibitor to 100µM 
caused a high degree of inhibition confirming that these cells have functional 
MRP1 (Figure 5-3D). The requirement for increased doses of MK571 reflected the 
high level of MRP1 in this cell line. In contrast, the WT cell line showed no further 
inhibition in the presence of the higher MK571 concentration (Figure 5-3B). As 
CML samples had similar expression levels of MRP1 to K-WT, 30µM MK571 was 
used for inhibition of CML CD34+ cells.  
The assay was then repeated in 2 CML samples (Figure 5-3E). The fluorescence 
observed in cells with 30µM MK571 was considered to be maximally loaded and 
classed as the control condition. In the absence of MK571, there was a significant 
decrease in fluorescence demonstrating almost complete efflux by functional 
MRP1 protein (4.89±0.2% retention in comparison to the control, p=0.01 (Figure 
5-3F). 
5.4 Interaction of IM with MRP1 by a substrate 
displacement assay 
Due to the GFP potentially concealing the functional efflux of fluo-3 AM in the 
transduced cells and the need for increased inhibitor concentration to inhibit the 
protein, it was decided that all further substrate displacement assays assessing 
the interaction of TKIs would be carried out in the wild-type cell line. Unfortunately, 
there was no cell line available as a negative control due to high MRP1 expression 
observed in every cell line tested in the laboratory and no MRP1-ve cell line 
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identified in the current literature. Therefore, the parental cell line K-WT and 30µM 
were used as a control for all substrate displacement assays. 
To determine whether IM interacts with MRP1, increasing concentrations were 
added to the substrate displacement assay using the K-WT cell line (Figure 5-4A). 
The addition of IM resulted in no inhibition of efflux, even at 5µM IM, suggesting 
that IM did not interact with this drug transporter as either a competitive substrate 
or inhibitor. 
Similarly, when this assay was repeated with CML CD34+ cells, IM did not reduce 
the level of fluo-3 AM efflux, confirming that IM does not interact with MRP1 in 
primary cells either (Figure 5-4B). 
 
Figure 5-4 Efflux inhibition of a MRP1 substrate by IM 
Interaction of IM with the protein MRP1 in the cell line K-WT; n=3 in 
duplicate (A) and CML CD34+ cells; n=2 in duplicate (B). Unstained cells 
(black fill), with fluo-3 AM (light grey fill), with fluo-3 AM and 30µM MK571 
(dark grey fill), with fluo-3 AM and [IM] (black line no fill)  
B. 
A. 
CML 
CD34+ 
K-WT 
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5.5 Assessment of IM as a substrate of MRP1  
The substrate displacement assay above demonstrated no interaction of IM with 
MRP1, suggesting that it was not an inhibitor or a strongly competitive substrate. 
However, in order to determine whether IM was a substrate of MRP1, increasing 
concentrations of 14C-IM were added to assess the cellular concentration in K-WT 
(MRP1+ve) and K-MRP (MRP1++ve) cells. There was no significant accumulation 
of 14C-IM in either cell line in the presence of the inhibitor MK571, compared to the 
cell line in the absence of the specific inhibitor, suggesting that IM was therefore 
not a substrate of MRP1 (Figure 5-4A).  
The assay was also repeated using CD34+ cells from 5 CML patients. There was 
no difference in the cellular accumulation of IM in the presence or absence of the 
inhibitor, again supporting the conclusion that IM was not a substrate for this 
transporter in cell lines or primary CD34+ cells (Figure 5-4B). 
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Figure 5-5 Radiolabelled IM in cell lines and CML CD34+ cells 
Cellular concentration of 14C-IM in cell lines (A) and CML CD34+ (B) cells in 
the presence and absence of 30µM MK571. A.  K-WT (MRP1+ve) (blue 
lines, circles) and K-MRP (MRP1++ve) cell line (red lines, triangles) in the 
presence (black symbols) or absence (white symbols) of MK571, n=3 in 
duplicate. B. CML CD34+ cells in the presence (black symbols) or absence 
(white symbols) of MK571; n=5 in duplicate. 
 
B. 
A. 
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5.6 Interaction of nilotinib with MRP1 by a substrate 
displacement assay 
To test whether other TKIs interact with MRP1, the substrate displacement assay 
was repeated, this time with the tyrosine kinase inhibitor nilotinib. This drug was 
again added at increasing concentrations in K-WT loaded with fluo-3 AM, to 
determine the effect on the MRP1 protein. The addition of nilotinib resulted in a 
dose dependent decrease in efflux of fluo-3 AM, although complete reduction of 
the protein comparable to 30µM MK571 was not reached with 5µM nilotinib 
(Figure 5-6A). 
The assay was again repeated in CML CD34+ cells. The efflux of fluo-3 AM was 
inhibited with increasing nilotinib concentrations (Figure 5-6B), however the 
retention values observed with 5µM nilotinib (15.31±6%) although slightly higher, 
were not significantly different to the substrate alone (4.89±0.2%, p=ns) and were 
significantly lower than 30µM MK571 (100% control, p=0.03) (Figure 5-6C). This 
incomplete reduction in fluo-3 AM efflux suggests that nilotinib might be either a 
weak inhibitor or a competitive substrate in CML CD34+ cells. 
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Figure 5-6 Efflux inhibition of a MRP1 substrate by nilotinib  
Interaction of Nilotinib with the protein MRP1 in cell line K-WT (A) and CML 
CD34+ cells (B). Unstained cells (black fill), with fluo-3 AM (light grey fill), 
with fluo-3 AM and 30µM MK571 (dark grey fill), with fluo-3 AM and nilotinib 
(black line no fill); n=3. C. Percentage of efflux by fluo-3 AM. Fluo-3 AM and 
30µM MK571 (dark grey-fill) was considered to have maximal retention, 
fluo-3 AM alone (light grey-fill) and fluo-3 AM with 5µM nilotinib (white fill); 
n=3 *=p<0.05. F-Fluo3-AM 
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5.7 Assessment of nilotinib as a substrate of MRP1  
The substrate displacement assay demonstrated an interaction of nilotinib with 
MRP1, however, it cannot delineate between a competitive substrate and an 
inhibitor. To clarify the interaction, increasing concentrations of radiolabelled 
nilotinib were added and the cellular CPM measured in the presence and absence 
of MK571.  
There was no reduced accumulation of 14C-nilotinib in the cell line transduced to 
over-express MRP1 (K-MRP) compared to the wild type that had some MRP1 
protein (K-WT). Similarly, there was no significantly increased accumulation of 
radiolabelled nilotinib in K-WT or K-MRP in the presence of MK571 compared to 
the cell lines alone, demonstrating nilotinib was not a substrate for MRP1.  
The assay was repeated in 3 CML CD34+ samples. As with the cell lines, there 
was no significant difference of 14C-nilotinib in the presence or absence of MK571, 
suggesting the interaction observed in the substrate displacement assay was most 
likely due to nilotinib acting as a weak inhibitor but certainly not a competitive 
substrate. 
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Figure 5-7 Assessment of radiolabelled nilotinib accumulation in the 
presence of MRP1 protein 
Cellular concentration of 14C-nilotinib in cell lines (A) and CML CD34+ (B) 
cells in the presence and absence of MK571. A.  K-WT (MRP1+ve) (red 
lines with circles) and K-MRP (MRP1++ve) cell line (blue lines with 
triangles) in the presence (black symbols) and absence (white symbols) of 
MK571. B. CML CD34+ cells in the presence (black symbols) and absence 
(white symbols) of MK571. All data are mean of duplicate analyses of n=3. 
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5.8 Interaction of dasatinib with MRP1 protein by a 
substrate displacement assay 
The substrate displacement assay was repeated by replacing the specific inhibitor 
with the tyrosine kinase inhibitor dasatinib. As demonstrated earlier, there is 
significant reduction of efflux in the presence of MK571 demonstrating active 
protein. However, replacing the inhibitor with dasatinib did not result in an increase 
in fluo-3 AM retention in the K-WT cell line, suggesting that dasatinib was not an 
inhibitor for this drug transporter (Figure 5-8A).  
 
Figure 5-8 Efflux inhibition of a MDR1 substrate by dasatinib 
To investigate the interaction with MRP1, IM was added into this assay in 
place of the known inhibitor, MK571 in K-WT cells (A) and CML CD34+ cells 
(B). A. K-WT cells unstained (black fill), with fluo-3 AM (light grey fill), with 
fluo-3 AM and 30µM MK571 (dark grey fill), with fluo-3 AM and dasatinib 
(black line no fill). B. CML CD34+ cells unstained (black fill), with fluo-3 AM 
(light grey fill), with fluo-3 AM and 30µM MK571 (dark grey fill), with fluo-3 
AM and 150nM dasatinib (black line no fill). All data are mean of n=3 in 
duplicate. 
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The assay was repeated in 3 CML samples. There was no significant retention of 
fluo-3 AM in the presence of dasatinib, even at the maximum clinical dose of 
150nM, demonstrating that dasatinib was not an inhibitor of MRP1 (Figure 5-8A). 
5.9 Assessment of dasatinib as a substrate of MRP1  
The substrate displacement assay described above demonstrated no interaction of 
dasatinib with MRP1, and showed that dasatinib was not an inhibitor of this 
transporter. To determine whether dasatinib was a substrate of MRP1, 14C-
dasatinib was added to the cells in increasing concentrations. The addition of 
30µM MK571 did not significantly increase the accumulation of dasatinib in the K-
MRP cell line (p=ns). However, there was a significant increase in 14C-dasatinib 
accumulation in the K-WT cell line with 30µM MK571 compared to the cell line 
alone at 150nM (p=0.05), 300nM (p=0.01) and 600nM (p=0.01).  
Increasing the concentration of MK571 to 100µM in the K-WT cell line also 
demonstrated a significant accumulation at 10nM (p=0.01) and 50nM (p=0.02), as 
well as at 150 and 300nM (p<0.02). Increasing the concentration of MK571 to 
100µM in the transduced cell line K-MRP demonstrated significant accumulation at 
50nM (p=0.001).  
These results demonstrated that although 30µM MK571 resulted in significant 
accumulation in the wild-type cell line, it was insufficient to inhibit the MRP1 in the 
transduced cell line. This correlates to the increased concentration of MK571 
required in the substrate displacement assay (figure 4-3) whereby the elevated 
MRP1 expression was maximally inhibited by 100µM MK571. These results 
demonstrated that dasatinib was a substrate for MRP1. 
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Figure 5-9 Assessment of radiolabelled dasatinib accumulation in the 
presence of MRP1 protein  
Cellular concentration of 14C-dasatinib in the presence and absence of 
30µM MK571 (A) or 100µM Mk571 (B). K-WT (MRP1+ve) (red lines) and K-
MRP (MRP1++ve) cell line (blue lines) in the presence (black symbols) and 
absence (white symbols) of 30µM (solid lines) or 100µM (dashed lines, 
squares) MK571. All data are mean of duplicate analyses of n=3; *=p<0.05. 
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Despite the addition of 100µM MK571 in the transduced cell line, the accumulation 
in this cell line remained significantly lower than the wild-type cell line (p<0.05 for 
50-600nM). This may suggest that there is another transporter on the transduced 
cell line contributing to the reduced accumulation.    
The low specific activity of 14C-dasatinib prevented this assay from being repeated 
in CML CD34+ cells as the reduced radiolabelled 14C counts accumulated in the 
low cell numbers available for each determination would not be above the 
threshold of detection. 
5.10 Effect of MRP1 inhibition on CML CD34+ cells 
following 72hrs culture 
The combination of substrate displacement assays and cellular concentration 
measurements demonstrated that nilotinib was an inhibitor, dasatinib was a 
substrate and IM had no effect on MRP1. To determine the effect of MRP1 
inhibition on the capacity of these TKIs to kill CML cells, CD34+ cells were 
incubated for 72hrs in the presence of TKIs alone or TKI and MK571 to inhibit 
transport via MRP1. 
As in the previous chapters (chapters 3 and 4), treatment with the TKIs alone 
resulted in a reduction in the total number of cells in comparison to cells in 5GF 
alone. Blocking the MRP1 transporter by the addition of 30µM MK571 resulted in 
no reduction of the total number of viable cells compared to 5GF alone 
(20.1±1.6x105 with MRP1, 17.7±2.2 alone; p=ns), indicating that MK571 alone 
does not reduce proliferation. 
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When the cells were co-treated with IM, nilotinib or dasatinib and MK571, there 
was no difference in the total number of cells remaining in comparison to TKIs 
alone (IM 90.3±17.4% vs. IM + MK571 88.5±22.9%, nilotinib 61.7±9.2% vs. 
nilotinib + MK571 59.5±12%, dasatinib 80±12.5% vs. dasatinib + MK571 
81.3±21.4%, p=ns for all combinations). This suggested that blocking the MRP1 
protein does not further enhance the effect of TKI in reducing total cells.  
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Figure 5-10 Inhibition of MRP1 in total viable cells 
Total number of cells following 3 days in culture, in the presence of TKIs 
alone (dark-grey fill) or combined with MK571 (light grey fill). In addition, 
total number of cells in 5GF alone (ND, black fill), or MK571 alone (white fill) 
are plotted. CD34+ cells were seeded at 1x105 cells at d0 (dotted line); n=4 
for IM, n=4 for nilotinib, n=3 for dasatinib. All data are mean of duplicate 
analysis, *=p<0.01 
 
5.11 Assessment of q34+ cells following 72hrs culture 
The quiescent population remaining following 72hrs of culture was examined for 
further reduction in 2 CML patients. There was no reduction in the presence of 
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MK571 alone (ND 4.6±1% vs. MK571 4.6±3.2%) suggesting blocking the 
transporter alone does not reduce the quiescent population. The co-treatment of 
MK571 with IM, nilotinib or dasatinib did not further reduce the accumulation of 
q34+ cells (IM 11.7±8.3% vs. IM + MK571 12.2±8.5%, nilotinib 8±4.4% vs. nilotinib 
+ MK571 15±10.5%, dasatinib  5.2±1.7% vs. 5.6±2.9%, p=ns for all 
combinations), suggesting that blocking MRP1 does not enhance the reduction of 
the quiescent population. 
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Figure 5-11 Inhibition of MRP1 on quiescent CD34+ CML cells 
Percentage of q34 following 72hrs of culture as a percentage of input in 
5GF alone (ND, black fill), with MK571 (white fill), in the presence of TKIs 
alone (dark grey fill) or combined with PSC 833 (light grey fill). n=4 for IM, 
n=6 for nilotinib, n=7 for dasatinib 
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5.12 Effect of MK571 on cell division in CML cells 
following 72hrs culture  
The effect of MK571 in CD34+ cells following 72hrs culture was examined further 
using the stain CFSE to track cell division. The data was analysed as previously, 
measuring the population remaining following treatment (Figure 5-12A) and the 
cells that are still CD34+ (Figure 5-12B). There was no significant difference either 
in the absolute number of cells or CD34+ cells remaining compared to 5GF alone 
either in the proliferating or non-proliferating cells (p=ns for all combinations). In 
addition there was no further difference at each division, suggesting that MK571 
alone is not toxic to the cells and does not alter the divisional kinetics of the cells.  
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Figure 5-12 Effect of MK571 on cell division in CML cells following 
72hrs culture 
Cells were labelled with CFSE to allow tracking of their proliferative history. 
The number of (A) total cells or (B) CD34+ cells that remain undivided 
(U.D), have divided once (Div 1), twice (Div 2) etc. were calculated using 
the % of cells detected in each division, the cell number and % CD34+ cells 
within each division. Cells treated with 5GF alone (black fill) compared with 
cells treated with 30µM MK571 alone (grey fill), n=3 
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5.13 Assessment of CrkL phosphorylation 
To further define the effects of MRP1 inhibition on the efficacy of TKI to inhibit 
BCR-ABL activity, the phosphorylation of the downstream substrate CrkL was 
examined at 16 and 72hrs. As demonstrated earlier, p-CrkL was significantly 
reduced at 16hrs with the addition of TKIs, with p-CrkL reduction maintained at 
72hrs with nilotinib and dasatinib (see section 3.13). Combining IM or nilotinib with 
MK571 did not further reduce p-CrkL, demonstrating that MRP1 inhibition does not 
enhance the effect of TKIs at 16hrs (IM 52.5±11.3% vs. IM + MK571 59.4±6.9%, 
nilotinib 46±5.2% vs. nilotinib + MK571 43.5±6.6%, p=ns) or 72hrs (p=ns for all 
combinations). Surprisingly however, the combination of dasatinib with TKI also 
did not further reduce p-CrkL either at 16hrs (dasatinib 45.4±5.5% vs. dasatinib + 
MK571 38.5±3.7%, p=ns) or 72hrs (p=ns), despite being shown to be a substrate 
for this transporter. The inhibition of MRP1 with MK571 alone also demonstrated 
no difference in the activity of CrkL at 16 or 72hrs (n=3, p=ns at both timepoints), 
suggesting that inhibition of MRP1 does not further reduce BCR-ABL activity.   
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Figure 5-13 BCR-ABL inhibition as a measure of percentage of p-CrkL 
in CML CD34+ cells 
Percentage p=CrkL remaining relative to no drug control (ND) at 16hrs 
(black bars) or 72hrs (grey bars) n=3 
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5.14 Assessment of apoptosis  
In order to fully investigate the effect of blocking the MRP1 transporter, CML 
CD34+ cells were stained with annexin and viaprobe to determine apoptosis. 
Increased apoptosis was observed in the presence of nilotinib as demonstrated 
earlier (see section 3-14). In contrast to FTC though, there was also a small but 
significant increase in apoptosis in the presence of MK571 compared to growth 
factor alone (23.9±4.4% vs. 19±4.69%, p=0.004), demonstrating slight toxicity to 
the cells. The co-treatment with TKI however did not further increase apoptosis (IM 
31.8±2.6% vs. IM + MK571 33.2±3.3%, nilotinib 37.7±3% vs. nilotinib + MK571 
36.1±4%, dasatinib 31.3±2% vs. 32.8±3.7%, p=ns for all combinations), 
suggesting that the effect of TKI was not further enhanced by inhibition of MRP1.  
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Figure 5-14 Apoptosis in the presence and absence of MK571 
Percentage of apoptosis in the presence (dark grey) or absence (black) of 
MK571 and TKIs; n=3. ND-no drug, MK-MK571 
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5.15 Summary 
The above experiments conclusively demonstrate that MRP1 was expressed in 
both CML CD34+ and normal CD34+ at similar levels. In addition, the protein was 
functional demonstrating effective translation. 
Replacing the known inhibitor, MK571, with TKIs demonstrated an interaction with 
nilotinib, although this did not reach statistical significance. Further analysis with 
radiolabelled nilotinib demonstrated no additional accumulation in the presence of 
the known MRP1 inhibitor, suggesting that nilotinib is at best a weak inhibitor of 
MRP1.  
In contrast, replacing the known inhibitor, MK571, with either IM or dasatinib had 
no effect, suggesting that these agents were not inhibitors of MRP1. Further 
analysis with radiolabelled IM demonstrated no additional accumulation in the 
presence of MK571, concluding that IM is neither a substrate nor an inhibitor for 
this protein. However, blocking the transporter with MK571 in the cell lines 
significantly increased the accumulation of dasatinib, suggesting that dasatinib is 
indeed a substrate for, and not an inhibitor of, MRP1.  
The effect of blocking the transporter either in the presence or absence of TKIs 
was then studied. The treatment with MK571 alone did not affect the overall 
number of cells remaining and the proportion of cells in each division was not 
altered, indicating that MK571 does not have an anti-proliferative effect like 
PSC833. However, there was a small increase in apoptosis observed at 72hrs, 
demonstrating that MK571 alone was slightly toxic to the cells. 
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However, the co-treatment of MK571 with IM, nilotinib or dasatinib did not further 
reduce the cells in comparison to TKIs alone, despite dasatinib being a substrate 
for this transporter. Furthermore, the inhibition of MRP1 did not enhance the 
reduction of total cells and more importantly did not reduce the quiescent 
population. In addition, the co-treatment of MK571 and TKIs did not further reduce 
p-CrkL or increase apoptosis compared to TKIs alone. These results therefore 
suggest that although MRP1 is functional and dasatinib is a substrate, the 
expression does not mediate resistance in CML CD34+ cells. It may therefore 
suggest that, as detailed in chapter 3 (section 3.19) the maximal concentration 
required for full inhibition is limited by active efflux of dasatinib by ABCG2 and 
possibly other transporters as yet unidentified. Indeed, the co-treatment of FTC 
and MK571 with dasatinib may further enhance the overall cell kill of the progenitor 
and quiescent population and further limit BCR-ABL activity. Alternatively, these 
data may again suggest that dasatinib may be inhibiting BCR-ABL to its maximum, 
such that increasing the cellular concentration will not further reduce p-CrkL. 
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6 Results 4- Drug transporters in cell lines and 
CML CD34+ cells 
The results presented in the previous chapters have investigated the three main 
clinically relevant drug transporters in CML CD34+ cells and compared their 
expression to normal counterparts. Following confirmation of protein function, their 
interaction with the TKIs was determined. Nilotinib was identified as an inhibitor for 
every drug transporter examined, while IM was an inhibitor for ABCG2 and MDR1. 
In contrast dasatinib was found to be a substrate for ABCG2 and MRP1, which 
were the two transporters that were highly expressed in CML CD34+ cells. Yet 
despite this, co-treatment of TKIs in the presence of drug transporter inhibitors did 
not further reduce the total number of cells or further reduce p-CrkL. This suggests 
that either dasatinib is inhibiting BCR-ABL activity to its maximum efficiency such 
that increasing the concentration will not further reduce p-CrkL, or that the 
dasatinib concentration is still being limited by the active efflux of other 
transporters. Indeed, the previous three chapters have only investigated the effect 
of inhibiting each transporter in isolation and have only looked at the 3 clinically 
relevant transporters. The transporter family have many members and they are 
inherently promiscuous, sharing many substrates. It is therefore likely that other 
transporters, perhaps not yet identified, may also mediate resistance by actively 
effluxing the TKIs. In addition, treatment of cells with TKIs may induce expression 
of transporters that are inactive at initial diagnosis, or may stimulate 
overexpression of the currently active transporters. This chapter therefore looked 
at a wider selection of transporters, including the solute carrier family SLC22a, 
which might be expressed on CML CD34+ cells, either at diagnosis or post 
treatment with TKIs and which may have a role in drug resistance. The first three 
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members of this family (SLC22a1-3) are organic cation transporters and are also 
known as OCT1-3, the following 2 members (SLC22a4 and SLC22a5) are organic 
cation/carnitine transporters and are also known as OCTN1 and OCTN2 and the 
next 4 members are organic anion transporters (OAT1-4). For clarity and 
elimination of confusion due to their similarity in nomenclature, in figures the first 3 
members will be referred to as OCT1-3 and the remaining will be referred to by 
their family gene names SLC22a4-9.    
6.1 Experimental variation of TLDA cards 
The expression of drug transporters was investigated by designing a custom-made 
TLDA card with a range of drug transporter genes. The advantage of analysis by 
this method is the small amount of material required. Each card possesses 384 
wells of which 48 are supplied by 1 port (i.e. 8 ports in total) and each port requires 
only 100ng of RNA converted to cDNA for optimum experimentation, which 
therefore amounts to only ~2ng per well.  
Prior to any sample testing, the technique was validated in our hands. Firstly, the 
layout of the TLDA card was such that each gene for every sample was tested in 
duplicate. Table 6-1 represents an example from one of the cell lines showing the 
change in crossing thresholds (∆Ct) between the endogenous control (GAPDH) 
and gene, and the corresponding standard deviation (S.D.), generated by the 
Taqman software “RQ Manager 1.2”. A ∆CT value that is lower in one gene 
compared to another represents a higher relative expression and vice versa. 
Similarly, when comparing genes from two samples, the sample with the lower 
value will have higher gene expression. Negative values, as demonstrated with 
18S and β-ACTIN, represent genes that had a signal detected earlier than GAPDH 
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and hence have higher expression than this endogenous control. Genes that have 
no signal after 40 cycles were termed “nd” demonstrating an expression level 
below the threshold of detection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-1 A representative example of one sample tested in duplicate 
with the corresponding S.D. 
GAPDH was used as the endogenous control, nd=not detected 
 
Secondly, in excess of 3 samples were tested on different days in different port 
positions to determine inter-experimental variation. Table 6-2 details the CT and 
∆Ct of K-WT tested on TLDA cards on different days with the corresponding S.D. 
 Plate 1 
Detector Avg ∆Ct ∆Ct S.D. 
18S -13.16 0.03 
MDR1 nd nd 
MRP1 6.38 0.13 
MRP4 6.46 0.09 
ABCG2 0.84 0.03 
ABL1 5.19 0.06 
Β-actin -0.91 0.09 
AKT1 3.09 0.19 
BCR 6.91 0.24 
CASP3 6.82 0.06 
CD34 nd nd 
CD38 2.61 0.31 
GAPDH Endogenous control 
HIF1A 4.43 0.03 
PROM1 nd nd 
SLC22a1 (OCT1)  nd nd 
SLC22a2 (OCT2) nd nd 
SLC22a3 (OCT3) nd nd 
SLC22a4 (OCTN1) 8.35 0.35 
SLC22a5 (OCTN2) 8.19 0.09 
SLC22a6 (OAT1) nd nd 
SLC22a7 (OAT2) nd nd 
SLC22a8 (OAT3) nd nd 
SLC22a9 (OAT4) nd nd 
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The analysis from the combined data in the two tables confirmed that the data 
obtained from the TLDA cards was optimised and valid for comparative analysis. 
 Plates 1-3 
Detector Mean Ct Ct S.D. Mean ∆Ct ∆Ct S.D. 
18S 6.56 0.12 -14.07 0.13 
MDR1 21.08 0.05 0.60 0.11 
MRP1 24.49 0.05 3.87 0.28 
MRP4 25.84 0.02 5.22 0.23 
ABCG2 25.22 0.26 4.59 0.48 
ABL1 27.40 0.14 6.78 0.39 
β-actin 19.56 0.09 -1.07 0.30 
AKT1 24.99 0.38 4.37 0.49 
BCR 26.37 0.31 5.74 0.08 
CASP3 27.25 0.20 6.62 0.18 
CD34 >40.00 N/A Nd nd 
CD38 >40.00 N/A Nd nd 
GAPDH 20.62 0.25 Endogenous control 
HIF1A 24.94 0.14 4.32 0.34 
CD133 >40.00 N/A 19.38 0.25 
SLC22a1 (OCT1)  33.47 1.89 12.85 1.85 
SLC22a2 (OCT2) >40.00 N/A Nd nd 
SLC22a3 (OCT3) >40.00 N/A Nd nd 
SLC22a4 (OCTN1) 27.88 0.18 7.26 0.22 
SLC22a5 (OCTN2) 27.59 0.09 6.96 0.33 
SLC22a6 (OAT1) >40.00 N/A nd nd 
SLC22a7 (OAT2) >40.00 N/A nd nd 
SLC22a8 (OAT3) >40.00 N/A nd nd 
SLC22a9 (OAT4) >40.00 N/A nd nd 
 
Table 6-2 An example of one sample tested in duplicate on different 
plates representing the S.D. both at Ct and ∆CT 
The experiment was completed in 40 cycles. A value of greater than 40 
cycles suggested either expression was below the level of detection or 
there was no expression. GAPDH was used as the endogenous control; 
n=3, nd=not detected, n/a= not applicable 
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6.2 Expression of drug transporters in cell lines 
Following validation, the cell lines used as models for optimisation of experiments 
in the previous chapters were analysed. Table 6-3 details the ∆Ct of the drug 
transporters in the cell lines. 
 K-WT ∆Ct K-MDR ∆Ct K-MRP ∆Ct AML3 ∆Ct AML6.2 ∆Ct 
Detector Mean S.E Mean S.E Mean S.E Mean S.E Mean S.E 
MDR1 nd nd 0.51 0.56 15.91 0.56 nd nd nd nd 
MRP1 4.71 0.21 3.93 0.09 -0.03 0.09 6.42 0.02 6.54 0.16 
MRP4 4.76 0.20 5.22 5.28 4.30 0.20 7.09 0.12 6.47 0.02 
ABCG2 8.77 0.28 4.73 0.26 6.13 0.26 nd nd 0.81 0.03 
GAPDH Endogenous control 
SLC22a1 
(OCT1)  
2 of 5 12.85 1.07 1 of 2 1 of 3 5.46 6.98 
SLC22a2 
(OCT2) 
nd nd nd nd nd nd nd nd nd nd 
SLC22a3 
(OCT3) 
nd nd nd nd nd nd nd nd nd nd 
SLC22a4 
(OCTN1) 
8.20 0.15 7.27 0.02 7.08 0.02 9.98 0.23 8.62 0.27 
SLC22a5 
(OCTN2) 
6.11 0.34 7.05 0.09 6.60 0.09 8.98 0.05 8.17 0.01 
SLC22a6 
(OAT1) 
nd nd nd nd nd nd nd nd nd nd 
SLC22a7 
(OAT2) 
nd nd nd nd nd nd nd nd nd nd 
SLC22a8 
(OAT3) 
nd nd nd nd nd nd nd nd nd nd 
SLC22a9 
(OAT4) 
nd nd nd nd nd nd nd nd nd nd 
 
Table 6-3 Expression of drug transporters in parental and transfected 
cell lines 
n=5 for K-WT, n=3 for K-MDR, n=2 for K-MRP, n=3 for AML3, n=3 for 
AML6.2. All samples were carried out in duplicate, nd=not detected 
 
The genes analysed demonstrate effective MDR1 and MRP1 transduction of the 
parental cell line (K-WT) to produce the cell line K-MDR and K-MRP respectively 
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(MDR1 in K-WT ∆CT=nd vs. K-MDR ∆Ct=0.51; MRP1 in K-WT ∆Ct=4.71 vs. K-
MRP ∆Ct=-0.03, p=0.02). Similarly, effective ABCG2 transduction of the parental 
AML3 cell line was observed to produce AML6.2 (AML3 ∆CT=nd vs. AML6.2 
∆Ct=0.81).  
However, in addition to the elevated expression of the transduced genes, other 
drug transporters also demonstrated significant differences of expression in these 
cell lines compared to the parental cell line. In K-MDR cell line, there was a 
significant increase in the ∆CT of MRP1 (p=0.02), ABCG2 (p=0.001) and 
SLC22a4 (p=0.02), compared to K-WT cell line. The ∆CT for ABCG2 and 
SLC22a4 were also increased in the K-MRP cell line, compared to K-WT (p=0.003 
and p=0.008 respectively) and MDR1 was expressed in the transduced K-MRP 
cell line (K-MRP ∆Ct=15.91), compared to K-WT, where expression was below the 
threshold of detection or not expressed (K-WT ∆CT=nd). Similarly, the ∆Ct of 
MRP4, SLC22a4 and SLC22a5 were also elevated in the AML6.2 cell line, 
compared to the AML3 parental line (p=0.03, p=0.03, p=0.001 respectively). These 
findings suggest that manipulation of one transporter resulted in the modulation of 
the endogenous levels of other transporters. This therefore emphasises the 
necessity to fully characterise cell lines before interpreting results. 
The ∆Ct values were analysed with the RQ equation (see section 3-1), thereby 
translating the ∆CT values into relative differences, which allows the comparison 
of the target sample (i.e. transduced cell line) against the calibrator sample (i.e. 
parental cell line, Figure 6-1). Although the MDR1 cell line had statistically 
elevated ∆Ct values for MRP1, ABCG2 and SLC22a4, only the gene ABCG2 
demonstrated greater than 3 fold increase in K-MDR compared to K-WT (1.72 fold 
for MRP1, 16.39 fold for ABCG2 and 1.9 fold for SLC22a4).  
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The RQ equation was also used to compare the ∆Ct values of drug transporters in 
the K-MRP cell line with K-WT. The transduction of MRP1 resulted in a 26.7 fold 
overexpression of the gene in the transduced cell line. In addition, ABCG2 was 6.2 
fold higher in K-MRP compared to K-WT. However, although there was a 
significant difference in ∆CT values with SLC22a4, the relative difference resulted 
in only 2.2 fold increase in K-MRP compared to K-WT.  
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Figure 6-1 Relative expression of drug transporters in the transduced 
cell lines K-MDR and K-MRP relative to the parental cell line K-WT 
Relative expression of K-MDR (A) and K-MRP (B) relative to the parental 
cell line K-WT; nd=not detected, ++= signal, *∆CT=p<0.05, n=3 
16.4x 
1.7x 1.9x 
26.7x 
6.2x 
2.2x 
1.4x 1.9x 
1.4x 1.4x 
nd ++ 
* 
* 
* 
* 
* 
* 
* 
nd ++ 
A. 
B. 
SLC22a4    SLC22a5    
SLC22a4  SLC22a5    
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Similarly, the transduction of ABCG2 in the parental AML3 cell line resulted in 
differences in the ∆Ct values of MRP4, SLC22a4 and SLC22a5; although none 
demonstrated greater than 3 fold relative difference (1.5 fold, 2.6 fold and 1.8 fold 
greater expression in AML6.2 compared to AML3, Figure 6-2). 
 
ABCG2 MRP1 MRP4 OCTN1 OCTN2
R
Q 
(2-
D
D
CT
)
0
1
2
3
4
5
AML3
AML6.2
 
Figure 6-2 Relative expression of drug transporters in the transduced 
cell line AML6.2 relative to the parental cell line AML3 
nd=not detected, ++= signal, *∆CT=p<0.05, n=3 
 
6.3 Expression of drug transporter genes in a CML cell 
line (K562) following drug treatment with TKIs 
The parental cell line was then treated with TKIs to determine whether the 
exposure to these drugs modulated the expression of drug transporters (Figure 
6-3).  
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Figure 6-3 Relative expression of drug transporters in a K-WT cell line 
during treatment with TKIs. 
The relative expression of ABCG2 (A), OCT1 (B), SLC22a4 (C), SLC22a5 
(D), MRP1 (E), MRP4 (F) and MDR1 (G) in K-WT cell line treated with 5µM 
A. 
G. 
F. E. 
D. C. 
B. 
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IM (black fill), 5µM nilotinib (dark grey fill), or 150nM dasatinib (light grey 
fill), compared to no drug control (ND, white fill) at days 1, 2 and 3; n=1 in 
duplicate, nd=not detected, ++= signal. Figure G has a larger RQ scale 
compared to the other figures 
The relative expression of ABCG2 (Figure 6-3A) was increased in the presence of 
TKIs at day 1, 2 and day 3, with the maximal increase observed on day 2 
compared to the control. Similarly, this trend was also observed with MRP1 
(Figure 6-3E), although the fold change in MRP1 did not reach above 3 fold. In 
addition, there was maximal expression of MDR1 at day 2 (Figure 6-3G), although, 
in contrast to the trend for ABCG2 and MRP1, there was much lower relative 
expression of the treated arms compared to the untreated control at day 1.  
The expression of OCT1 (Figure 6-3B) was elevated at day 1 with active 
expression observed at day 2 with all three TKIs. However, at day 2 there was no 
expression of OCT1 detected in the control group after 40 cycles, suggesting that 
either there was no expression or the expression was below the threshold of 
detection. Therefore, although OCT1 was detected on day 2 in the presence of 
TKIs, the expression could not be quantified due to the absence in the untreated 
control. At day 3 the expression of OCT1 was reduced compared to the control 
with IM and reduced to less than 2 fold higher with nilotinib and dasatinib. This 
suggested that the TKIs maintain increased OCT1 expression in cells that may 
have very little or no expression otherwise.   
This suggested that TKIs induced the expression of these drug transporters to 
varying degrees, with the maximal effect shown on day 2. It might be that this 
trend was related to cell death caused by the TKIs, which may affect the 
expression of these transporters. Also by cells dying that did not express the 
transporters you would get an apparent increase in expression in the remaining 
cells.  
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In contrast the greatest expression of SLC22a4 (Figure 6-3C) and SLC22a5 
(Figure 6-3D) were shown on day 1, which was increasingly reduced at days 2 and 
3. Indeed the expression of SLC22a5 was similar to the control group by day 3. 
This suggested that the TKIs exert their maximal effect on these transporters 
earlier compared to transporters ABCG2 and MDR1 where the maximal effect was 
demonstrated on day 2. These transporters are present on the same chromosome 
and hence are co-regulated, which would support the similar trend.  
In contrast to these transporters the expression of MRP4 (Figure 6-3F) was 
elevated slightly on day 1 and 2, but did not reach greater than 2 fold, suggesting 
there was minimal effect by TKIs on this transporter. 
The greatest elevation at each day was shown in the cells treated with dasatinib 
and indeed this trend was shown for every transporter with the exception of OCT1, 
suggesting that dasatinib had the most effect in modulating the regulation or 
expression of drug transporters. 
6.4 Expression of drug transporters on CML and normal 
CD34+ cells 
In total, 11 CML CD34+ samples were analysed and compared to 7 normal 
counterparts. In table 6-1, the values presented are of the crossing thresholds 
normalised to GAPDH.  
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 Normal ∆Ct CML ∆Ct  
Detector Mean S.E. Mean S.E. ∆∆CT 
ABCG2 9.09 0.33 7.55 0.22 -1.54 
MDR1 5.44 0.24 8.33 0.47 2.89 
MRP1 4.70 0.39 4.81 0.35 0.11 
MRP4 6.55 0.22 4.31 0.20 -2.24 
SLC22a1 (OCT1)  nd nd nd nd nd 
SLC22a2 (OCT2) nd nd nd nd nd 
SLC22a3 (OCT3 nd nd nd nd nd 
SLC22a4 (OCTN1) 10.28 0.22 8.68 0.26 -1.60 
SLC22a5 (OCTN2) 7.53 0.40 7.36 0.43 -0.17 
SLC22a6 (OAT1) nd nd nd nd nd 
SLC22a7 (OAT2) nd nd nd nd nd 
SLC22a8 (OAT3) nd nd nd nd nd 
SLC22a9 (OAT4) nd nd nd nd nd 
 
Table 6-4 ∆CT values of drug transporters in CML and normal CD34+ 
with their corresponding ∆∆CT values 
n=11 for CML, n=7 for normal, nd=not detected 
 
In comparison to normal ∆CT values, CML samples demonstrated significantly 
higher levels of ABCG2 (p<0.001), MRP4 (p<0.0001) and SLC22A4 (p<0.001) and 
significantly lower expression of MDR1 (p=0.0028). 
Using the RQ equation comparing the target CML sample against the calibrator 
sample (normal mPB), the difference in the drug transporters was calculated 
(Figure 6-4). The mRNA levels of ABCG2, MRP4 and SLC22A4 were 2.91 fold, 
4.72 fold and 3.03 fold higher respectively in CML CD34+. In contrast CML CD34+ 
cells had 7.42 fold less MDR1 expression than the normal counterparts. There 
was no difference with either MRP1 or SLC22a5. 
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Figure 6-4 Relative expression of drug transporters in CML CD34+ 
The relative expression of the drug transporters in CML CD34+ (light grey) 
relative to normal (black) counterparts, n=11 for CML, n=7 for normal 
 
In addition, 4 CML samples and 4 normal counterparts were also analysed on a 
separate TLDA card specific for another project. GAPDH was again used as the 
endogenous control (Table 6-5). 
 
 Normal ∆Ct CML ∆Ct  
Detector Mean S.E. Mean S.E. ∆∆CT 
ABCA1 7.97 0.32 11.33 0.66 3.36 
ABCG1 6.1 0.13 9.67 0.48 3.57 
 
Table 6-5 ∆CT values of drug transporters in CML and normal CD34+ 
with their corresponding ∆∆CT value (second set) 
n=4 for CML, n=4 for normal, nd=not detected 
7.42x 
2.91x 
4.72x 
3.03x 
SL 22a4  SLC22a5    
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In comparison to normal ∆CT values, CML samples demonstrated significant 
lower levels of ABCA1 and ABCG1 (p<0.001), two additional transporters from the 
ABC family that mainly efflux cholesterol. Using the RQ equation comparing the 
target CML sample against the collaborator sample, the mRNA of ABCA1 and 
ABCG1 were 10.27 and 11.88 fold lower in CML cells. 
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Q
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Table 6-6 Relative expression of drug transporters in CML CD34+, 
(second set) 
The relative expression of the drug transporters in CML CD34+ (light grey) 
relative to normal (black) counterparts, n=4 for CML, n=4 for normal 
 
6.5 Expression of drug transporters following treatment 
with TKI 
Following expression analysis of drug transporters, CML CD34+ cells were treated 
with 5µM IM for 72hrs in an attempt to identify the drug transporters that are 
modulated. 
10.27x 11.88x 
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Significant differences of CT were observed with every drug transporter, however, 
significant differences of CT were also observed with the endogenous controls, 
which were not consistent, raising the possibility of technical issues. Further 
investigation of the quality of the RNA demonstrated significant degrading by 
72hrs (Figure 6-5). Indeed, degradation was observed as early as 24hrs post 
culture even in the absence of TKI treatment, preventing comparative analysis. 
This may be due to the high levels of proteases and endonucleases in CML cells 
which will decrease the possibility of isolating good quality RNA from these cells.   
 
 
Figure 6-5 Agilent gel of RNA extracted from CML CD34+ cells ± IM 
treatment 
L-Ladder, 1- untreated CML CD34+ at day 0, 2- untreated CML CD34+ at 
day 3, 3- CML CD34+ cell treated with 5µM IM, 4- K-WT, 5- AML3. 
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6.6 Summary 
This chapter demonstrated the expression of drug transporters in cell lines, CML 
CD34+ and normal counterparts and attempted to investigate the expression 
following treatment with TKIs. Prior to any investigations however, the TLDA card 
was validated in our lab.  
The cell lines used as models for optimisation in the previous chapters were then 
analysed. Surprisingly, when individual transporters were overexpressed, we 
observed modulation of not only the transduced gene but also other related 
transporters. Indeed the ∆CT of ABCG2 was significantly lower (demonstrating 
higher expression) when either MDR1 or MRP1 were transduced, demonstrating 
>6 fold increased expression by the relative quantification calculation. Similarly, 
the overexpression of MRP1 induced the endogenous expression of MDR1, which 
was either absent or below the level of detection in the wild-type cell line. This 
observation may be due to two possibilities. It may suggest that the induced 
expression of drug transporters in cell lines modulate the expression of other drug 
transporters, demonstrating a linkage between ABCG2, MDR1 and MRP1, which 
are the clinically relevant efflux transporters in CML. Alternatively, the induced 
expression may be due to the presence of GFP, either directly acting as a 
substrate and hence inducing transporter activity, or indirectly inducing transporter 
expression via an unknown mechanism. In order to confirm whether GFP alone 
can induce the expression of transporters, the same K-WT cell line used to 
transduce the specific transporters should also be transduced with an empty 
vector containing only GFP to be tested as a control. Unfortunately, such a control 
was not available during this project and hence the cause of the modulation was 
not confirmed. These modulations however, do highlight the possible limitations of 
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relying on experiments directly comparing engineered cell lines to wild-type, and 
re-affirm the importance of using specific inhibitors that target only the gene in 
question.     
The treatment of the wild-type K562 with IM, nilotinib or dasatinib demonstrated an 
effect on the drug transporters tested. Indeed, modulation was shown in all the 
drug transporters with at least a 3 fold increase compared to the no drug control 
group in all transporters except for MRP4 during a 72hr period. Treatment with 
TKIs showed greatest modulation of MDR1, reaching >17 fold higher expression at 
48hrs. These data suggest that the presence of the TKIs induce the cell to 
increase the expression of the drug transporters. This may be as a cellular 
defence mechanism as the role of transporters is to actively extrude foreign toxic 
compounds. However, these results are only based on one experiment and 
require several repeats for confirmation of these trends.   
The expression of drug transporters in CML CD34+ cells was compared to normal 
counterparts. As detailed in the earlier chapters, there was a significant reduction 
of MDR1 mRNA in the CML cells compared to the normal counterparts and similar 
expression of MRP1 in both cohorts. In this population, the ABCG2 expression 
was significantly elevated in CML cells (2.91 fold) compared to the normal 
counterparts. However the fold change was much lower than that detailed in 
chapter 3. The CD34+ cells in this cohort were handled in the same manner yet it 
includes a different set of patients, which may explain the variation. 
The comparison of drug transporter expression in CML CD34+ cells following 
treatment with TKIs was not possible due to the problems faced in obtaining RNA 
of good quality. Even after 24hrs, the RNA extracted had significantly degraded. 
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The isolation of RNA was attempted with several kits, including Qiagen (Qiagen, 
Crawley, United Kingdom) and PARIS RNA isolation (Ambion, Austin, USA), but 
the problem persisted. This outcome was also faced by colleagues in a 
collaborative laboratory who also were unable to extract good quality RNA 
following IM treatment (personal communication), and other laboratories, 
suggesting that this may not be achievable. 
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7 Discussion 
Although CML was probably first described as early as the nineteenth century, 
until recently there was little progress in understanding the biology of the disease, 
and hence the treatment options available were limited to either allogeneic 
transplantation, for a minority of patients, or a combination of IFNα and Ara-C; 
both of which were associated with risks and problems. However, the discovery of 
the Ph+ chromosome in the 1960’s (Rowley 1973) and realisation that the resulting 
BCR-ABL fusion gene was the molecular cause of disease in >95% of patients 
(Druker et al. 2001), presented the opportunity for molecularly targeted therapy. 
The first targeted small molecule drug IM was the result of this insight and 
dramatically altered the course of CML treatment. Following the success of Ph+ 
tumour eradication in murine models, IM has been part of an ongoing multicentre 
phase III clinical trial (IRIS) designed to compare this agent to the previous best 
treatment of conventional IFNα and Ara-C. Within the first 18 months of the clinical 
trial, patients treated with IM demonstrated excellent cytogenetic responses and 
fewer patients progressed to more aggressive disease compared to conventional 
treatment (O'Brien et al. 2003). This resulted in the widespread use of IM for the 
initial treatment of CP CML and currently it is the first choice in patients, even for 
those who are eligible for transplantation. However, it is now becoming evident 
that only a few patients treated with IM achieve CMR, and another set of patients 
lose their initial cytogenetic and haematological response (Hochhaus et al. 2002; 
Hughes et al. 2003). The underlying reasons for this have not been resolved and 
are the topic of much debate (Figure 7-1). 
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Figure 7-1 Mechanisms of resistance 
 
One of the most described mechanisms of resistance observed in relapsed 
leukaemia patients is the development of point mutations within the kinase domain 
(Gorre et al. 2001). To date, there are approximately 50 different aa substitutions 
(Azam et al. 2003) described in IM resistant clinical samples and the emergence of 
these mutations generally confers a poor prognosis (Branford et al. 2003). 
Although these mutations have been shown to exist prior to IM therapy (Roche-
Lestienne et al. 2002), it has been suggested that they offer no survival advantage 
until the cells are exposed to IM. In order to overcome such resistance, there has 
been the development of new generation agents that have successfully inhibited 
most of the kinase domain mutations and can bind to both the active and inactive 
conformations of BCR-ABL. However, the incidence of mutations as the underlying 
mechanism for resistance is uncertain. Some studies have detected a low level of 
BCR-ABL kinase mutations in CD34+ cells from patients both pre (Jiang et al. 
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2007a) and post IM treatment (Chu et al. 2005) however other studies have 
demonstrated no mutants in the resistant population in vitro (Copland et al. 2006).  
BCR-ABL amplification has also been described as a resistance mechanism, as it 
may lead to increased mRNA and protein concentration. Amplified transcripts have 
been shown in Ph+ BC cell lines and patients with advanced disease (Gorre et al. 
2001). Furthermore, prolonged IM exposure has been shown to increase gene 
amplification (le Coutre et al. 2000). However, gene amplification has not 
previously been reported in early CP. Indeed, it has been reported that primitive 
CD34+ cells have higher transcript levels despite only having one copy of BCR-
ABL (Copland et al. 2006; Jiang et al. 2007b). Therefore, it is possible that high 
protein level is still important, but not as a result of gene amplification. 
Although many groups have described these mechanisms, resistance cannot be 
wholly attributed to gene mutations or amplifications, as IM does not eradicate all 
the leukaemic cells even in the best responders. Recently a small subpopulation of 
cells that remains resistant to IM has been detected; these qSC are resistant even 
at IM concentrations 10 fold higher than those achievable in vivo ((Holyoake et al. 
1999; Graham et al. 2002). It has therefore been hypothesised that it is these 
primitive cells that are responsible for MRD and may form a pool of cells that can 
reactivate and cause disease relapse. Indeed, patients who stopped IM after 
achieving CMR relapsed rapidly (Cortes et al. 2004), demonstrating the existence 
of this population. Furthermore, in vitro studies have shown that these cells still 
persist with nilotinib treatment (Jorgensen et al. 2007a) and, although a little more 
responsive, persist in the presence of dasatinib (Copland et al. 2006). 
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In light of these qSC there have been 2 mathematical models proposed that 
discuss the potential ability of IM to eradicate CML cells, including this qSC 
population, which may then also be applied to the activity of other TKIs. Michor et 
al (Michor et al. 2005) suggest that although IM can reduce the proliferating and 
differentiating cells, it will not reduce the qSC population. This assumption is 
based on the initial biphasic decline in the BCR-ABL transcripts, whereby the initial 
rapid decline represents the death of the differentiated cells followed by the much 
slower decrease of the more primitive CML progenitors. Indeed the BCR-ABL 
transcripts rapidly increased in patients who discontinued IM therapy following 
CMR (Cortes et al. 2004; Mauro et al. 2004). Therefore, this model suggests that 
IM is unlikely to eradicate CML. 
In contrast, the second hypothesis is based on the key assumption that stem cells 
will be recruited into cell cycle periodically (Roeder et al. 2006). When this occurs 
these cells will begin cycling and become sensitive to IM. Hence, over time, the 
qSC pool will be depleted, supporting the observation that levels of MRD continue 
to fall over prolonged periods of IM treatment (Branford et al. 2004). Thus, 
assuming no IM resistant clone arises, this model predicts that IM may eventually 
completely eradicate the leukaemic cells, although it is estimated it will take in 
excess of 20 years to achieve. They further propose however, that the IM effect 
may be accelerated using agents that induce cycling activity, producing a more 
efficient tumour load reduction.  
Based upon the latter proposal, Jorgensen et al (Jorgensen et al. 2006) have 
investigated the effect of treating CML CD34+ cells with IM in combination with the 
growth factor G-CSF. A significant reduction of primitive CD434+ cells was 
observed following intermittent exposure to G-CSF compared to continuous 
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treatment of IM alone, which was further enhanced when the cells were treated 
with a combination of IM and intermittent G-CSF, supporting the above 
mathematical model. Indeed, the enhanced reduction of cells in vitro led to a 
multicentre clinical trial that further investigated the potential clinical use of growth 
factors in combination with IM to improve long-term outcomes in CP CML. 
However, no significant difference was observed in patients treated with the 
combination of G-CSF and IM compared to continuous IM alone, indicating no 
further benefit compared to standard IM treatment (Heaney 2007). 
In addition, combinations of IM with other agents have been attempted to optimise 
established therapies, but with limited success. However, lonafarnib, a farnesyl 
transferase inhibitor (FTI), showed effects on the quiescent CD34+ population in 
combination with IM (Jorgensen et al. 2005a) and as a single agent, lonafarnib 
improved treatment in a limited number of patients who failed IM (Borthakur et al. 
2006).  
However, for these models to succeed, optimal TKI plasma and intracellular 
concentrations are necessary. It has been suggested that suboptimal intracellular 
TKI concentration may contribute to drug resistance. Gambacorti et al suggested 
that excessive IM binding to plasma proteins might significantly alter the 
availability of active drug. Alpha-1 acid glycoprotein (AGP) is a hepatic acute 
phase protein that was shown to bind and inhibit IM (Gambacorti-Passerini et al. 
2000), although another study did not support this finding and demonstrated that 
CML-derived AGP does not contribute to the leukaemic resistance (Jorgensen et 
al. 2002). 
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Alternatively, active efflux transporters may prevent optimal TKI concentrations 
being achieved in the cell. It is well established that ABC transporters are present 
on normal stem cells and their role is to extrude toxic substances. Furthermore, 
these transporters have been shown to efflux chemotherapeutic substrates and 
small molecule drugs, therefore it can be postulated that intracellular TKI 
concentrations are limited by active transport by this family of transporters. Indeed, 
until recently, an option for patients failing IM was to increase the dose. Although 
some found that this improved or reinstated the previous response, (Kantarjian et 
al. 2003; Zonder et al. 2003) this was not universal (Marin et al. 2003). This thesis 
has concentrated on the role of ABC proteins in mediating drug resistance, with 
the aim of further enhancing the TKI effect in the CML CD34+ cell population and 
the IM resistant qSC. 
7.1 Expression and function of drug transporters 
In this study, we compared the expression of the most clinically relevant of these 
transporters and demonstrated that, at the mRNA level, ABCG2 was significantly 
elevated in CML samples compared to normal counterparts, while MDR1 was 
significantly reduced. This is in partial agreement with Jiang et al (Jiang et al. 
2007b) who have reported elevated expression of both genes in leukaemic CD34+ 
cells. However, the disparity in the results may be due to a number of factors that 
would render valid comparison of these two studies impossible. First and foremost, 
the choice of samples may influence the expression levels. Jiang et al examined 
only the specimens in which long-term culture initiating cells (LTC-ICs) were 
predominately Ph+/BCR-ABL+ and may therefore be preferentially selecting the 
samples with more aggressive CML. Secondly, it seems that all of the Jiang et al 
samples were subject to cell sorting into different populations by Hst and Py prior 
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to experimental analysis. Both stains are actively effluxed by the ABCG2 and MDR 
proteins (Goodell et al. 1996) thus this selection protocol may preferentially select 
the CD34+ cells with the more active transporters or induce their expression. 
Indeed, as demonstrated in chapter 6, the expression of drug transporters are 
often linked, hence the induced efflux by the use of substrate dyes of one 
transporter may also alter or induce the expression of another. In contrast, in our 
study we randomly selected a number of CML samples from the cell bank for 
investigation, which were then thawed and the RNA was immediately extracted for 
analysis. Hence, the cohort analysed in this project was selected in a different 
manner, without manipulation or subfractionation, other than CD34+ enriching by 
positive immunomagnetic selection. We consider that our data will therefore better 
reflect the baseline expression in standard CML CP CD34+ cells, as increased 
MDR1 may be a sign of aggressive disease or sample manipulation. We would 
also suggest that caution should be employed in using substrate dyes for selection 
of samples to be used in transporter assays. 
In addition we determined that the mRNA level of MRP1 in CML CD34+ cells was 
similar to that in normal mPB CD34+ cells. The transcript levels of MRP1 in CML 
CD34+ cells has not previously been reported by other groups, although Carter et 
al (Carter et al. 2001) have demonstrated equal mRNA transcripts in MNCs from 
healthy donors and CML patients. However, these populations had less than 3% 
CD34+ content so, again, a direct comparison cannot be made.  
Further analysis confirmed that these drug transporters were also functional in 
these cells, suggesting that it is reasonable to propose that active efflux of TKIs 
from cells may take place and may have a role in drug resistance. Interestingly, 
the expression pattern of ABCG2 on these CML cells contrasted to that previously 
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observed in AML patient samples. In this study we observed that a greater 
proportion of the cell population had active ABCG2 expression rather than higher 
expression on a small subpopulation, suggesting that ABCG2 expression is not 
only restricted to the primitive CD34+38- population as in normal cells (Figure 7-2).  
 
Figure 7-2 ABCG2 expression in normal and CML haemopoietic cells 
ABCG2 is normally highly expressed in CD34+38- HSC and switched off in 
the more maturing cell lineages. In CML we propose that the expression of 
ABCG2 may be found on the majority of the CD34+ cells, suggesting a 
greater proportion have the active transport rather than a high expression 
level restricted to a small subpopulation; SC-multipotent stem 
cell/haemangioblast, HSC- haemopoietic stem cell, HPC-haemopoietic 
progenitor, CPC- CML progenitor. Green shading indicates ABCG2 
expression levels. 
 
Our observation that ABCG2 expression was also detected in the more mature 
CD34+ cells suggests that the activity is regulated by BCR-ABL in the CML cells. 
Indeed, it has been shown that BCR-ABL phosphorylates the tyrosine kinase AKT 
(Mayerhofer et al. 2002) and that AKT also increases the translocation of ABCG2 
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(Mogi et al. 2003; Takada et al. 2005), supporting this hypothesis. In addition, the 
activation of AKT induces HIF1α (Mayerhofer et al. 2002), which has also been 
shown to up-regulate the expression of ABCG2 mRNA (Mogi et al. 2003; 
Krishnamurthy et al. 2004), suggesting that BCR-ABL driven AKT activity would 
both upregulate ABCG2 mRNA and increase translocation to the surface. More 
recently, Nakanishi et al (Nakanishi et al. 2006) have confirmed this connection 
and demonstrated that BCR-ABL enhances the expression of ABCG2 via 
activation of the AKT pathway; although this work was carried out in cell lines, it 
complements our data that ABCG2 is up-regulated in CML CD34+ cells (Figure 
7-3). 
 
Figure 7-3 ABCG2 regulation by BCR-ABL activity 
BCR-ABL phosphorylates the tyrosine kinase AKT, which in turn may 
increase the translocation of ABCG2. In addition, phosphorylated AKT may 
induce HIF1α, which in turn regulates ABCG2 mRNA. 1. (Mayerhofer et al. 
2002). 2. (Mogi et al. 2003). 3. (Takada et al. 2005), 4. (Krishnamurthy et al. 
2004) 
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Furthermore, we can postulate that ABCG2 may be regulating the expression of 
the CD34 protein itself as inhibition of this transporter resulted in a reduction of 
proliferating CD34+ cells by a mechanism other than apoptosis or 
maturation/differentiation. Indeed, over-expression of ABCG2 in HSC has been 
shown to result in an accumulation of CD34+ cells (Krishnamurthy et al. 2004; 
Takada et al. 2005) and over-expression in human BM cells has resulted in an 
increase in proliferation of progenitor cells and myeloid engraftment in NOD/SCID 
mice (Ahmed 2005). If ABCG2 therefore does regulate CD34+ expression, then it 
may further question whether all the CML cells that are ABCG2+ and CD34+ are 
immature or whether the expression of both these “stem cell” markers are 
aberrantly regulated by BCR-ABL. Indeed, some CML CD34+ cells have been 
shown to have aberrant expression of other surface proteins such as CD56 (Lanza 
et al. 1993) and CD7 (Yong et al. 2006), so it may therefore not be unrealistic to 
postulate that BCR-ABL has an effect on the expression of such surface proteins. 
These suggestions could be confirmed using murine transplantation assays to 
investigate the reconstituting capacity and tumourgenicity of CML CD34+ cells 
treated with FTC, an inhibitor of ABCG2, in comparison to control CML and normal 
cells. 
7.2 Interaction of TKIs with drug transporters 
7.2.1 Influx transporters 
Having confirmed that the transporters are expressed and functional in these cells 
we aimed to further establish their role with regard to TKIs. There has been much 
debate as to the role of both influx and efflux transporters in limiting the 
intracellular concentration of IM and other TKIs. Several recent studies have 
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identified that the active transport of IM is dependent upon OCT1 (Thomas et al. 
2004; White et al. 2006). Indeed, low activity of OCT1 has been identified as a 
cause of suboptimal clinical response to IM in CML patients (White et al. 2007), 
which may be overcome by increasing the IM dose. Surprisingly, nilotinib is not 
transported by OCT1, despite being highly structurally related to IM (White et al. 
2006), therefore suggesting that there may be other transporters not yet identified 
that also play a role in TKI transport. Alternatively, the increased lipophilic nature 
of nilotinib compared to IM may also suggest that uptake may be a passive 
process (unpublished data). 
However, there is controversy as to whether the baseline expression of OCT1 
prior to therapy correlates with disease progression. Wang et al (Wang et al. 2007) 
showed high baseline OCT1 mRNA and demonstrated that expression of this 
transporter was a powerful indicator of CCR within 6 months. However, most of 
these patients had prior treatment or were in the late stages of CP. Similarly, 
Crossman et al (Crossman et al. 2005a) also demonstrated OCT1 expression 
although their cohort also comprised of patients who had undergone prior therapy. 
In contrast, White et al (White et al. 2007) demonstrated that despite a correlation 
with OCT1 mRNA and activity, the expression of OCT1 alone is not itself a strong 
indicator of molecular response. The limiting factor of all these expression studies 
however, was that they were all examined in MNCs of PB or BM and Jiang et al 
(Jiang et al. 2007b) have previously shown that the expression differs in the cell 
populations, with the highest OCT1 mRNA expression in the lin+CD34- subset. 
Therefore, the varying level of expression in the different lineages may conceal the 
correlation of OCT1 expression and activity in the primitive progenitor population. 
We examined the expression of OCT1 in CD34+ cells from newly diagnosed CP 
patients prior to commencement of IM treatment, but demonstrated the level to be 
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below the threshold of detection. We have not monitored these patients during 
their treatment, but can say that due to the lack of expression of OCT1 levels prior 
to onset of therapy in CP patients, this is unlikely to be a useful indicator of 
molecular response at onset of treatment. It is probable that the expression may 
develop with disease progression and/or it may be induced by therapy. Indeed, 
although only demonstrated once, we have shown that treatment with TKIs in K-
WT cell lines induced the expression of OCT1. If this is confirmed with further 
testing, then induction of OCT1 may prove to be a valuable prognostic tool in late 
CP patients and for disease monitoring rather than as a predictive tool prior to 
treatment commencement.  
In addition to OCT1, there are many other influx transporters that may also 
mediate TKI transport. To date, the studies reported on influx transporters have 
been limited to OCT1-3. In our study, we also included other members of the 
SLC22 family. Our data showed that the cation and carnitine transporters 
SLC22A4 and SLC22A5 (OCTN1 and OCTN2) were also expressed on the 
primary CML CD34+ cells, with 3 fold higher expression of SLC22a4 compared to 
expression levels on their normal counterparts. This suggests that they may have 
a role in TKI transport. Future studies of TKI uptake should be extended to include 
these transporters in addition to OCT1-3. 
7.2.2 Efflux transporters 
There have also been many reports investigating the interaction of efflux 
transporters with the current TKIs, but with strongly contrasting results. The 
interaction of IM with ABCG2 was first examined by Houghton et al (Houghton et 
al. 2004), who reported that IM is not a substrate but rather a potent inhibitor for 
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this transporter. However, shortly after, Burger et al (Burger et al. 2004) 
demonstrated that ABCG2 over-expressing cell lines were resistant to IM, 
concluding IM to be a substrate for ABCG2. This was supported by another report 
describing the active transport of IM across transepithelial layers of MDCKII cells 
that have been transfected with ABCG2 (Breedveld et al. 2005). However, there 
has been a recent study that has suggested the interaction between ABCG2 and 
IM is more complex and concentration dependent so IM may be both acting as an 
inhibitor and a substrate due to its high affinity for ABCG2 (Hegedus et al. 2002; 
Nakanishi et al. 2006; Shukla et al. 2007). At very low concentrations, IM behaves 
like a substrate, but becomes an inhibitor at high concentrations. Shukla et al 
(Shukla et al. 2007) have demonstrated that IM does not interact at the ATP 
binding site of ABCG2, but that it stimulates ATP hydrolysis, which is coupled with 
efflux function. However, IM can effectively inhibit the binding of a known ABCG2 
substrate with an IC50 value of 0.47µM (Shukla et al. 2007) and another group has 
further reported that 0.8µM IM can effectively inhibit ABCG2-mediated Hst 
transport (Brendel et al. 2007). Therefore, the high affinity of IM for ABCG2, 
suggests that there is a narrow concentration range in which ABCG2 can transport 
IM, and that it can inhibit the protein at a higher concentration (Shukla et al. 2007). 
This may therefore explain why Burger et al observed active IM efflux when they 
used 200nM 14C IM in their transport studies, where as Houghton et al confirmed 
inhibition with a higher IM concentration of 1µM. 
Nevertheless, the observation that IM is a substrate at <0.8µM is not relevant in a 
clinical scenario as a standard 400mg once-daily administration of IM produces 
plasma cellular concentration ranging between 1.2µg/ml (2µM) at trough to 
2.6µg/ml (4.8µM) at peak levels (Peng et al. 2005). Therefore, in vivo, the 
concentration of IM will be 2-3 fold higher than that required for ABCG2 inhibition, 
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even at trough levels. Also, it has been shown that the IM concentration is similar 
in plasma and BM (unpublished data), therefore, in compliant patients, IM will 
never be at a level at which active efflux will occur, but instead IM will inhibit this 
transporter.  
Although these reports hint at the interaction of IM with ABCG2, the limitation of all 
these transport studies is that they have not been carried out in primary tumour 
cells, hence do not resemble in vivo conditions. Indeed, they have not even been 
performed in the correct cell lines that represent the clinical targets for IM - that is 
CML or gastro-intestinal stromal tumour (GIST) lines, but instead in cell lines 
engineered to over-express ABCG2. Furthermore, the interaction of IM with 
ABCG2 should be tested at a clinically relevant therapeutic concentration. In our 
studies, we investigated the interaction of IM with ABCG2 and initially established 
the assays in CML cell lines that had not previously been selected for drug 
resistance, which is closer to the situation found in clinical settings, and then 
confirmed all the findings in primitive CD34+ CML cells, harvested from newly 
diagnosed patients prior to therapy. We observed that, at 5µM, IM is an inhibitor of 
ABCG2, which is in agreement with the current view of the IM/ABCG2 interaction. 
In addition, we have performed HPLC analysis of IM levels in our laboratory on 
CML CD34+ cells and have observed no difference in cellular accumulation in the 
presence or absence of the specific ABCG2 inhibitor, FTC, confirming these 
findings (unpublished data).  
However, with hindsight, the experimental procedure chosen to determine the 
interaction of TKIs with drug transporters could be criticised and might be 
improved by a different approach. We compared the cellular concentration of 
radiolabelled IM, in the presence and absence of the specific ABCG2 inhibitor 
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FTC, to determine whether IM is a substrate of ABCG2. The washed cells were 
then lysed and counted. With this experiment therefore, any residual radiolabelled 
drug that may have attached to the external surface of the cell membrane that may 
not have been washed off was also counted. It may therefore be suggested that 
any differences in the two treatments in terms of genuine intracellular levels may 
have been masked by excessive amounts of cell-bound IM, hence the similar 
cellular IM concentrations in the presence or absence of FTC. A more accurate 
analysis would require a HPLC measurement of the IM concentration in the 
cytoplasm derived from a membrane-free preparation of the cells. However, not 
only is this difficult, if not impossible to achieve with current laboratory techniques, 
but there is also every chance that the agents such as IM will be lost with the 
membrane. 
However, our conclusion that IM is an inhibitor of ABCG2 at therapeutic 
concentration corresponds with the recent reports. Furthermore, we also tested 
the effect of drug transporter inhibition in the presence of IM and further confirmed 
no increase in apoptosis or in BCR-ABL inhibition. The activity of BCR-ABL cannot 
be directly measured, but may be assessed by detection of CrkL phosphorylation 
(Hamilton et al. 2006), either by flow cytometry or by Western blotting. Due to the 
low cell numbers available however, we were restricted to measuring by flow 
cytometry and although this has the advantage of separating and observing 
different subpopulations, recent comparative experiments carried out in our lab 
demonstrate that Western blotting is more sensitive. Therefore, small differences 
in BCR-ABL inhibition may have been present, but were not detected with the less 
sensitive flow technique. In addition, CrkL has also been suggested to be a 
substrate for SRC kinases (Qiao et al. 2006), therefore IM, which does not inhibit 
SRC kinase activity, will not achieve complete p-CrkL inhibition in cells in which 
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SRC kinase signalling is active. It may therefore be that a different indirect target 
for measuring BCR-ABL activity, or a few alternative methods to allow 
confirmation, may be preferable, such as inhibition of STAT5 phosphorylation. 
Regardless of these potential weaknesses in our approach, our investigations 
demonstrated no further IM effect in the presence of FTC, using a range of 
methods and hence, in our opinion conclusively demonstrate that IM is an inhibitor 
of ABCG2 in primary CML CD34+ cells when used at therapeutic levels. Therefore, 
inhibiting ABCG2-mediated substrate efflux will not further enhance the cellular 
concentration of IM; hence, the increased expression of ABCG2 on CML cells 
compared to their normal counterparts is not relevant in the context of this drug. 
A similar debate has been ongoing regarding the interaction of IM with MDR1. The 
over-expression of MDR1 in K562 cell lines resulted in increased IM resistance 
(Mahon et al. 2003) and a reduced intracellular drug concentration (Widmer et al. 
2003). Indeed, RNAi mediated knockdown of MDR1 in IM-resistant CML cell lines 
has been shown to restore IM sensitivity (Rumpold et al. 2005). These data are 
consistent with other reports suggesting that IM is a substrate for MDR1 (Mukai et 
al. 2003; Illmer et al. 2004). However, in contrast, other groups have shown that 
over-expression of MDR1 in K562 cells does not confer resistance to IM (Ferrao et 
al. 2003). The recent study by Shukla et al (Shukla et al. 2007) though suggests 
that, like ABCG2, IM may interact with MDR1 as a substrate at low concentrations, 
but as an inhibitor at higher concentrations. Yet again, as with the reports with 
ABCG2, these studies were limited, as they have been performed in cell lines 
engineered to over-express MDR1, achieved by in vitro passaging of cells in 
progressively increasing doses of chemotherapeutic agents. In addition, the 
increased sensitivity of cells, in the presence of specific MDR1 inhibitors, may also 
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not be wholly attributed to enhanced intracellular concentrations of IM. Indeed, 
clinical trials that have administered PSC 833 (valspodar) as a MDR1 modulator 
have had to terminate early due to increased morbidity and mortality in the 
patients (Baer et al. 2002). We investigated the effect of PSC 833 in CML CD34+ 
cells alone in vitro and demonstrated that PSC 833 alone was profoundly anti-
proliferative and caused significant apoptosis. Therefore, we can postulate that 
previous reports demonstrating increased overall kill by MDR1 inhibition with PSC 
833 in combination with IM may not be due to increased IM effect, but either due 
to the inhibition of MDR1 leading to anti-proliferative effects or to off target toxicity. 
Surprisingly, PSC 833 as a single agent also demonstrated significant reduction in 
p-CrkL at 16hrs. This may reflect either the increased concentration of an 
endogenous substrate that has p-CrkL inhibitory activity, caused by blocking 
MDR1, or the direct inhibition of p-CrkL by PSC 833. However, as PSC 833 is a 
cyclosporin, we do not anticipate that it is the latter, although the underlying 
mechanism has not been resolved and will need further investigation.  
In our studies we also investigated the interaction of IM with MDR1. In our studies, 
we demonstrated that IM was an inhibitor of MDR1 and although the combination 
with PSC 833 reduced total cell numbers, this did not appear to be due to an 
enhanced IM effect. Therefore, like ABCG2, the expression of MDR1 does not 
appear to mediate IM resistance in CML cells. This is in agreement with in vitro 
studies by Ferrao et al (Ferrao et al. 2003) and in vivo studies by Zong et al, who 
demonstrated that IM response in a CML murine model was not improved by 
inhibiting MDR1 (Zong et al. 2005). Indeed, they suggested one of the reasons 
leukaemia initiating cells were not sensitised to IM by loss of MDR1 might be due 
to the inhibitory effect of IM on this drug transporter. Furthermore, a previous 
clinical study reported no significant difference in MDR1 expression in BM cells 
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from patients who responded to IM compared to those that had not (Crossman et 
al. 2005b), and showed that low levels of MDR1 gene expression in CML blast 
cells was not a predictor of response to IM (Lange et al. 2003). 
For completeness, the interaction of IM with MRP1 was also investigated. 
Previously, Mukai et al had demonstrated that IM was not a substrate for MRP1 in 
cell lines (Mukai et al. 2003). We confirmed this finding and additionally 
demonstrated that IM is not an inhibitor of MRP1, nor does MRP1 modulation 
increase the IM effect in vitro. The difference in interaction between the drug 
transporters and IM may be due to the mechanism of action of MRP1. In contrast 
to ABCG2 and MDR1, MRP1 cannot transport or interact with unmodified 
substrates, but requires them to be conjugated to glutathionine. It may therefore 
be that IM is not conjugated to glutathionine in these cells and hence is neither 
transported by, nor interacts with, MRP1.  
The interaction of nilotinib with the drug transporters has previously been 
investigated, although to a much lesser extent than IM. A recent publication has 
demonstrated that, like IM, nilotinib was as effective as the known specific inhibitor 
FTC in preventing Hst transport by ABCG2 (Brendel et al. 2007). Indeed, nilotinib 
was more potent than IM and only 100nM was required for complete inhibition in 
mouse SP cells. This is in agreement with our results, which confirmed that at 
therapeutic concentrations, nilotinib is a potent inhibitor of ABCG2. In addition, 
Brendel et al observed that at very low molecular concentrations, nilotinib interacts 
at the substrate binding site of ABCG2 in K562 cell lines. This suggests that like 
IM, nilotinib may be a substrate at very low doses. However, as discussed with IM, 
these concentrations are considerably lower than those in compliant CML patients, 
with peak-trough levels of 3.6-1.7µM when treated with a standard twice-daily 
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dose of 400 mg (Kantarjian et al. 2007), therefore nilotinib concentrations will 
always be in the range that cause inhibition. We have also demonstrated that 
nilotinib is an inhibitor for MDR1 and MRP1 at therapeutic concentrations. This 
finding is in agreement with White et al (White et al. 2006), who also demonstrate 
that inhibition of MDR1 in MNCs from CP CML patients did not increase the 
intracellular nilotinib concentration.  
Surprisingly, the addition of PSC 833 resulted in a reduction in the accumulation of 
14C-nilotinib. In support of this White and colleagues also reported unexpected 
results when treating CML cells with PSC 833 (White et al. 2006), with significant 
reduction in nilotinib uptake. It may suggest that PSC 833 is directly competing 
with nilotinib uptake, or down-regulating the nilotinib uptake mechanism. 
Alternatively, PSC 833 might be forming a complex with nilotinib, which in turn 
reduces the active transport into the cells. 
As with IM, the effect of drug transporter inhibition in combination with nilotinib was 
investigated and resulted in no further cell kill or BCR-ABL inhibition. We can 
therefore conclude that the ABC transporters do not mediate resistance to IM or 
nilotinib in these primary CML CD34+ cells. Hence, in a clinical setting, the effect of 
IM or nilotinib cannot be further enhanced by the inhibition of these drug 
transporters. 
In contrast to the Novartis agents above, there have been fewer studies of the 
Bristol-Myers Squibb agent dasatinib. Kamath et al (Kamath et al. 2007) have 
demonstrated that the absorption of dasatinib in MDR1 knock-out mice was no 
different compared to the wildtype, and that dasatinib did not alter the absorption 
or disposition of known MDR1 substrates, suggesting that dasatinib is neither a 
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substrate nor an inhibitor of MDR1. This is in agreement with our studies, which 
have also demonstrated that dasatinib is neither a substrate nor an inhibitor of this 
drug transporter.  
However, Kamath et al (Kamath et al. 2007) did observe that dasatinib was 
actively effluxed from Caco-2 cells, suggesting that it may be a substrate for 
another efflux transporter. We investigated dasatinib further and observed that, in 
contrast to IM and nilotinib, dasatinib was a substrate for both ABCG2 and MRP1. 
These results are of great interest, as they would suggest that in clinical practice, 
the cellular concentration of dasatinib might be increased and the potency of this 
drug may be enhanced by blockade of these transporters. This is an attractive 
possibility and one that could efficiently be put into practice with specific inhibitors. 
There are now clinically safe drug transporter inhibitors such as Ko 143 for 
ABCG2, or alternatively a second TKI that inhibits the transporter, such as nilotinib 
or IM, could also be used. The use of the latter would then also provide a dual hit 
against BCR-ABL, although caution is also advisable in using these agents as 
transporter inhibitors in patients, as nilotinib has been associated with detrimental 
side effects, including QT prolongation, which may result in an increased risk of 
developing ventricular arrhythmias. Furthermore, the combination of two TKIs may 
lead to an increased antiproliferative effect (Copland et al. 2006; Jorgensen et al. 
2007b), therefore, secondary usages may not be permitted. 
However, before clinical application becomes feasible there are a number of 
questions that need to be addressed. Although dasatinib has been identified as a 
substrate for ABCG2 and MRP1, there is no confirmation that drug transporter 
blockade will increase BCR-ABL inhibition and cell kill. In this study, we tested the 
effect of drug transporter inhibition in the presence of dasatinib and surprisingly did 
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not observe any enhanced kill with either ABCG2 or MRP1 inhibition, and, more 
importantly, no further BCR-ABL inhibition or reduction in q34+ cells.  
The studies that were carried out only examined one transporter at a time though, 
and therefore it may be that a combination of inhibitors may alter the outcome. If 
the combination of inhibitors with dasatinib produced further BCR-ABL inhibition 
and reduced q34+ cells, then it may provide a basis for increased effect. 
However, caution must still be employed, as targeting these transporters will also 
have an effect on normal primitive progenitor cells. Indeed, the role of these drug 
transporters is to actively extrude toxic substances from essential sites such as the 
blood brain barrier and the kidney. If this role is inhibited in normal cells, and 
especially stem cells, then the effect may have disadvantageous consequences. It 
is reasonable to assume that there may be no short term problems with the 
inhibition of ABCG2, as abcg2 null mice show normal haematological response 
with no developmental or observable organ defects (Zhou et al. 2002). However, it 
is not confirmed that ABCG2 functionality is not required for normal human stem 
cell function or whether the activity of this transporter is substituted by other 
transporters; a point that requires further investigation. 
Furthermore, this hypothesis is reliant upon there being the only two transporters 
involved in dasatinib efflux. It is not improbable that as both ABCG2 and MRP1 
actively efflux dasatinib, then there may be other, as yet, unidentified transporters 
that may also actively efflux the TKI, which would therefore still maintain a 
suboptimal intracellular concentration. Our expression studies identified MRP4 
mRNA to be significantly elevated in CML CD34+ cells compared to their normal 
counterparts, and it is extremely likely there are other transporters present. Thus, 
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the concentration of dasatinib within the cell may still be suboptimal even with the 
combination of ABCG2 and MRP1 inhibitors. Our pilot data in chapter 6 may also 
indicate that dasatinib and other TKIs induce the expression of other transporters; 
hence we can speculate that the cell may still find a way to extrude these drugs. 
This is in agreement with Burger et al (Burger and Nooter 2004), who also 
observed induced mRNA and protein expression of ABCG2 and MDR1 in Caco2 
cells when exposed to IM. 
However, it may be revealed that, even if all the transporters that efflux dasatinib 
are identified and inhibited, and the intracellular concentration is further increased, 
the activity of BCR-ABL and cell kill may still not be reduced. It may be that, even 
with active efflux, the current cellular concentration of dasatinib is such that 
maximal inhibition of BCR-ABL is already achieved. Indeed, significant inhibition of 
CrkL phosphorylation is already achieved in primitive progenitor CD34+38- cells at 
the IC50 dose of 10nM (Copland et al. 2006). Furthermore, we have recently 
treated 2 CML CD34+ samples with >1000nM dasatinib compared to 10nM 
dasatinib for 72 hrs and shown no measurable difference in p-CrkL inhibition, 
suggesting that even extreme doses still do not fully inhibit this pathway 
(unpublished data). Thus, the very low effective dose range of this agent suggests 
that a low cellular concentration will still have a strong inhibitory effect on BCR-
ABL, with no further demonstrable effect at much higher doses. Therefore, as 
supported by our inhibition data from ABCG2/MRP1, further increasing the cellular 
concentration of dasatinib may not further enhance BCR-ABL inhibition after all. 
An alternative explanation for the persistence of CML stem cells may be that TKI 
such as dasatinib do maximally inhibit BCR-ABL activity, but that the cells are no 
longer reliant upon BCR-ABL for survival. Indeed, the residual p-CrkL observed 
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may not be due to suboptimal inhibition, but may be residual normal p-CrkL levels 
which are not dependent on either BCR-ABL or SRC activity. In addition, it may be 
that the cells have acquired secondary genetic abnormalities that provide 
alternative pathways for proliferation. If this is the case even complete inhibition of 
BCR-ABL by TKI will never eradicate these cells. Indeed, despite the ability of 
dasatinib to target BCR-ABL cells deeper in to the stem cell compartment, the 
quiescent CML cells still appear to be intrinsically resistant to dasatinib (Copland 
et al. 2006). It may be suggested therefore that BCR-ABL has a minimal effect on 
the qSC population. Evidence for BCR-ABL independence has been demonstrated 
in a murine model, whereby inactivation of p190BCR-ABL did not rescue the 
malignant phenotype, suggesting that p190BCR-ABL is not required for disease 
maintenance (Perez-Caro et al. 2007) once initiated. It was hypothesised that 
other epigenetic changes or mutations in the LSCs may have rendered them 
insensitive to inactivation of p190BCR-ABL. In contrast however, there have been 
other studies clearly demonstrating the requirement of BCR-ABL for disease 
maintenance and a recent study has demonstrated that dasatinib treatment 
achieved complete remission of Ph+ B-ALL in a murine model (Hu et al. 2006). 
Therefore to confirm whether CML SCs are oncogene dependent, studies are 
currently been undertaken to combine siRNA knockdown of BCR-ABL with 
dasatinib to completely inhibit the oncogenic protein.    
7.3 Summary and future directions 
Overall, based on these findings, there are avenues to continue this study to 
identify new drug transporters involved in active TKI transport. There is evidence 
that there will be other influx transporters in addition to OCT1 that mediate the 
intake of TKIs. However, it is unlikely that a suitable technique will be devised to 
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exploit this effect in vivo, as methods of increasing the expression and function of 
these transporters are not yet established. However, identifying which influx 
transporters are involved in the uptake of the TKIs may be utilised as prognostic 
tools to direct treatment by allowing the clinician to select the most suitable TKI 
and also monitoring for treatment response. In contrast, there is more scope to 
actively manipulate efflux transporters using specific inhibitors. The data presented 
here indicate that with the current drug transporters, the effect of the Novartis 
agents cannot be enhanced. However the cellular concentration of dasatinib can 
be increased and may, with a suitable combination of inhibitors, further inhibit 
BCR-ABL activity and increase overall cell kill. Hence a more comprehensive 
analysis of all the transporters in primitive CML cells would be of interest, which 
may then lead to combination studies with specific inhibitors and TKIs to maximise 
the cellular TKI concentration and determine whether resistance can be overcome. 
However, it is my opinion that even after identifying all the transporters that 
actively efflux TKIs and maximal BCR-ABL inhibition by these agents is achieved, 
the TKI effect will not be enhanced, nor will it prove to be a cure for CML. The 
evidence suggests to me that the resistance of progenitor and primitive cells is not 
the result of limiting intracellular concentration of dasatinib. This is certainly not the 
case for IM and nilotinib and yet disease still persists. I believe the primary 
direction for future therapy lies in conclusively confirming whether the cells are 
addicted to BCR-ABL as this will impact on the development of agents or protocols 
to combat this disease. If the qSC population are not oncogene dependent, then 
there will be a need to identify and develop agents that target other essential 
aspects of SC maintenance for effective eradication and cure.  
One such novel agent that has shown promising results in CML is the farnesyl 
transferase inhibitor (FTI) BMS-214662. This agent has demonstrated favourable 
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activity in patients with acute leukaemias (Cortes et al. 2005) and preferentially 
targets the non-proliferating cells in tumour models (Rose et al. 2001). Copland et 
al (Copland et al. 2005) have demonstrated induction of apoptosis in both 
CD34+38+ progenitors and the more primitive CD34+38- CP CML cells, including 
the quiescent population, with synergism when combined with TKIs. LTC-IC data 
has also demonstrated almost total ablation of CML SC and preferential 
cytotoxicity for these cells compared to their normal counterparts, demonstrating 
novel and potent activity in eliminating quiescent CML stem cells. Furthermore, 
BMS-214662 was equally cytotoxic in cell lines harbouring the mutant BCR-ABL 
with T315I kinase domain mutation (Copland et al. 2007), demonstrating superior 
activity to IM and nilotinib. However the mode of action of this novel agent is to 
date unknown. Elucidation of this mechanism is essential, as it will prove a useful 
tool for developing novel therapeutic strategies for targeting cancer stem cells. 
An alternative novel approach to efficiently target the leukaemic SC may be by 
working in partnership with BCR-ABL. Instead of attempting to eradicate SC by 
actively inhibiting this oncogene itself, its presence in SC may be used as a 
marker to deliver an apoptotic agent that is only activated in a BCR-ABL cell. For 
example, this apoptotic agent may be delivered in two inactive halves that are 
completely harmless to normal cells. However, upon binding to BCR-ABL, the two 
separate halves may be brought in close proximity such that they may bind, 
causing activation and subsequent apoptosis only in the cell with the oncogene. 
This will therefore specifically target the tumour population, while avoiding the 
normal SC. Furthermore, this form of targeting will be effective regardless of 
whether the SC is found to be dependent or independent upon BCR-ABL activity, 
as this technique only requires the oncogene to be present. Indeed, such a 
mechanism for delivering an agent that can specifically target an oncogenic 
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marker will also prove to be useful in other cancers with a SC origin. Such 
technology is currently being developed in mitochondrial RNA (Ozawa et al. 2007; 
Valencia-Burton et al. 2007), but will prove extremely useful if it can be 
manipulated to target specific oncogenes such as BCR-ABL. 
Overall, this thesis provides a comprehensive study of the current TKIs and their 
interaction with transporters. Although there have already been numerous studies 
on this interaction, the reports have been conflicting and the experiments carried 
out have been in unsuitable cell lines that have been engineered to over-express 
the transporter. This thesis has significantly improved upon the existing literature 
as the interaction of TKIs and transporters has been investigated in drug naïve 
primary CML CD34+ cells and tested at clinically relevant doses. Therefore, the 
results more closely reflect the true interaction of TKIs with these transporters and 
their effect on these cells. Furthermore, this thesis presents a promising lead for 
drug transporter modulation in combination with dasatinib for overcoming TKI 
resistance, although further testing is required. Finally, we can summarise with 
conviction that although ABC transporters are present and functional in CML 
CD34+ cells, blockade of these proteins by specific inhibitors do not increase IM 
and nilotinib accumulation or enhance their effect, providing evidence that 
resistance to these agents is not mediated by active drug efflux. More importantly, 
neither inhibitor was able to target the quiescent population, highlighting the 
importance of finding agents that specifically target the cancer stem cells. It is 
likely therefore, that future directions will most likely focus on understanding the 
biology of the CSC to identify other characteristics specific for the leukaemic cell 
and to develop agents with a different mechanism of action, or to develop novel 
approaches of delivering agents that specifically target the known oncogenic 
markers. 
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